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ABSTRACT OF DISSERTATION

EARLY EVENTS OF HUMAN METAPNEUMOVIRUS INFECTION
Human metapneumovirus (HMPV) is a worldwide respiratory pathogen that belongs to
the paramyxovirus family of enveloped viruses and affects primarily the pediatric, geriatric, and
immunocompromised populations. Despite its prevalence and importance to human health, no
therapies are available against this pathogen. For paramyxoviruses, it is believed that infection
starts by attachment of the virus to the surface of the cell through the viral attachment protein
followed by fusion between the viral and cellular membranes, a process mediated by the fusion
(F) protein at the plasma membrane and at neutral pH. Previous work showed that HMPV
infection can occur in the absence of the attachment protein and membrane fusion triggered by
the F protein can be promoted by low pH. The work presented here are significant advances in
our understanding of the entry process of HMPV. We confirmed that the F protein has receptorbinding functions and identified the cellular binding partner to be heparan sulfate proteoglycans
(HSPGs). Additionally, we provide evidence that electrostatic interactions at two different
regions play important roles for the proper folding, stability, and low pH triggering of the HMPV
F protein. We confirmed the hypothesis that protonation of H435 is important for HMPV F
triggering and provide additional evidence that the entry of HMPV may be occurring through
endocytosis. Therefore, we hypothesize that HMPV entry occurs through endocytosis after viral
binding to HSPGs through the F protein and membrane fusion occurs in an acidified
compartment.
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Chapter 1: Introduction

Paramyxoviruses: Classification and Relevance to Human Health
The paramyxovirus family includes multiple viruses that are of importance to global
economics and human health. Among the members of the family are well-known, highly
infectious worldwide human pathogens such as measles virus (MeV), one of the most
contagious human diseases known and the causative agent of an estimated 164,000 deaths in
2008 despite aggressive eradication efforts (1); respiratory syncytial virus (RSV), the leading
cause of lower respiratory tract infections in infants and children worldwide causing about 34
million infections and approximately 3.4 million hospitalizations every year in children under the
age of five (130, 229); and the more recently characterized human metapneumovirus (HMPV,
described below). Besides causing respiratory disease, human parainfluenza virus types 2 and 3,
like mumps virus (MuV), have also been implicated as causative agents of myopericarditis (111,
375). Parainfluenza viruses have also been identified as a significant cause of morbidity and
mortality in pediatric organ transplant patients (10). Furthermore, two highly pathogenic
zoonotic paramyxoviruses, Hendra (HeV) and Nipah (NiV) virus, emerged at the turn of the
century and cause fatal encephalitis and mortality rates that can reach 70% (379).
Paramyxoviruses also cause disease in other species (such as parainfluenza virus 5 [PIV5] and
Sendai virus [SeV]), some of which bring about a tremendous economic burden to society by
causing serious, and sometimes fatal, disease in poultry (Newcastle disease virus [NDV] and
avian metapneumovirus [AMPV]), cattle (bovine RSV [BRSV]), horses (HeV), and pigs (NiV) (68,
127, 180, 183, 208, 225).
While these viruses share many common characteristics, such as possessing a anti-sense
single-stranded RNA genome and a lipid bilayer envelope (180), there are also many unique
aspects in their lifecycles. Based on morphologic criteria, the activity of their proteins, and
sequence homology, viruses in this family are divided into seven distinct genera, of which five
belong to the paramyxovirinae subfamily and the remaining two are grouped in the
pneumovirinae subfamily. Thus, viruses like RSV and HMPV are classified in the pneumovirinae
subfamily while MeV, SeV, NDV, the henipaviruses, and the parainfluenza viruses are part of the
paramyxovirinae subfamily (Figure 1A). Several recently discovered paramyxoviruses such as J
virus, Mossman virus, and Salem virus have not yet been classified within a subfamily (180).
1

Human Metapneumovirus and Medical Relevance
HMPV was discovered in 2001 in the Netherlands in nasopharyngeal aspirate samples
from children suffering from respiratory tract infections, making it the first representative of the
metapneumovirus genus to cause human disease and the third paramyxovirus that primarily
infects the respiratory tract (352). Despite the relatively recent discovery of HMPV, serological
studies confirmed that HMPV has been infecting humans for over half a century (352).
Phylogenetic analysis divides HMPV strains into 2 major genetic lineages which can be further
subdivided into 2 subgroups each (designated A1, A2, B1, and B2). While concurrent circulation
of all four subtypes is common, a single, usually different, subtype usually predominates each
year (46, 148, 195, 261).
HMPV causes respiratory tract disease worldwide, producing yearly epidemics with a
typical seasonal distribution in temperate climates (105, 154, 159, 196, 238, 258, 261, 352). Due
to the ubiquitous presence of HMPV across the world, virtually all children are exposed to this
virus by age five (252, 352). Unfortunately, this virus induces only incomplete immunity,
increasing the chances of multiple infections throughout life (363). Thus, HMPV infection is not
only a concern in the pediatric population but also a concern in older populations (112, 113,
252, 363). Symptomatic and severe disease usually occurs in young children, older adults, and
immunocompromised individuals, many times resulting in admission into the intensive care unit
and the use of mechanical ventilation. However, HMPV can cause upper and lower respiratory
tract infection in all age groups (38, 39, 113, 172, 252, 300, 363). Furthermore, adults with
cardiopulmonary conditions are far more likely to require medical attention as a result of HMPV
infection (112, 363).
Symptoms of HMPV infection are clinically indistinguishable with those seen with RSV,
likely contributing to mis- and under-diagnosis of the disease (93, 374). The most common signs
and symptoms of HMPV infection include cough, rhinitis, fever, and wheezing (376). More
severe infections can result in bronchiolitis, croup, asthma exacerbation, and pneumonia
requiring hospitalizations (38, 87, 109, 178, 352). Febrile seizures are more common with HMPV
than RSV (113) and acute otitis media is seen in up to one third to one half of HMPV infections
(87). Though largely restricted to respiratory tract disease, HMPV RNA has been detected in the
brain of a patient who suffered from a fatal case of encephalitis (294). Most studies indicate that
between 5 and 15% of respiratory tract infections are caused by HMPV infection – second in
frequency only behind RSV (39, 110, 112, 205, 261, 353, 354, 363). Despite the high prevalence
2

of HMPV and the burden it signifies to human health, there are currently no approved antiviral
therapies against infection from this virus.

Paramyxovirus Structure, Its Surface Glycoproteins, and Their Role in Entry
Paramyxoviruses possess a lipid bilayer envelope that is derived from the plasma
membrane of the host cell. The non-segmented RNA genome of paramyxoviruses, which contain
six to ten tandemly linked genes, is contained within the helical nucleocapsid core composed of
the nucleocapsid (N), phospho- (P), and large (L) protein. The overall morphology of the viral
particle is thought to be regulated by the matrix protein (M), which interacts with the
nucleocapsid core, the viral envelope, and the surface glycoproteins. Some paramyxoviruses
also encode accessory proteins, usually as additional transcriptional units interspersed with the
invariant genes (180). Compared to pneumoviruses like RSV, metapneumoviruses lack the nonstructural proteins NS1 and NS2 and the order of the genome is different: RSV (3’-NS1-NS2-N-PM-SH-G-F-M2-L-5’), HMPV (3’-N-P-M-F-M2-SH-G-L-5’) (29, 164, 352).
Out of the six to ten genes present in the genomes of paramyxoviruses, only two or
three of the encoded proteins are expressed at the surface of the virus (Figure 1B). For
enveloped viruses, the surface glycoproteins are used by the virus to identify and attach to their
cellular receptors and promote viral-cell membrane fusion, a process that allows the
nucleocapsid to enter the cellular cytoplasm. The rest of the encoded proteins are primarily
involved in viral genome transcription/replication or assembly. Paramyxovirus entry occurs
through virus-cell membrane fusion and is usually mediated by the attachment protein (H, HN,
or G) and the fusion protein (F) (180).
In addition to the presence of the fusion and attachment glycoproteins on the viral
surface, three of the seven genera of paramyxoviruses, including members of the
pneumovirinae subfamily, also express a third putative viral surface glycoprotein, the small
hydrophobic protein (SH). To date, there is no evidence to suggest that the SH protein plays a
direct role in the virus attachment and entry steps. Interestingly, unlike the fusion and
attachment proteins, the SH protein is much less conserved across the family; in addition to the
low sequence conservation among members of the family, some SH proteins are type I proteins
and some, like that of PIV5 and the pneumoviruses, are type II (31, 339). The exact function of
the SH protein is not known and studies have shown that mutant viruses devoid of this protein
remain infectious and retain their growth properties in vitro ((27, 31, 136)and see results). In
3

fact, it has been shown that the rate of mutation for wild type HMPV SH is the highest compared
to the rest of the proteins in the genome (26). Even though these studies suggest that SH is not
essential for viral infection and replication, all clinical isolates at least for HMPV (26) and mumps
(377) contain an intact SH gene, suggesting that the SH protein must be serving an important
function for the virus to retain this protein in its genome. Furthermore, several in vivo studies
have shown that viruses like RSV and PIV5 (53, 137, 370), but not HMPV (31), are attenuated
when the SH protein is absent. This difference between in vitro and in vivo studies could be due
to the role of SH in cell signaling. Indeed, studies with RSV (117), PIV5,and mumps suggest that
SH antagonizes the induction of apoptosis and, like HMPV (13) , may also block the activity of
NF-κB (377).

Paramyxovirus Attachment Proteins and Viral Receptor Binding
The attachment proteins of rubulaviruses, respiroviruses, and avulaviruses have both
hemaglutinin (sialic acid binding) and neuraminidase (sialic acid cleaving) functions and are
called HN proteins. Viruses with an HN protein use cellular surface sialic acid as their receptors
with various degrees of affinity (360). The attachment proteins of morbilliviruses (H) lack
neuraminidase activity but can bind sialic acid. However, morbilliviruses use cellular proteins,
such as CD46, CD150/SLAM, and nectin-4, in the case of MeV (223, 240, 264), as receptors for
attachment. Henipaviruses and members of the pneumovirinae subfamily have attachment
proteins that do not bind sialic acid and are named G (for glycoprotein). Hendra and Nipah G
bind to cellular Ephrin B2/B3 (41, 232, 233) whereas previous reports have shown that
pneumovirinae G proteins bind to heparan sulfate proteoglycans (174, 347). In addition to
mediating the initial attachment of the virus to a cell, attachment proteins of most
paramyxoviruses also have fusion promoting activity as coexpression of the homotypic
attachment and fusion proteins is required for membrane fusion and viral spread to occur (4,
185, 251, 264, 266, 271, 272, 330, 340, 382). The cascade of events occurring after receptor
binding that leads to the triggering of the F protein, however, remains largely unknown.
All paramyxovirus attachment proteins characterized to date are homotetrameric type II
integral membrane proteins (180). They are made up of a membrane-proximal stalk and a large
c-terminal globular head domain anchored by a single-pass N-terminal transmembrane domain
(180). The crystal structure of the globular head domain of several paramyxovirus attachment
proteins, including NDV HN, PIV5 HN, PIV3 HN, MeV H, HeV G, and NiV G, has been solved,
4

showing that this domain is composed of four six-blade β-propeller fold monomers arranged in a
four-fold symmetry (43, 50, 79, 135, 184, 381, 386). Substantial evidence suggests that the stalk
domain of paramyxovirus attachment proteins is likely a helical coiled-coil that in many cases
interacts with and determines the specificity of the fusion protein (89, 90, 209, 264, 341). The
latest crystal structures of NDV and PIV5 HN have, in fact, provided further evidence that the
stalk domain is a tetrameric coiled-coil as the portion proximal to the head domain was
observed (43, 385). For most HN attachment proteins, the binding site to sialic acid is located at
the top of the globular head and at the center of the β-propeller fold of each monomer (386).
However, the crystal structure of NDV HN protein shows a second sialic acid binding site located
at the dimer interface (48, 387). Inhibitor-based studies and studies of mutant viruses also
suggest the presence of a second sialic binding site for PIV3 HN that is important for fusion
promotion and not for receptor avidity (250, 269, 270). Interestingly, this the second binding
site was not detected in the crystal structure of PIV3 HN (184) and a more recent study provided
evidence that, similar to PIV1 HN (9), this site in PIV3 HN may be covered by N-linked glycans
(216). Thus, the importance of this second sialic acid binding site is still not fully understood.
Though the morbillivirus H and henipavirus G proteins have adapted to bind to their
proteinaceous receptors, a site analogous to the sialic acid binding site of HN proteins can be
found in these H or G proteins, suggesting that they have evolved from a HN-like protein (49, 70,
135). While the binding site for Ephrin B2/B3 in the henipaviruses is also located at the top of
the head domain of each monomer (50, 381), the binding site in MeV H to CD46/SLAM is located
toward the sides of the β-barrel of each monomer (70, 134).
While multiple reports indicate that the interaction between the attachment and the
fusion proteins regulates the fusogenic activity of paramyxovirinae virus F proteins, studies have
shown that both RSV and HMPV are infectious in the absence of their highly glycosylated G
protein ((27, 31, 65, 164, 346) and results). Furthermore, cell-to-cell fusion promoted by the F
protein of HMPV occurs without coexpression of HMPV G ((65, 143, 298, 299) and results).
Recent reports have shown that RSV F interaction with cell surface nucleolin and HMPV F
interaction with heparan sulfate proteoglycans can mediate viral binding to target cells ((65, 80,
342) and results). In addition, it has been shown that β1 integrin plays an important role in
promoting HMPV infection (65, 80). These observations suggest that, unlike members of the
paramyxovirinae subfamily, receptor binding activity for members of the pneumovirinae
subfamily can occur through the F protein and receptor interactions with the G protein are not
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essential. Interestingly, RSV produces a soluble form of the G protein that plays a role in
immune evasion (306). Therefore, while the attachment protein is required for viral entry of
members of the paramyxovirinae subfamily, more studies are needed to determine the precise
role of the pneumovirinae G protein in viral entry.

Paramyxovirus F Proteins: Structure and Function
All paramyxoviruses discovered to date express a homotrimeric type I fusion protein.
Like other class 1 fusion proteins such as those of influenza, Ebola and HIV, paramyxovirus F
proteins have a hydrophobic fusion peptide (FP), two heptad repeat regions (HRA and HRB), are
anchored at the surface by a single-pass transmembrane domain (TM), and contain a short, 20
to 40 amino acid residue c-terminal cytoplasmic tail (180). Paramyxovirus fusion proteins are
synthesized as a biologically inactive F0 precursor form which must then be cleaved into the
fusogenically active F1+F2 metastable prefusion form (Figure 2A). Upon triggering, the F protein
undergoes extensive and irreversible conformational changes that result in the repositioning of
the heptad repeat regions to form a stable six-helix bundle (6-HB), a process intimately linked to
membrane fusion. Due to its ability to fuse two different membranes, the expression of the F
protein in the surface of transfected or infected cell can result in the fusion of the membranes of
neighboring cells resulting in the formation of giant, multinucleated cells named syncytia.
Syncytia formation is a hallmark of infection by many of these viruses and a valuable tool in the
diagnosis and study of paramyxoviruses (144, 180, 243).
While amino acid sequence alignment shows minimal sequence conservation, structural
and biochemical analysis suggest a similar structure among paramyxovirus F proteins. Analysis
of the crystal structure of the uncleaved, GCNt-stabilized PIV5 F protein in its prefusion
conformation showed a large globular head domain connected through the HRB-linker region to
a membrane-proximal stalk region composed of the three HRB domains forming a three-helix
coiled-coil (Figure 2B) (384). In this metastable state, HRA (orange) is located at the top of the
globular head domain and the fusion peptide (blue) is buried between two subunits of the
trimer with its N-terminus exposed to the surface for cleavage. HRB (green) is located proximal
to the lipid bilayer and is anchored by a TM domain which, in the crystal structure, was replaced
by a GCNt trimerization domain. Though the structure of the TM domain is absent from the
crystal structure, evidence supports a helical structure which self-interacts (36) and recent
studies indicate that TM domains of paramyxoviruses self-associate into trimers and may help
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stabilize the prefusion conformation ((313) and Smith, et. al, manuscript submitted for
publication). Furthermore, several studies indicate that this domain is important for the activity
of class 1 F proteins and serves as more than just an anchor to the lipid membrane (36, 211, 217,
313).
Crystal structures of the fusion protein in the more stable postfusion conformation
obtained from NDV F (336), hPIV3 (383), and RSV F (207) revealed a strikingly different
conformation (Figure 2B). While these proteins remained trimeric in the postfusion state, the
extensive intersubunit contacts in the prefusion form are disrupted, HRA (orange) forms a new
three-helix coiled-coil projecting away from the base region of the head domain, and HRB
(green) translocates to the opposite side of the protein, packing against the HRA coiled-coil and
creating the characteristic 6-HB. This drastic refolding of the fusion protein creates new
intersubunit contacts and disrupts many of those found in the prefusion conformation, creating
an overall more compact and stable structure (180). Recent studies suggest that the FP adopts a
helical structure important for fusion (Smith, et. al. manuscript in preparation), and that the FP
both associates with itself and with the TM domain (95).

Paramyxovirus F Cleavage Activation
To be fusogenically active, paramyxovirus F proteins must be proteolytically cleaved
from the precursor F0 form to a disulfide-linked F1+F2 heterodimer (Figure 2A). Indeed, cleavage
of the F protein is an essential step for pathogenicity of the virus. Cleavage activation, which
occurs after one or more basic residues (180), creates a new N-terminus in F1, properly positions
the fusion peptide, and may lower the activation energy barrier for triggering (100, 256, 280).
The cleavage event for most paramyxovirus F proteins such as those of PIV3, NDV, RSV, and
MeV occurs during transport through the trans-Golgi network, and is promoted by furin, a
ubiquitous subtilisin-like cellular endoprotease that recognizes an R-X-K/R-R motif (40, 125, 126,
170, 247). Cleavage by a furin protease, however, is not ubiquitous for F proteins, as not all
paramyxovirus F proteins contain this consensus sequence. Henipavirus F proteins do not
contain a furin cleavage site and are cleaved after a single basic residue by the cysteine-protease
cathepsin L following an endocytic event that brings the F0 precursor protein from the surface
back to an endosomal compartment (91, 92, 248, 249). Furthermore, some F proteins such as
those of HMPV and Sendai virus are cleaved by an extracellular protease, a process supplanted
in cell culture by the addition of trypsin (31, 224, 299, 352). In vivo, the F proteins of these
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viruses are likely cleaved by exogenous proteases such as TMPRSS2 and mini-plasmin after
budding to further promote infection (30, 224, 307). Interestingly, all paramyxovirus F proteins
described to date are activated with a single cleavage event with the exception of RSV F protein,
which expresses two consensus sequences for furin cleavage. Cleavage at both sites is necessary
for fusion activity of RSV F (19, 125).
The cleavage of the F protein may result in structural rearrangements of the F protein,
as peptide antibodies against the heptad repeat regions of PIV5 recognized primarily the
uncleaved form of PIV5 F (99). Furthermore, replacement of the cleavage site in Sendai F with
the cleavage sites of RSV F rendered the F chimera capable of promoting syncytium formation in
the absence of its homotypic HN protein (280), suggesting that alterations at the cleavage site
can affect triggering of the F protein. While some studies with NDV F indicate that cleavage of
the F protein is a determinant of virulence, as NDV F proteins with multibasic cleavage sites are
more virulent than those with a single basic cleavage site (227, 228), a recent study with APMV2 strain Yucaipa, which lacks the furin consensus sequences but replicates in the absence of
exogenous proteases (332), suggests that the cleavage site plays an important role for viral
replication in vitro but does not alter the virulence of the virus (331). Therefore, the cleavage
event may determine pathogenicity in some paramyxoviruses.

Triggering of Fusion, the Role of the Attachment Protein, and Low pH
Because the refolding of the fusion protein from the prefusion to the postfusion
conformation is essentially irreversible, it is critical that the fusion protein is triggered at the
right place and time. Triggering in the absence of a proper target membrane would inactivate
the F protein (44, 57, 73). Therefore, the triggering of paramyxovirus F proteins must be
temporally and spatially regulated. For the majority of paramyxoviruses, it is hypothesized that
specific interactions between cell surface receptors and the viral attachment proteins trigger the
F protein conformational changes as the expression of the homotypic attachment protein is
required for F to promote membrane fusion (104, 180). Studies have shown that the F protein
and the attachment protein interact for a number of paramyxoviruses and that these specific
interactions are required for triggering (4, 34, 230, 266, 268, 272, 330, 340, 382). Interactions
between the F protein and the attachment protein have been primarily shown to occur at the
head region (185) of F. While many studies indicate that the stalk domain of the attachment
protein is responsible for interactions with the F protein (33, 90, 209, 230, 271, 341), residues in
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the TM domain (47, 206) and the globular head domain (3, 34, 215) have also been shown to
affect F interactions. It is hypothesized that upon receptor binding, conformational changes in
the attachment protein alter the interaction with the F protein, signaling the F protein to trigger
(79, 230, 381, 387). However, a recent study indicates that the continuous activation of the F
protein by the attachment protein was required throughout the fusion process (268), suggesting
a more complex interaction.
For some paramyxoviruses such as NDV and PIV3, it has been shown that the extent of
fusion activity is directly proportional to the strength of the interaction between the fusion
protein and the HN attachment protein (210, 268, 271). It is therefore hypothesized that the
attachment protein could be acting as a molecular scaffold that facilitates the triggering of the
fusion protein upon receptor binding (180). However, fusion activity is inversely related to the
strength of morbillivirus H and henipavirus G interactions with their respective F protein (5,
266), suggesting that the mechanism by which the attachment protein regulates the triggering
of the fusion protein is different between viruses. Interestingly, previous studies have shown
that MeV H associates with MeV F intracellularly (265). Therefore, it is hypothesized that the
dissociation of the intracellularly-formed F-H complexes at the surface upon receptor binding
allows the F protein of MeV to trigger (152). An intracellular interaction was not detected
between HN and F of PIV5and hPIV3 (255), and studies detected either no interaction (191) or
extremely low levels of interaction (330) between NDV F and HN. In addition, cotrafficking of
Hendra F and G proteins was not observed (372), suggesting that the MeV model for
intracellular association is not a universal feature for the paramyxovirus family.
Triggering of the F protein in the absence of its homotypic attachment protein has been
documented for some paramyxoviruses like PIV5 and SeV, although the presence of the
attachment protein dramatically enhances fusion activity in these cases (102, 189).
Furthermore, mutations in the NDV F, Sendai F, and PIV5 F can remove the dependency on the
homotypic attachment protein for triggering (12, 102, 280, 301, 303). Other mutagenesis studies
have shown that the HRB-linker region (289, 298), portions of HRA (193), and a region in F2 that
interacts with HRA (121) are all important for the triggering of F, suggesting that multiple
regions of the F protein regulate this process. For viruses belonging to the paramyxovirinae
subfamily, fusion can be triggered by raising the temperature in the absence of the attachment
protein (256, 369), suggesting that the attachment protein of these viruses helps lower the
energy of activation for F triggering to occur.
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Interestingly, it has been shown that the fusion protein of wild type RSV and HMPV
alone can promote membrane fusion. Furthermore, RSV and HMPV virions remain infectious in
the absence of their homotypic G protein (31, 160, 163, 164, 299, 343). While the majority of
paramyxoviruses induce cell-cell fusion when their glycoproteins are expressed in cultured cells
(17, 35, 180, 302), suggesting that the F proteins of these paramyxoviruses promote fusion
under neutral pH conditions, low pH has been shown to trigger the F protein of some strains of
HMPV (143, 299). Studies of viruses with better-characterized low pH-triggering fusion proteins
such as influenza and rhabdovirus vesicular stomatitis virus (VSV) suggest that triggering of
these fusion proteins are also regulated by multiple regions within the protein, with histidine
residues within the protein having particularly important regulatory role in the regulation of this
process (282, 323, 325, 348). With a pKa of 6.04, histidine residues are the amino acids most
likely to ionize within the physiological pH range (361). However, several charged, non-histidine
residues have also been shown to play an important part alter the pH threshold for triggering
influenza HA (325, 348). Mutagenesis studies of low-pH dependent HMPV also suggest that the
protonation of a critical histidine residue at position 435 plays a large role in the low pH
dependency of the F protein (65, 203, 298). While the exact mechanism by which low pH
triggers certain HMPV F protein is still unclear, changes in electrostatic interactions between
residues that become protonated at low pH could provide the driving force for F protein
triggering (56, 146, 298). The low pH dependency of certain HMPV strains and the observation
that wild type F proteins of members of the pneumovirinae subfamily can trigger in the absence
of the attachment protein suggest that the regulation of this process is different between the
two subfamilies. Therefore, a precise role for the G protein of pneumovirinae viruses is still
unknown.
It is apparent that the regulation of F triggering is a complex process and varies between
members of the family. For most paramyxoviruses, it is thought that receptor interactions with
the attachment protein trigger the fusion protein. While more studies are needed to elucidate
the details on the precise mechanism by which triggering is regulated, five models have been
proposed for the role of attachment protein interactions on triggering of the F protein. One
model, supported by studies of MeV (265, 266) and NDV (330), suggests that the fusion and
attachment proteins interact at the endoplasmic reticulum during synthesis and trafficking to
the cell surface, with the attachment protein potentially holding the fusion protein in its
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prefusion conformation. After receptor binding, the attachment protein releases the fusion
protein and allows it to trigger (Figure 2C, model A).
Alternatively, the fusion and attachment proteins could travel independently to the cell
surface, where they then interact until receptor binding disrupts this interaction and allows the
fusion protein to trigger (Figure 2C, model B). This model is supported by studies in HeV and NiV,
where fusion activity and F-G avidity are inversely correlated (4, 5, 34), but HeV and NiV F
undergo a unique endocytic recycling process for cleavage (92, 248, 249), and differential rates
of F and G folding in the ER and trafficking through the secretory pathway have been observed
(371, 372). Recent studies with hPIV3 show that the attachment and fusion proteins associate
before receptor engagement, and this interaction is required beyond the triggering step (268,
272). These observations are in agreement with an earlier study showing that the extent of
fusion promoted by hPIV3 F was dependent on the surface density of hPIV3 HN (102) and
suggest that the attachment protein actively participates in the entire fusion process.
A third proposed model suggests that the attachment and fusion proteins do not
interact until after receptor attachment, with the subsequent interaction between the two
glycoproteins allowing F to trigger (Figure 2C, model C). This model is supported by studies with
NDV where F-HN interactions are seen only in the presence of receptor, and mutations altering
receptor binding of HN decrease F-HN interactions and fusion (76, 210). In addition, bimolecular
complementation studies of PIV5 F and HN showed increased association of the tagged proteins
and corresponding increases in fusion, suggesting that much of the F protein was not normally
associated with HN (74).
Fusion proteins from RSV, HMPV, and other paramyxoviruses that do not require the
expression of the attachment protein to induce membrane fusion demonstrate that interactions
between the two glycoproteins are not absolutely required for triggering of all paramyxovirus F
proteins (299). For these viruses, interactions between the attachment protein and cell surface
proteins such as heparan sulfate proteoglycans (344, 347) may facilitate fusion by bringing the
two membranes in close proximity, with F subsequently interacting with a cellular receptor
(Figure 2C, model D). However, attachment protein interactions with cellular proteins are
dispensable for RSV and HMPV, indicating that the F proteins of these viruses are capable of
performing the attachment step (65, 176, 344) (Figure 2C, model E).
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Paramyxovirus F-Induced Membrane Fusion
For paramyxoviruses to gain access to the host cell, they must overcome two lipid
barriers that separate the genomic contents of the virus from the cytoplasm. Therefore,
paramyxoviruses must unite two lipid bilayers during entry, a process that is very energetically
unfavorable. This energy barrier is thought to be surmounted in an ATP-independent manner
through the irreversible conformational changes of the fusion protein that occur after triggering
which provide the energy required to merge the two membranes. Refolding from the
metastable prefusion form to the lower energy postfusion state ultimately leads to the creation
of a fusion pore allowing the viral contents to be released into the cytosol.
Our understanding of the mechanism of paramyxovirus F protein-mediated membrane
fusion has increased greatly over the last decade largely due to the availability of crystal
structures of fusion proteins in the prefusion and postfusion conformations. The postfusion F
structures of three paramyxoviruses, hPIV3 F (383), NDV F (336), and RSV F (207), have been
solved and show that key elements are conserved, such as the formation of a six-helix bundle
through the juxtaposition of HRA and HRB. The prefusion structure of PIV5 F (384) is also
available and, together with the postfusion structures, suggest that paramyxovirus fusion
proteins undergo a “spring-loaded mechanism” of fusion similar to that of influenza HA (57, 58).
It is hypothesized that, upon triggering, the HRB coiled-coil present in the prefusion form region
melts, creating the open stalk form. Changes in interactions around HRA and the fusion peptide
lead to projection of the fusion peptide towards the target membrane and refolding of HRA into
a trimeric alpha-helical coiled-coil (pre-hairpin intermediate). Mutagenesis and peptide
inhibition studies support the existence of both intermediates, as peptides that mimic HRA can
block fusion at an earlier step compared to peptides that mimic HRB (256, 288, 289). More
direct evidence of the existence of the pre-hairpin intermediate was recently obtained through
electron microscopy and computational studies, which confirmed a distance between the
membranes consistent with a pre-hairpin intermediate (167). Changes in the globular head then
reposition HRB in an anti-parallel fashion with the grooves of HRA, forming a stable 6-HB and
facilitating the opening of the fusion pore (Figure 3). The formation of the fusion pore likely
requires the simultaneous refolding of more than one trimeric F protein, as cells expressing PIV5
HN and very low amounts of PIV5 F were able to bind red blood cells without promoting
membrane fusion (102).
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The requirement for the formation of the 6-HB in paramyxovirus F proteins for
membrane fusion underscores the importance of the HRA and HRB domains as well as the
regions around them for the fusion activity of the protein. However, several studies suggest that
both HRA and HRB play other important roles in addition to forming the 6-HB. Conserved
domains in the F2 subunit and in HRA, for instance, are seen packed against each other in the
crystal structure of the prefusion form of PIV5 F and are likely stabilizing the prefusion state
(384). Mutations in these domains were shown to modulate the fusion activity of PIV5 F (121,
368). Furthermore, a single mutation in the F2 subunit of PIV5 F (L22P) allowed for the triggering
of the fusion protein in the absence of the homotypic attachment protein (256). Residues
around the HRB domain have also been implicated in modulating the fusogenic activity of PIV5
F. Mutagenesis studies showed that changes in residues located in the HRB-linker region led to
an increase or decrease in fusion depending on the side chain substituted (289). Furthermore,
the mutation S433P, located just N-terminal of HRB, led to an increase in the rate and the extent
of fusion promoted by PIV5 F (256).
While the importance of HRA and HRB in promoting membrane fusion has clearly been
established, a substantial amount of evidence recently obtained also suggests a regulatory role
for the cytoplasmic tails of paramyxovirus glycoproteins. It is thought that cytoplasmic tails
transmit a signal to the ectodomain that regulates the conformational changes during
membrane fusion, as changes in both the length and sequence of the cytoplasmic tail have been
reported to alter the fusogenic activity of the F protein (267, 366). Furthermore, deletion of the
cytoplasmic tail of PIV5 F affects fusion pore expansion (103), and F protein chimeras with
cytoplasmic tails from other paramyxoviruses also led to changes in F protein expression and
activity indicating that the correct sequence needs to be in place for fusion to occur (391).
Interestingly, truncation of the MeV H tail also alters fusogenic activity, suggesting that the
cytoplasmic tails of attachment proteins also play a regulatory role in membrane fusion (219).
Recent work on fusion peptides has also shed light on the importance of these
membrane-interacting regions in the refolding of paramyxovirus fusion proteins. Evidence to
date indicates that fusion peptides are highly conserved between paramyxoviruses and adopt an
alpha-helical structure upon contact with membranes (95). Analytical ultracentrifugation studies
have determined that fusion peptides assemble cooperatively into hexamers in a lipid
environment (95). Indeed, mutations affecting the alpha-helical nature of the peptide decrease
the efficiency of HeV F protein-promoted membrane fusion (Smith, et al, manuscript submitted
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for publication). Interestingly, alanine substitution of conserved glycine residues in the fusion
peptide of PIV5 F resulted in an increase in fusion activity and a loss of dependency on the HN
protein. However, mutations of the same glycine residues in hPIV3 F and NDV F did not allow
the fusion protein to promote fusion in the absence of the attachment protein (287).
Furthermore, mutation of the conserved glycine residues altered the expression and processing
of HeV F (Smith, et al, manuscript submitted for publication). These observations suggest that
these residues may be important in providing stability to the prefusion form and in regulating
the kinetic barrier of F protein activation.
More than serving as mere anchors for the ectodomains of paramyxovirus F proteins,
TM domains have been shown to play an important role in regulating F triggering and fusion. A
glycophosphatidylinositol (GPI) anchored influenza HA protein, another class I fusion protein,
does not promote aqueous content mixing in fusion assays, indicating that, for a class I fusion
protein, a proteinaceous TM domain is required to promote membrane fusion (165, 200).
Interestingly, membrane fusion was abolished when the TM domain of NDV F was replaced with
that of MeV F or SeV F even though these mutant proteins were transported to the cell surface
and proteolytically cleaved (128), suggesting that either the TM domain is important in
triggering, or alterations in the TM affect F ectodomain conformations, resulting in fusion
defects. Though structures of paramyxovirus fusion protein TM domains are not available,
current evidence suggests that they are composed of interacting alpha-helices (36).
Furthermore, recent sedimentation equilibrium studies showed that the TM domains of several
paramyxovirus F proteins self-associate into trimers and that mutations in the GxxxG motif of
the HeV F TM domain, known to mediate helix-helix association (286), altered this association
leading to a decrease in fusogenic activity (Smith, et. al., manuscript submitted for publication).
Interestingly, the addition of the HRB domain to the isolated HeV F TM domain destabilized the
trimeric interactions between TM domains suggesting that interactions in the head domain and
in the TM domain are important for stabilizing the prefusion coiled-coil formed by HRB (313).

Endocytosis and Viral Entry into Cells
Viruses have evolved a variety of mechanisms to gain access to host cells and ensure
their survival despite the complex protective machinery implemented by the host. In general,
after receptor binding, enveloped viruses enter the target cell either through direct penetration
at the plasma membrane or by receptor-mediated endocytosis. Endocytosis is a process utilized
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by cells to internalize molecules from the extracellular environment. Undoubtedly, the most
studied pathway is that of clathrin-dependent endocytosis (20), a process that is orchestrated by
the AP-2 complex, which, aided by Eps15, allows clathrin to form a network around an area that
invaginates and becomes a vesicle. The final formation of the clathrin-coated vesicle, however,
is dependent on the GTPase activity of dynamin (20). Influenza, VSV, and dengue virus are
among the many viruses that use this pathway for entry (81, 201, 355).
A second characterized pathway is caveolin-dependent endocytosis (204, 260), where
the small invaginations of the plasma membrane (caveolae) are rich in cholesterol, lined with
the protein caveolin-1, and regulated by cavin-1 (145, 260). While cargo uptake through this
pathway has been difficult to study due to its infrequent budding, the pathway also requires
dynamin to form the final vesicle (204, 253, 260). BK virus and echovirus-1 are examples of
viruses that have been proposed to enter in a caveolin-dependent manner (98, 201, 234).
Pathways independent of clathrin and caveolin also exist (204) and viruses like HIV and the
human papilloma virus (HPV) are hypothesized to use some of those pathways for entry (319,
357). These pathways, however, are not well understood and their players have yet to be
elucidated.
Regardless of the initial endocytic pathway used for cargo uptake, it appears that these
vesicles transport cargo into acidified endosomes (259), where cargo is subsequently sorted and
delivered to their target compartment. Much of this intracellular trafficking is regulated by Rab
GTPases (Figure 5) (326). For instance, Rab5 is required for the formation of early endosomes
while Rab7 is needed for early to late endosomal trafficking. Rab9 and Rab11 are both needed
for trafficking to the trans-Golgi network. Rab11 is also needed for recycling endosomal
trafficking (326). Many viruses need to reach different stages in the endocytic pathway before
triggering membrane fusion. HIV-1, for instance, needs Rab5 and Rab7 but not Rab11 for
infection indicating that HIV-1 likely needs to reach the late endosomal stage but not the
recycling endosomes for fusion (358). HPV-31, on the other hand, requires Rab5 but not Rab7,
which suggests that this virus escapes the endosomal pathway at an early stage (317).
A significant amount of knowledge has been obtained on the route of entry for viruses
with low-pH dependent fusion proteins such as influenza and VSV. These viruses take advantage
of the increased acidity of the endocytic pathway to trigger their fusion proteins and deliver
their genomic content to the cytoplasm of the cell (37, 81, 116, 311). Some of these viruses,
however, still require prior receptor binding to trigger fusion (221, 316). Additionally, some
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viruses like Ebola exploit the presence of cellular proteases in these low-pH environments to
activate their fusion proteins (62).
In contrast to viruses with low-pH dependent fusion proteins, viruses that have pHindependent fusion proteins such as most paramyxoviruses, herpesviruses, and retroviruses
have been thought to enter cells at the plasma membrane, where the pH is neutral (Figure 4A)
(35, 144, 179). This hypothesis is substantiated by the ability of their fusion proteins to promote
syncytium formation when expressed at the cell surface under neutral pH and by infectivity
studies in the presence of agents that prevent the acidification of endosomes (bafilomycin and
ammonium chloride among others) (203, 320). However, direct evidence of viral entry at the cell
surface has not been obtained. Indeed, low pH does not inhibit the activity of the fusion
proteins of paramyxoviruses like PIV5 (35), HeV (A. Chang and R.E. Dutch, unpublished results),
RSV (320), NDV (54, 292), and pH-independent strains of HMPV (203). Furthermore, RSV and
NDV fusion, as assessed by a R18 dequenching assay, is enhanced in acidic environments (54,
292, 320). Therefore, the pH requirement for fusion does not necessarily clarify the location of
the fusion reaction.
Recent studies suggest a more complex mechanism of cell entry for viruses with pHinsensitive fusion proteins. Using sophisticated imaging techniques, it was shown that HIV entry
occurs through a dynamin-dependent pathway and blockage of this step prevented HIV particles
from attaining complete fusion at the plasma membrane (85, 218). Furthermore, entry of HSV-1
can also occur through endocytosis in a dynamin-dependent manner (235, 277). Image
correlation spectroscopy studies showed that SeV fusion can occur in the plasma membrane or
in intracellular membranes (279). Other studies using chemical inhibitors, microscopy, and RNAimediated knockdown of proteins involved in endocytosis have shown that multiple
paramyxoviruses (54, 92, 171, 262, 298) could at least be partially using endocytic pathways to
establish infection (Figure 4B). NDV infection was significantly inhibited by agents that sequester
cholesterol, and NDV particles were found to colocalize with early endosomal markers,
suggesting that NDV may be using the caveolae-dependent endocytic pathway (54). Despite
being largely insensitive to traditional lysosomotropic agents such as bafilomycin A1 and
ammonium chloride, RSV infection was significantly decreased when clathrin light chain, AP1B1,
dynamin 3, and Rab5A among others players of the clathrin-mediated endocytosis pathway
were knocked down (171). Disruptions of the cellular endocytic and macropinocytic pathways
through chemical inhibitors and the expression of dominant negative proteins have been shown
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to inhibit NiV infection (Figure 4C) (92, 262). Furthermore, we recently reported that infection
with the low-pH dependent HMPV strain CAN97-83 was significantly inhibited by treatment with
lysosomotropic agents, with the inhibitor of clathrin-mediated endocytosis chlorpromazine, or
with the dynamin inhibitor dynasore (298). Interestingly, the extent of the effects of
lysosomotropic agents on HMPV infection appears to be strain dependent (203). Therefore,
more studies are needed to determine the exact entry pathway for most paramyxoviruses.

Glycosaminoglycans and Their Importance in Viral Infection
Most cells express a broad array of different carbohydrates which are linked to lipids
(glycolipids) or proteins (glycoproteins). These glycoconjugates have important functions
including cell adhesion, growth, and signaling (284). The glycan synthesis of glycoproteins is
based on two main processes: N-glycosylation, which consists of the addition of two molecules
of N-acetylGlucosamine (GlcNac) to the nitrogen atom of an aspargine residue, or Oglycosylation, which involves the addition of N-acetylGalactosamine (GalNac) or xylose (xyl) to
the oxygen atom of a serine or a threonine residue. O-glycosylation involving GalNac addition
leads to the synthesis of mucins, whereas xylose addition, with the exception of keratin sulfate,
leads to synthesis of glycosaminoglycans (GAGs) (273). The addition of two molecules of
galactose and one molecule of glucuronic acid to xylose forms the core on which linear chains of
disaccharides branch off to form GAGs. The disaccharide is composed of two alternate
monosaccharides: one aminosugar (usually GalNac or GlcNac) plus a molecule of glucuronic or
iduronic acid. As these GAG chains are synthesized, they undergo various degrees of
epimerization and sulfation which, coupled with variations in the lengths of the GAG chains,
result in molecules with very high degrees of structural heterogeneity (284). Due to the
extensive network of sugar residues and the high degree of sulfation of some GAG chains,
proteoglycans, proteins modified by GAGs, have a very high negative charge (273). The
biosynthesis of GAGs is very a complex process and is catalyzed by many specific enzymes both
in the Golgi as well as in the extracellular compartment (11). While GAGs are considered to be
the most complex biological polymer (246), as it is estimated that 1036 potential structures can
be formed by heparan sulfate alone (11), they can be classified into six different groups based
on their composition: heparan sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate,
hyaluran, and heparin (24, 273, 334).
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Proteoglycans can be found in intracellular granules (like serclycin, and chromogranin
A), the extracellular matrix and basement membranes (like aggrecan, versican, decorin, biglycan,
fibromodulin, and Type IV collagen), and on the cell surface (like fibroglycan, betaglycan,
thrombomodulin, CD44, NG2, and the syndecan and glypican families of proteins) (106, 190,
284). While some proteoglycans such as NG2, glypicans, and thrombomodulin are modified by
one specific type of glycan chain, others such as syndecan and serglycin contain more than one
type of GAG chain (106, 284). Additionally, some proteoglycans like CD44 and chromogranin A
exist in GAG free forms (106). The tremendous variability in proteoglycan structure and
expression allow these proteins to interact with different binding sites of different proteins
(291).
Because GAGs are expressed ubiquitously, they are frequently implicated in hostpathogen interactions. Bacteria, parasites, fungi, and viruses have all been shown to exploit
GAGs to facilitate infection (11). It is thought that many pathogens use GAGs as initial, lower
affinity attachment sites to facilitate a subsequent interaction with a higher affinity receptor
that would mediate tissue tropism and facilitate internalization (11, 284, 318). Of the many
GAG-modified proteins known, those modified with heparan sulfate (HS), or heparan sulfate
proteoglycans (HSPGs), are the ones most often implicated in virus-cell interactions. HS has
been described as a receptor for multiple herpesviruses and is also necessary during the first
step of adhesion of other viruses such as adenoviruses, HIV, dengue, several hepatitis viruses,
and influenza (reviewed in (318) and (11)). Furthermore, it has previously been shown that HS
also has an important role in the initial steps of PIV3 (42) and RSV entry, the closest related
human pathogen to HMPV (45, 131, 132, 174). This interaction, however, appears to be largely
mediated by RSV G, and viruses lacking G show a significant decrease in binding to CHO-K1 cells
(344). A recent study showed that the HMPV G protein also has the ability to bind GAGs and
suggested that this interaction might be a significant factor for virus-cell interactions (347).
Even though virus-GAG interactions are generally thought to be low-affinity and
relatively non-specific, some viruses recognize a specific HSPG as cellular receptors. It has been
shown, for instance, that HSV-1 can bind to HSPGs through its surface glycoproteins gB and gC
(182), likely facilitating the interaction between gD and HVEM, nectin-1, or nectin-2 that
promotes internalization (138). However, studies have shown that HSV-1 gD can bind directly to
3-O-sulfated HSPGs and mediate internalization (241, 308) and peptides that bind to these
HSPGs were capable of blocking HSV-1 infection in vivo (349). HSV-1 binding to HS enhances the
18

formation of filopodia which is then used by the virus for internalization (244). Furthermore, the
nonenveloped hepatitis E virus (HEV) targets primarily the HS present in syndecan-1 through the
major capsid protein pORF2 (161). Different papillomaviruses also show preferential binding to
different HSPGs (157). Thus, these studies indicate that the preference of one HSPG over
another likely results from sulfation differences between different HSPGs and suggest that, for
some viruses, attachment to HSPGs may be a more than mere nonspecific electrostatic
interactions.
Previous studies have also shown that pathogens can use GAGs as scaffolds to alter
virulence factors or to facilitate transmission and systemic dissemination. Binding of HS by the
capsid protein L1 of the papillomavirus HPV16, for instance, induces a conformational change in
the capsid protein L2 that exposes the binding site for the internalization receptor (11, 157).
Interestingly, HPV appears to bind first to basement membrane HSPGs that are exposed after
tissue injury (168). The conformational change of L2 likely involves the activity of furin and
cyclophilin B, a protein isomerase that colocalizes with HSPGs (32, 157). Additionally, viruses like
foot-and-mouth disease virus (FMDV) hijack different endocytic pathways for entry depending
whether it binds to HS or to other receptors (11, 242). It has also been shown that HIV binds to
HS in several cell types including dendritic cells, prolonging the infectivity of the virus and its
transmission to T cells (11). Thus, viruses have evolved a wide array of mechanisms to take
advantage of GAGs in their infectious lifecycle.

Integrins and Their Multiple Roles in Viral Infection
Integrins are a superfamily of cell adhesion proteins that are expressed in all cell types
and have critical roles in the regulation of cell-to-cell, cell-to-matrix adhesion, tissue growth,
differentiation, attachment, migration, thrombus formation, and apoptosis (reviewed in (15,
151)). These transmembrane heterodimers, composed of at least 18 different α and 10 different
β subunits, contain several domains important for binding to a myriad of proteins including
some HSPGs, and proteins that express the amino acid sequence Arg-Gly-Asp (RGD) (285, 338).
At least nine different α subunits contain an I or A domain, a conserved metal-ion-dependent
adhesion site (MIDAS) that, under physiological conditions, binds Mg+2 or Ca+2 and, when
present, is usually the ligand binding site (328). The binding site of integrins that lack the I
domain is typically formed by the β-propeller domain of the α subunit and the I domain of the β
subunit and recognizes RGD peptides. Some integrins are known to be promiscuous and bind a
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variety of ligands like laminin, collagen, connective tissue growth factor, fibrillin, ICAM-4, L1,
HSPGs, ADAM family members, and those with LDV and SVVYGLR motifs (150). Structural details
of many of these interactions, including the binding sites in integrins, remain to be elucidated.
In addition to mediating cell attachment to the extracellular matrix, integrins also serve
an important role by conveying signals from the outside to the inside of cells and vice versa (61,
328). This is achieved through interactions between the cytoplasmic domains of the α and β
integrin subunits with a variety of intracellular proteins including kinases and cytoskeletal
proteins like talin. Importantly, it has been shown that integrins play an important role in the
regulation of cell signaling through receptor-mediated endocytosis and the recycling of many
surface proteins. Integrins α5β1, for instance, can retain phosphorylated caveolin-1 in focal
adhesions, inhibiting lipid raft endocytosis and keeping active Rac at the surface of adherent
cells. Upon cell detachment, phosphorylated caveolin-1 is recruited to lipid rafts and
endocytosis ensues (88).
It has been shown that integrin heterodimers are endocytosed by clathrin-dependent
and clathrin-independent pathways including caveolin-dependent endocytosis (61). The integrin
β subunits contain a conserved NXXY motif in their cytoplasmic tails, which is known to interact
with endocytic adaptor proteins like AP2 in clathrin-coated pits (61). It is, however, likely that
integrins can enter cells through several endocytic pathways as both clathrin and caveolar
uptake of α5β1 and αvβ3 integrins has been documented (61). Following endocytosis, integrins
travel to the early endosomes and are usually recycled to the plasma membrane in a Rab4and/or Rab11-dependent route (61). The internalization and recycling of integrins also allows
them to direct the traffic of receptors and other cargo through the several intracellular
compartments. Thus, it has been shown that integrins regulate the recycling and degradation of
receptor tyrosine kinases like VEGFR2 (281) and EGFR1 (60). The presence of αvβ3 blocking
agents, for instance, promotes the recycling of VEGFR2, rescuing it from its usual rapid
internalization and degradation (281). Thus, ligand association with integrins can initiate
multiple signaling events that facilitate cellular uptake and dictate the trafficking pathway of the
ligand.
Given the importance of integrins in signaling, their promiscuity in ligand binding, and
their broad distribution on cell surfaces of many cell types, it is not surprising that several
viruses have evolved to take advantage integrins for infection. Indeed, studies indicate that
integrins are receptors for some picornaviruses, papillomaviruses, adenoviruses, and
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hantaviruses (194, 222, 328). Certain strains of adenoviruses can use αv integrins in the absence
of their primary receptor coxsackie adenovirus receptor (CAR) (194, 278). Interestingly, while
the picornavirus echovirus-1 recognizes the human α2β1 integrin as its receptor, the virus is also
able to infect cells and rodents expressing human α2 and rodent β1 integrin but cannot infect
cells expressing either the rodent α2 subunit or other β1 integrins (21, 140, 149). Furthermore,
pathogenic strains of hantaviruses bind to the inactive conformation of β3 coupled either to an
αIIb or an αV subunit in an RGD-independent manner (328). Thus, even though integrins are
expressed as heterodimers, in many cases a certain integrin subunit seems to play a more
prominent role in viral cell invasion. The integrin that a particular virus recognizes can also be a
determinant for the pathogenicity of the virus. Pathogenic strains of hantaviruses, for instance,
recognize β3 integrins as their receptors while nonpathogenic strains recognize β1 integrins
(122, 328).
In addition to using integrins as initial cellular receptors, studies have shown that many
viruses including adeno-associated virus, ebola virus, β and γ herpesviruses, reoviruses, and,
more recently, paramyxoviruses exploit integrin signaling and trafficking processes for cell entry
and infection (80, 84, 222, 297, 328). Proper regulation of expression and activity of endosomal
cathepsins by integrins, for instance, is required for ebola virus infection (297). Furthermore,
after initially binding to CAR (22) or CD46 (119), several adenoviruses interact through a RGD
loop on the viral surface with αv and β1 integrins for internalization by clathrin-mediated
endocytosis (373). Through the activation of focal adhesion kinase (FAK) and phosphoinositide
3-kinase (PI3K), the interaction of adenovirus with integrins also promotes actin polymerization
and increases the survival of the host cell, facilitating viral internalization and the production of
progeny virions (328). Rotaviruses and other reoviruses also associate with integrins after
cellular attachment to promote internalization (84, 328).
Integrins also play an important role in host cell invasion for enveloped viruses. While
human cytomegalovirus (CMV) and Kaposi’s sarcoma virus (HHV-8 or KSHV), both members of
the herpesvirus family binds to host cells via association with HSPGs, efficient cell entry and
infection requires interactions between the viral gB protein and integrins, particularly β1 and β3
(7, 114). Interestingly, studies indicate that CMV interacts with integrins through a RX6-8DLXXF
motif present in the gB protein (114) and also through a RGD motif in the gH protein (365),
suggesting that viruses can use different proteins and different motifs to interact with integrins.
Interactions with integrins have also been shown to be important for efficient infection by other
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enveloped viruses such as members of the retrovirus (69) and togavirus (177) families. While
very little is known about integrin interactions with members of the paramyxovirus family, it has
recently been reported the αvβ1 integrin is a major component for HMPV infection (80).

Dissertation Overview
HMPV is a recently discovered paramyxoviruses that causes widespread disease
worldwide. Despite the relevance of this virus to human health, very little is known about the
infectious cycle of the virus. Therefore, the goal of this dissertation was to add knowledge about
the attachment and fusion steps in the viral entry cycle of HMPV. A few reports have provided
information about the lifecycle of the virus and the mechanism that HMPV uses for cell entry.
These studies, nonetheless, highlighted the uniqueness of this respiratory pathogen compared
to other members of the family. Indeed, studies have shown that the fusion protein needs an
exogenous protease for proteolytic activation in vitro (352), can be triggered at low pH (299),
and viruses devoid of the other putative surface glycoproteins besides F remain infectious (31).
At the time I started my studies, the mechanism by which low pH triggers HMPV F and the
implication of low pH triggering on entry was being studied by Dr. Rachel Schowalter. She
identified a histidine residue at position 435 in the HMPV F protein to be important for low pHmediated fusion and we worked together to complete the work showing initial data that HMPV
infection requires a low pH environment in cells and that entry requires the activity of dynamin,
a protein that is required for the formation of endocytic vesicles (298). This work led us to
hypothesize that HMPV entry occurs through endocytosis and that protonation of H435 under
acidic environments was responsible for the triggering of HMPV F. I performed more studies
with mutants at position H435 to test whether the presence of a constant positive charge at this
position could rescue the fusogenic activity of the protein at neutral pH. My results indicate that
a positive charge at this position is required but not sufficient for low pH-mediated fusion and
that substitution with residues bearing negative charges abolished fusion. The inability to rescue
fusion activity by placing a positive charge at position 435 suggested that changes at more than
one site are required for low pH triggering. Thus, with the help of Brent Hackett, a second area
with a high concentration of charged residues located between the HRA domain and the F2
portion of the F protein was identified. Studies with HMPV F proteins carrying mutations in this
region showed that electrostatic interactions across different regions of the protein play
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important roles in stabilizing the metastable prefusion form and in allowing for proper folding
and triggering of HMPV F.
In order for viral infection to occur, the virus must first bind to a cellular receptor to gain
entry into cells. Before my studies began, the receptor for HMPV was not known and, in
collaboration with Dr. Cyril Masante, we developed techniques to assess viral binding and
infection in different cell types in the hopes of identifying the receptor(s) and the cellular factors
that mediate the initial attachment of the virus to cells. Shortly after our studies began, a report
was published showing an important role for the integrin αvβ1 in promoting HMPV infection
(80). My studies indicate that interactions between the RGD motif of HMPV F and β1 integrins
are not essential for fusion activity. Furthermore, we learned that HMPV binding and infection
was greatly dependent on the presence of GAGs in the target cell surface. Through enzymatic
cleavage of different GAGs and studies with cells carrying different mutations that prevented
them from synthesizing certain GAGs, we discovered that heparan sulfate was the GAG required
for HMPV infection. The use of recombinant viruses lacking the G and SH proteins allowed us to
confirm that the initial interaction between GAGs and the virus is mediated by the F protein. Our
studies therefore conclude that the initial binding of HMPV to cells is mediated by an interaction
between HSPGs present in the cell surface and the HMPV F protein. We hypothesize that
integrins play an important role to promote efficient infection at a step downstream of the
initial binding to HSPGs. The work presented here is an important step forward in our
understanding of the lifecycle of this important human pathogen. Further investigations on the
early events leading to HMPV infection will provide valuable information that could be
translated into the development of therapeutics.
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Figure 1. Paramyxovirus family and structural organization of the virus (64).
A. Classification of representative members of the paramyxovirus family. B. Schematic of a
paramyxovirus. Genomic RNA is wrapped by nucleocapsid core proteins (brown), which are
connected to the viral envelope (red) by the matrix protein (blue). The attachment (green),
small hydrophobic (present only in certain paramyxoviruses, orange), and fusion proteins (cyan)
are depicted at the virus surface.
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Figure 2. Paramyxovirus fusion protein: structure and triggering (64).
A. Schematic of the cleaved, disulfide-linked paramyxovirus fusion protein. B. Structure of the
uncleaved form of PIV5 F in its prefusion conformation (384) and structure of the hPIV3 F in its
postfusion conformation (383). C. Schematic of the different models of paramyxovirus
triggering. (a) The attachment and F proteins could interact while trafficking through the
different biosynthetic compartments and dissociate upon receptor interaction with the
attachment protein, allowing the F protein to trigger. (b) Alternatively, the attachment and F
proteins could travel separately through the biosynthetic pathway, associate at the cell surface,
and dissociate after attachment protein interaction with receptor, triggering the F protein. (c)
The attachment and F proteins could also travel separately and not associate until the
attachment protein interacts with its receptor. The association between the attachment protein
and the F protein allows the latter to trigger. (d) Direct interaction between the attachment and
F proteins may not be required for some viruses as receptor binding by the attachment protein
could facilitate binding of another receptor (illustrated as a brown pentagon) by the F protein,
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allowing the F protein to trigger. (e) Finally, some paramyxoviruses do not require the
expression of an attachment protein. For these viruses, the F protein binds to its receptor and
then promotes membrane fusion, which in some cases can be triggered by low pH. For all
images, the fusion peptide is represented in blue, heptad repeat A (HRA) in orange, heptad
repeat B (HRB) in green, the transmembrane (TM) domain in red, and brown represents the
cytoplasmic tail.
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Figure 3. Schematic of membrane fusion mediated by paramyxovirus fusion proteins (64).
After the prefusion form of the fusion protein A. is triggered, the coiled-coil HRB domain melts
leading to the formation of the open stalk form B. The FP is then projected towards the target
membrane and HRA refolds to a trimeric coiled coil (pre-hairpin intermediate, C. HRB then
translocates toward HRA, forcing the viral membrane and the target membrane into a
hemifusion state D. The complete refolding of HRB around HRA forms the stable 6HB and allows
for the formation of the fusion pore E. Blue: FP, Orange: HRA, Green: HRB, Red: TM.
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Figure 4. Schematic of different pathways of viral entry (64).
A. Viral-cell membrane fusion of pH-independent viruses could occur at the plasma membrane
under neutral pH after binding to receptor. B. A viral particle could enter the cell through an
endocytic pathway after receptor binding. Viral-cell membrane fusion could then occur in an
intracellular compartment. Low pH may or may not be required for membrane fusion to occur.
C. Viruses could enter cells through macropinocytosis, where the viral particle is engulfed by the
cell after receptor binding. Fusion between the viral and cellular membranes would then take
place at an intracellular compartment.
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Figure 5. Representation of intracellular trafficking pathways and selected Rab GTPases.
Rab 5 controls cargo delivery to the early endosome (EE) and recycling endosome (RE) while Rab
7 is responsible for delivering cargo from the EE to the late endosomal (LE) and lysosomal
compartments. Rab 11 is required for cargo recycling and transport to the trans-Golgi network
(TGN).
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Chapter 2: Materials and Methods

Cell Lines
Vero, BSR T7/5 (provided by Karl-Klaus Conzelmann, Max Pettenkofer Institut) (51),
GD25 and β1GD25 cells (provided by Deane Mosher, University of Wisconsin, Madison, WI)
(367), MEF cells (provided by Terence Dermody, Vanderbilt University, Nashville, TN), and HeLa
cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco Invitrogen, Carlsbad,
CA), supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA)
and 1% penicillin and streptomycin (P/S, Invitrogen). CHO-K1, pgsA745 (108) and Lec1 (322),
which were obtained from ATCC, IdIDLec1 (107, 321), which were derived from ldlD cells (169)
(provided by Craig Vander Kooi, University of Kentucky), and pgsD677 cells (192) (provided by
Jeff Esko, University of California, San Diego, CA) were grown in HyClone Ham’s F-12, Kaighn’s
Modification Medium (Thermo Scientific, Waltham, MA) supplemented with 10% FBS and 1%
P/S. A-549 cells (provided by Tianyan Gao, University of Kentucky) were grown in RPMI-1640
media supplemented with 10% FBS and 1% P/S. BEAS-2B cells (obtained from ATCC) were grown
in BEBM media supplemented with the supplied additives (Lonza, Walkersville, MD) and plated
in flasks and dishes precoated with a mixture of 10µg/mL fibronectin from human plasma
(Sigma, Saint Louis, MO), 30µg/mL bovine collagen type I (Invitrogen), and 10µg/mL bovine
serum albumin (Sigma). BSR cells were selected for T7 polymerase-expressing cells every third
passage with 0.5 mg/ml G-418 sulfate (Gibco Invitrogen). The media of β1GD25 cells was
supplemented with 10µg/mL puromycin (Gibco Invitrogen) every third passage to select for the
β1-expressing cells.

Plasmids and Antibodies
The HMPV F gene within the pGEM-3Zf(+) vector was provided by Ursula J. Buchholz and
Peter Collins (NIAID, Bethesda, MD) with permission from Dr. Guy Boivin (Centre Hospitalier
Universitaire de Québec, Quebec City, Quebec, Canada). The HMPV F H435R, H435K, H435D,
H435E, D331A (F RGA), E51A, D54A, E56A, R163A, R166A, E51K, E51K/H435R, D54A/E56A,
D54A/E56A/H435R, D54A/H435R, E56A/H435R, D54N/E56Q, and D54N/E56Q/H435R protein
mutants were created using QuikChange site-directed mutagenesis (Stratagene, La Jolla, CA).
The HMPV F wild type (WT) and mutant genes were released from pGEM-3Zf(+) and ligated into
the pCAGGS mammalian expression vector following digestion with EcoR1 and Sph1. All mutants
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were sequenced in their entirety after ligation. The wild type and K44A dominant negative
mutant dynamin-2 fused with mCherry plasmid was a generous gift from Gregory Melikyan
(Emory University, Atlanta, GA) (218). The wild type and the GTP-bound constitutively active
Rab5a Q79L mutant fused with mRFP plasmid was a generous gift from Emilia Galperin
(University of Kentucky, Lexington, KY).
Antipeptide antibodies against HMPV F (Genemed Synthesis, San Francisco, CA) were
generated using amino acids 524-538 of HMPV F. The monoclonal antibody 23H12 against VSV
M was a generous gift from Michael Whitt (University of Tennessee Health Science Center,
Memphis, TN) (188). 9EG7 anti-mouse-β1-integrin was purchased from BD-Pharmigen (San
Diego, CA). MAB2021Z anti-αv-integrin was purchased from Milipore (Billerica, MA). NBP121631 anti-HMPV N monoclonal antibody was purchased from Novus Biologicals (Littleton, CO).
R4654 anti-Rab5 and R4779 anti-Rab 7 polyclonal antibodies were purchased from Sigma. Antiheparan sulfate 10E4 antibody was purchased from US Biologicals (Swampscott, MA). Goat antimouse DyLight649 secondary antibody was purchased from KPL Inc. (Gaithersburg, MD).

Generation of GFP-tagged HMPV G and HMPV M
The HMPV G gene was amplified by PCR from the HMPV G-pCAGGS plasmid using
primers that contain 5’ BglII and EcoR1 and 3’ Kpn1 and BamH1 restriction sites
(AAAAGATCTGAATTCTATGGAGGTGAAAGTAGAG and TTTTGGATCCGGTACCGCGTTTTGCATTGTG
for C-terminal tagging of HMPV G; AAAAGATCTGAATTCAATATGGAGGTGAAAGTAGAG and
TTTGGATCCGGTACCCTAGTTTTGCATTGTG for N-terminal tagging of HMPV G). The resulting DNA
fragments were digested with EcoR1 and Kpn1-HF (New England Biolabs, Ipswich, MA) and
ligated into pEGFP-C1 or pEGFP-N1 (for N- and C-terminal tagging respectively) plasmid.
The HMPV M gene was amplified by RT-PCR from the HMPV genome using primers
containing 5’ BamH1 and 3’ NheI restriction sites (TATATAGGATCCGAGTCCTATCTGGTAGACACC
and TATATAGCTAGCTTATCTGGACTTCAGCACATATCTTGTTCC). The resulting DNA fragment was
digested with BamH1 and Nhe1 and ligated onto pEGFP-C1 plasmid. Inserts were sequenced and
GFP expression was confirmed by microscopy following transfection of Vero cells with these
plasmids.
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Viruses
Recombinant, GFP-expressing HMPV (rgHMPV) strain CAN97-83 (genotype group A2)
and the mutant viruses HMPV ΔG and HMPV ΔG/ΔSH with a codon stabilized SH gene (25) were
kindly provided by Peter L. Collins and Ursula J. Buchholz (NIAID, Bethesda, MD). Recombinant
WT, ΔG, and ΔG/ΔSH HMPV were propagated in Vero cells (starting MOI of 0.01 to 0.03)
incubated at 32˚C with Opti-MEM, 200 mM L-glutamine, and 0.3 μg/ml TPCK-trypsin replenished
every day. On the seventh day, cells and media were collected and frozen at -80°C. The viruscontaining suspension was thawed at 37°C the next day and subjected to centrifugation at 2500
g for 20 min at 4°C on a Sorvall RT7 tabletop centrifuge. The supernatant was then subjected to
centrifugation on a 20% sucrose cushion for 2 hours and fifteen minutes at 27,000 x g 4°C using
a SW28 swinging bucket rotor on a Beckman Optima L90-K ultracentrifuge. The resulting pellet
was resuspended in 300 µL of Opti-MEM and left at 4°C overnight. Aliquots of the samples were
made the next morning and stored at -80°C. Recombinant GFP‐expressing HMPV with the F
protein mutations K295A, R396A, H435A, H435N, and K438A were generated from cDNA. First,
adapters containing the HMPV G-F and F-M2 intergenic regions were added to the specific
mutant HMPV F genes by PCR; PCR fragments were cloned into pCAGGS and sequenced. Then, a
1653 bp NheI/PacI DNA fragment containing the wild type HMPV F gene was removed from the
pgHMPV full length cDNA plasmid, and replaced by the individual mutant HMPV F genes.
Recombinant GFP-expressing HMPV with mutant F genes were recovered from cDNA as
described previously (6). rgHMPV with F protein mutations K295A, R396A, H435A, H435R, and
K438A were propagated under the same conditions as wild type virus; virus stocks were
harvested either when cell death became prominent or when GFP expression was seen in all
cells. Mutant viruses were either harvested as described above or by addition of SPG (218 mM
sucrose, 0.0049 M L-glutamic acid, 0.0038 M KH2PO4, 0.0072 M K2HPO4) from a 10X solution
after collecting the cells and media. Aliquots of viruses in SPG solution were then made, frozen
in dry ice/methanol, and thawed twice before storage at -80°C.
Recombinant GFP-expressing PIV5 was kindly provided by Robert Lamb (Howard Hughes
Medical Institute, Northwestern University) and Jessica Robach (Northwestern University,
Evanston, IL). GFP was inserted between the P/V and M genes with a duplicate of the EIS
(End/Intergenic/Start) sequence that precedes M. PIV5 was propagated in MDBK cells as
described (254) and stored in 1 x SPG. Aliquots were frozen in a dry ice/methanol mix and
thawed twice prior to storage at -80˚C. Recombinant VSV, kindly provided by Michael A. Whitt
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(University of Tennessee Health Science Center, Memphis, TN) in which the G envelope gene
was replaced with the GFP gene and pseudotyped with the VSV G glycoprotein was propagated
as previously described (337).

Virus Titering
Viral titers were determined by titration of the viral samples on either a 24-well or a 96well plate and counting the number of GFP-expressing cells the following day. For non-GFP
expressing viruses, (rHMPV), a control rgHMPV was used as a reference. Five hundred thousand
Vero cells plated the day before were infected with the nonfluorescent virus and control
rgHMPV by serial dilution. Infected cells were suspended the following day, fixed in 4%
formaldehyde, permeabilized in 0.02% Triton X-100 at 4°C, and labeled with 70µL of anti-HMPV
N antibody for 90 minutes after resuspending the cells in 70µL FBS. Samples were analyzed by
FACS following incubation with a DyLight649-conjugated goat anti-mouse secondary antibody.
The ratio of rHMPV to rgHMPV at the same dilution was used to calculate the titer for the nonGFP expressing HMPV.

Syncytia Assay in Transfected Cells
Subconfluent monolayers of Vero cells plated in 6-well plates were transiently
transfected with a total of 0.5 µg of DNA consisting of pCAGGS-HMPV F WT, F protein mutant, or
the empty pCAGGS vector (control) using Lipofectamine and Plus reagents (Invitrogen)
according to the manufacturer’s instructions. The next morning, confluent cell monolayers were
washed twice with phosphate saline buffer (PBS) and incubated at 37˚C in 1 mL Opti-MEM with
0.3 µg/ml TPCK-trypsin for 1.5 hours. Afterwards, cells were rinsed once with PBS (pH 7.3)
before adding 1 mL of PBS of the indicated pH buffered with 10 mM HEPES and 10 mM MES.
Cells were incubated for 4 minutes at 37˚C under the indicated pH conditions. Media (1 mL OptiMEM with 0.3µg/ml TPCK-trypsin) was replaced and cells were incubated at 32°C until the next
pH pulse. The pH pulse was repeated for a total of four times (2-3 hours apart) throughout the
day and cells were incubated overnight at 32˚C in order to allow final cellular rearrangements to
take place. Digital photographs of syncytia were taken the next morning with a Spot Insight
Firewire digital camera mounted on a Carl-Zeiss Axiovert 100 inverted microscope using a 10x
objective (Thornwood, NY).
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Reporter Gene Fusion Assay
Vero cells in 60-millimeter dishes were transfected with 0.55 μg pCAGGS- HMPV F wildtype or mutant F protein and 0.55 μg T7 plasmid containing luciferase cDNA under control of the
T7 promoter (Promega, Madison, WI) using Lipofectamine and Plus reagents (Invitrogen)
according to the manufacturer’s instructions. The following day, Vero cells in one 60-millimeter
dish were lifted from the plate surface with 1 mL of trypsin, resuspended in 2 mL of DMEM plus
10% FBS and 1% P/S, and subjected to centrifugation at 400 x g, 4°C in a Sorval RT7 tabletop
centrifuge for 5 minutes. Pelleted cells were resuspended in 2 mL of DMEM plus 10% FBS and
1% P/S and overlaid onto two 35-millimeter dishes of confluent BSR T7/5 cells, which
constitutively express the T7 polymerase (1 mL of Vero cells per 35-millimeter dish). Cells were
incubated at 32°C for 1.5 hours to allow Vero cells to attach. Afterwards, cells were rinsed once
with PBS before adding 1 mL of PBS of the indicated pH (one 35-millimeter dish per pH) buffered
with 10 mM HEPES and 10 mM MES and incubated for 4 minutes at 37˚C. Buffered PBS was
replaced by 1 mL of Opti-MEM with 0.3 µg/ml TPCK-trypsin after the pH pulse and cells were
incubated at 37˚C for one hour. Treatment with low pH was repeated one more time and cells
were incubated afterwards in 2 mL DMEM plus 10% FBS and 1% P/S at 37°C for 4 hours to allow
for luciferase production. Finally, cell lysates were analyzed for luciferase activity using a
luciferase assay system (Promega) according to manufacturer’s protocol. Light emission was
measured using an Lmax luminometer (Molecular Devices, Sunnyvale, CA) for five seconds with
a 1.6 second delay between each measurement. Student-T tests or ANOVA tests were used to
determine statistically significant differences.

Expression, Metabolic Labeling, and Biotinylation of Surface Proteins
Cells in sixty-millimeter dishes were transfected with 1.10 µg pCAGGS-HMPV F wildtype, mutants, or empty pCAGGS as control using Lipofectamine and Plus reagents (Invitrogen)
according to manufacturers’ protocol. At 18-24 h post-transfection, cells were starved in
methionine- and cysteine-deficient DMEM for 1 hour and then metabolically labeled with media
containing Tran[35S] label (100 μCi/ml; Perkin Elmer, Waltham, MA) and 0.3 μg/ml TPCK-trypsin
for 4 hrs. Following radiolabeling, cells were washed three times with ice-cold pH 8 PBS and
incubated with 1 mg/ml EZ-Link Sulfo-NHS-Biotin (Pierce, Rockford, IL) diluted in pH 8 PBS for 30
min rocking at 4˚C, then 20 min at room temperature. Cells were washed three times again with
pH 8 PBS and then lysed in 1 mL RIPA buffer containing 100 mM Tris-HCl (pH 7.4), 150 mM NaCl,
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0.1% sodium dodecyl sulfate (SDS), 1% Triton X-100, 1% deoxycholic acid, protease inhibitors (1
KalliKrein inhibitory unit of aprotinin [Calbiochem, San Diego, CA], 1 mM phenylmethylsulfonyl
fluoride [Sigma]), and 25 mM iodoacetamide (Sigma). The lysates were subjected to
centrifugation at 136,500 × g for 15 minutes at 4°C. The supernatants were collected and the F
proteins were immunoprecipitated using 6 µL anti-HMPV F polyclonal antibody followed by
30µL of protein A-conjugated sepharose beads (Amersham, Piscataway, NJ) as previously
described (254). Immunoprecipitated protein was released from the beads by boiling using a
total of 100µL of 10% SDS (40µL for first boil and 60µL for second boil). Fifteen percent of total
protein collected was removed for total expression analysis and the remaining 85% was diluted
in 500µL biotinylation dilution buffer (20 mM pH 8 Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1%
Triton X-100, 0.2% bovine serum albumin) and incubated with immobilized streptavidin (Pierce)
for 1 hour at 4°C. Samples were washed, resolved by SDS-15% polyacrylamide gel
electrophoresis (SDS-PAGE), and visualized using the Typhoon imaging system (GE Healthcare,
Waukesha, WI) after 7 – 10 days of exposure to a phosphor screen. The intensities of the bands
were obtained using ImageQuant software, background corrected, and normalized to
expression of HMPV F WT. Student-T tests or ANOVA tests were used to determine statistically
significant differences.

Flow Cytometry Analysis of rgHMPV Infection
One hundred thousand cells plated in a 24-well plate the day before (except for
β1GD25, for which 50 thousand cells were plated instead to account for the difference in growth
rate) were infected with different multiplicities of infection (MOI) of rgHMPV diluted to a final
volume of 200µL/well. The cells were exposed to the virus for a total of 4 hours at 37°C.
Following an overnight incubation, cells were resuspended, fixed in 1% formaldehyde diluted in
PBS with 50mM EDTA, and analyzed either with a BD FACSCalibur or a BD LSR II flow cytometer
(BD, Franklin Lakes, NJ) for which GFP expression and intensity of at least 10,000 cells were
determined. Data analysis was performed using FCS Express V3 (De Novo Software, Los Angeles,
CA), and data presented in graphs represent the percentage of GFP-expressing cells in the total
percentage population or as a percentage of control. Student-T tests or ANOVA tests were used
to determine statistically significant differences.
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ELISA for HMPV Binding
Varying amounts of rHMPV were added to a confluent monolayer of cells plated in a 96well plate at 4°C and spinoculated at 1000 x g, 4°C in a Beckman Coulter Allegra X-15R (Brea, CA)
tabletop centrifuge for one hour to allow virus binding. Immediately after binding, cells were
thoroughly washed with ice-cold PBS, fixed with 4% paraformaldehyde, and permeabilized with
1% Triton X-100 at 4°C. Following fixing and permeabilization, cells were blocked in 1% normal
goat serum for 1 hour and blotted with 50µL of mouse anti-HMPV N monoclonal antibody
diluted 1:1500 for 1 hour. Cells were thoroughly washed with PBS and then blotted with 50µL of
HRP-conjugated goat anti-mouse monoclonal antibody diluted 1:500 for 1 hour. Cells were
thoroughly washed with PBS and assayed using a TMB 2-component microwell peroxidase
substrate kit (KPL Inc.) according to manufacturer’s protocol. Absorbance of each well was read
at 460nm using a µQuant microplate reader (Bio-Tek Instruments Inc., Winooski, VT) and values
normalized to the number of cells in a well which was obtained using a Beckman Coulter Z1
Coulter Particle Counter. Student-T tests or ANOVA tests were used to determine statistically
significant differences.

Western Blot Binding Assay
A constant number of cells (4x104 for β1GD25 and 6x104 for the other cell types to
account for differences in growth rate) were plated in a 24-well plate and exposed to rHMPV,
ΔG, or ΔG/ΔSH HMPV at an MOI of 10, 15, or 100 for 1.5 hours at 4°C to prevent internalization.
Cells were lysed in 45 µL of 20 mM Tris pH 7.9, 0.15 M NaCl, 1 mM Na2HPO4, 1 mM PMSF, 0.5 %
sodium deoxycholate, and 0.5% NP-40. The lysate was collected and subjected to centrifugation
at 14,000 x g for 10 mins. The supernatant was transferred to a tube containing 6 µL of 6X
loading buffer and a volume corresponding to 6 x 104 cells were loaded onto a 10% SDS-PAGE
gel. The proteins were transferred onto a PVDF membrane and the membrane was blocked at
4°C overnight in TBS containing 5% milk, 0.02% sodium azide, and 0.05% Tween 20. The gel was
analyzed using a rabbit anti-HMPV F antiserum followed by a IRDye680 conjugated goat antirabbit antibody and visualized using the Odyssey Infrared Imagining System (Li-Cor
Biotechnology, Lincoln, NE). Signal intensities were quantified using the Odyssey Application
Software, corrected for background, and normalized to WT binding to Vero cells. Student-T tests
or ANOVA tests were used to determine statistically significant differences.
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Protease Treatment
Cells plated the day before (2.4 x 105 cells for trypsin treatment and 6 x 105 for
proteinase K treatment) were resuspended with 50 mM PBS EDTA (pH 8) and treated with
different concentrations of trypsin for 10 minutes or 1.25% trypsin combined with 90 µL of FBS
as control (0% trypsin). Following trypsin neutralization by addition of 90µL of FBS, the cells
were transferred into a 15 mL conical tube, washed with 13 mL PBS, and exposed to virus
(rgPIV5 at an MOI of 20, and rgHMPV at an MOI of 5) for 1 hour at 4°C. Cells were then washed
with 14 mL PBS and plated in 35 mm dishes. The cells were detached the following day, fixed in
1% formaldehyde, and analyzed by flow cytometry. For proteinase K treatment, cells were
detached from the plate either with 2.5 mM EDTA PBS (pH8) or with 300 µL of 300 µg/mL
proteinase K in TBS 3 mM CaI2. For control cells (0 µg/mL proteinase K), 1 mL of PBS 2.5 mM
EDTA/1% phenylmethylsulfonyl fluoride (PMSF) and 300 µL of 300 µg/mL proteinase K were
added simultaneously. Proteinase K was neutralized by the addition of 1% PMSF before being
exposed to virus (at an MOI of 10, 50, and 50 for HMPV, PIV5, and VSV G* ΔG respectively). Cells
were incubated with the virus for 45 minutes at 4°C before being plated in a 12-well plate
overnight. The cells were detached, fixed in 1% formaldehyde, and analyzed by flow cytometry
the following day. Student-T tests or ANOVA tests were used to determine statistically
significant differences.

Heparinase Treatment
Cells plated the day before were treated with 2mIU/mL of heparinase 1, heparinase 3,
both (Sigma), or 20mIU/mL chondroitinase ABC as control for 1 hour at 37°C followed by the
standard protocol for binding or infection assays (described above).

Homology Modeling
A model of the prefusion conformation of the HMPV F protein from the molecular
coordinates (mmdbId: 37132) determined from the crystal structure of the prefusion form of
PIV5 F (384) was generated using DeepView/Swiss-PdbViewer v4.0.1 (www.expasy.org/spdbv/).
The HMPV F sequence was loaded and fitted to model each monomer of PIV5 F. The modeled
HMPV F monomers were merged, and structure was energy minimized with 100 steps of
steepest descent. For the postfusion HMPV F protein model, the F1 and F2 sequences of HMPV
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F were loaded to model the F1 and F2 domains of each NDV F monomer (mmdbId: 82359) (336),
fitted onto the structure, and then merged.

Isolation of Cell Surface Proteins for Receptor Identification
Cell surface proteins of different cell types were isolated using the Biotinylation Kit from
Pierce (Cat. 89881) according to manufacturer’s protocol. Briefly, the surface proteins of cells
from four T-75 flasks were biotinylated at 4˚C for 30 minutes. Cells were then transferred to a 50
mL conical tube and lysed in the presence of protease inhibitors. Complete lysis was achieved by
sonicating the samples with five 1-second bursts at low power followed by a 30-min incubation
on ice with occasional vortexing. The lysates were subjected to centrifugation at 10,000 x g for 2
mins at 4˚C and the clarified lysates were transferred to a capped column with 500 µL of
resuspended neutravidin beads previously washed with the supplied wash buffer. The lysates
were incubated for 1 hr at room temperature in a rotator. The samples were washed and then
incubated in a rotator for 1 hr at room temperature in 400 µL of SDS sample buffer
supplemented with DTT and without bromophenol blue. A280 readings were performed on each
sample following collection and then stored at -20˚C.

Virus Overlay Protein Binding Assay
Thirty microliters of isolated cells surface proteins were heated at 70˚C for 15 mins and
subjected to centrifugation at 2000 x g for 5 mins. Two sets of 15 µL sample/well were loaded
symmetrically into a 4-12 % NuPage Bis-Tris gel (Invitrogen) and migrated at 200 V for 40 mins.
One sample set was fixed with 50 % methanol and 10 % acetic acid for 30 mins, washed, and
stored at 4˚C in 10 mM Tris pH 8.8. The other sample set was transferred onto a PDVF
membrane, blocked with 5 % milk dissolved in TBS for 1 hour at room temperature, and
incubated with 1.6 x 107 PFU of rgHMPV diluted in 2 mL of 2.5 % milk in TBS for 4 hours. The
PDVF membrane was washed twice with TBS and one more time with t-TBS to permeabilize the
viral membrane before an overnight incubation at 4˚C with an anti-HMPV F polyclonal antibody
diluted 1:1000 in 2.5 % milk. The sample was then washed and incubated for 2 hours at 4˚C in
goat anti-rabbit conjugated with IRDye700 and developed using the Odyssey (Licor). The image
was placed under a glass plate and the fixed gel was aligned on top of the glass to excise the
bands of interest. The protein content of the samples of interest were determined by mass
spectrometry by the University of Kentucky Proteomics core.
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Immunofluorescence
Vero cells grown in coverslips transfected with either WT or DN forms of dynamin or
Rab5 fused with mCherry and mRFP respectively were infected with either rgHMPV or PIV5 for
three hours. Following an overnight incubation, cells were fixed with 4 % paraformaldehyde at
4˚C for 15 mins and mounted on slides with Vectashield + DAPI. Cell imaging was performed
using a 20X objective on a Nikon A1 spinning disk confocal microscope. For viral particle
colocalization studies, HMPV or VSV were bound to Vero cells grown in coverslips at 4˚C for 1 hr.
After extensive washing, cells were either incubated in media prewarmed to 37˚C for 5 mins to
allow viral entry before fixing or fixed right away (t = 0 mins) and then stained with Alexa Fluor
647-conjugated wheat germ agglutinin (Invitrogen) according to manufacturer’s protocol. Cells
were then permeabilized with 0.05 % Tween-20 in PBS for 10 mins at room temperature and
blocked with 4 % normal goat serum diluted in PBS supplemented with 0.02 % sodium azide
(PBSN) for 1 hr at room temperature and incubated overnight at 4˚C with primary antibodies
against EEA-1, Rab5, Rab7, or HS and HMPV N or HMPV F in a humidified chamber. Cells were
washed five times with PBSN the following morning, incubated in secondary antibodies (goat
anti-mouse and goat anti-rabbit) for 3 hours, and mounted on slides with Vectashield + DAPI.
Cell imaging was performed using a 60X objective on a Nikon A1 spinning disk confocal
microscope.

siRNA Electroporation
A549 cells were resuspended at a concentration of 3 x 106 cells / 400 µL in RPMI media,
transferred to an electroporation cuvette (Biorad, Hercules, CA), and incubated with 200mM
siRNA (purchased from Sigma) at room temperature for 10 mins. Cells were subjected to
electroporation in a Gene Pulser Xcell System (Biorad) at 400 V and 500 µF capacitance,
incubated for 10 mins at room temperature, and diluted by adding 600 µL of RPMI media
supplemented with 10 % FBS and 1 % P/S. Cells were then plated in 24- or 6-well plates (40 µL or
150 µL of cells per well respectively) and incubated at 37˚C for 72 hours before assaying.

RNA Isolation and Quantitative PCR
A549 cells were collected in 1.5 mL Eppendorf tubes and subjected to centrifugation at
1000 x g for 10 mins. The supernatant was discarded and the pellet resuspended in 800 µL
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Tripure Isolation Reagent (Roche Diagnostics, Indianapolis, IN). After incubating the samples at
room temperature for 5 mins, 200 µL of chloroform (Fisher) was added. Each sample was
shaken vigorously for 15 secs followed by a 15 min incubation at room temperature. The
solution was subjected to centrifugation at 12,000 x g for 15 mins at 4˚C and the colorless layer
was transferred to another tube. The RNA was precipitated with 500 µL of isopropanol for 10
mins at room temperature followed by centrifugation at 12,000 x g for 10 mins at 4˚C. The
precipitated RNA was washed once with 1 mL of 75 % ethanol and air-dried overnight. The
samples were then resuspended in DEPC-treated water (Ambion) the following morning and
stored at -20˚C. For quantitative PCR (qPCR), 3 µg of RNA diluted in 8 µL was treated with 1 µL of
DNAse 1 (Sigma) for 15 mins. DNAse activity was stopped with the addition of 1 µL of Stop
Solution (supplied by the manufacturer) and by incubation of the sample at 70˚C for 10 mins.
cDNAs from the RNA samples were made using qScript cDNA SuperMix kit (Quanta Biosciences,
Gaithersburg, MD) according to manufacturer’s protocol. The amount of cDNA was then
quantified with Brilliant II SYBR Green QPCR Master Mix (Agilent Technologies, Santa Clara, CA)
using a Stratagene Mx4000 Multiplex Quantitative PCR cycler.
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Chapter 3: Potential Electrostatic Interactions in Multiple Regions Affect HMPV F-Mediated
Membrane Fusion

* This work was completed with the help of Brent Hackett, who contributed intellectually to this
work and performed the initial mutagenesis reactions for the HMPV F E51A, D54A, E56A, R163A,
R166A, D54A/E56A, D54A/H435R, E56A/H435R, D54N/E56Q, and D54N/E56Q/H435R protein
mutants. Insertion of the mutant F proteins into the HMPV full length cDNA plasmid and the
initial rescue of mutant viruses were performed by Christine Winter and Ursula Buchholz. The
rest of the HMPV F protein mutants, the generation of plasmids with mutant HMPV F flanked by
intergenic regions, and the subsequent propagation of mutant viruses were performed by me.
Furthermore, I also performed all the experiments shown in the figures related to this chapter.

Introduction
Human metapneumovirus (HMPV) is a recently discovered paramyxovirus that is a
major cause of upper and lower respiratory tract disease worldwide in all age groups (38, 39,
252, 363). Numerous studies have shown that, in addition to exacerbating underlying diseases
such as COPD, HMPV can cause significant morbidity, and some mortality, especially in infants,
the elderly, and people with compromised immune systems (38, 112, 113). Indeed, studies have
estimated that HMPV is the second or third most common cause of severe acute respiratory
tract infection in children (252). Despite its widespread human pathogenicity, there is currently
no approved antiviral medication or vaccine against HMPV.
HMPV expresses three surface glycoproteins: the putative attachment protein, G, the
fusion protein, F, and the small hydrophobic protein, SH (180). The F proteins of
paramyxoviruses, including that of HMPV, are trimeric, type I fusion proteins. The membrane
fusion event is intimately linked to final formation of a six helix bundle in the F protein, after
extensive conformational changes bring two heptad repeat (HR) regions—HRA and HRB—into
close proximity (315). For paramyxovirus, the triggering event that drives these conformational
changes is hypothesized to occur following attachment of the virus to its receptor. This
triggering must be carefully regulated as the subsequent conformational change of the F protein
from its metastable prefusion form to its stable postfusion form is irreversible. Before a
paramyxovirus F protein can be triggered to promote membrane fusion, it must undergo one or
more proteolytic cleavage events, which cut the precursor form of the protein (F0) into an
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active, disulfide-linked form (F1+F2) (180, 315). Unlike most paramyxovirus F proteins, which are
processed by proteases present in the host cell, HMPV F requires exogenous protease cleavage
to be fusogenically active. Thus, for infection to occur, HMPV requires proteolytic activation
after budding. In vitro, the cleavage of HMPV F can be achieved by artificially adding a low
concentration of trypsin to the system (299).
Despite being classified as a paramyxovirus, HMPV is novel in several aspects. While
most other paramyxoviruses require the expression of an attachment protein to be infectious,
HMPV, like its near relative RSV, is infectious in vitro when devoid of the G protein (31, 164,
180). However, unlike RSV, HMPV lacking the G protein was also infectious in animals, including
non-human primates (27, 31). Additionally, the HMPV F protein alone was able to promote cellcell fusion in the absence of the G protein (299). These observations suggest that HMPV F can
promote both attachment and efficient membrane fusion.
Another distinguishing feature of HMPV is that, at least for some strains of the virus, low
pH can trigger the fusion activity of the F protein (143, 299) while most paramyxovirus F
proteins are triggered at neutral pH (180). Our laboratory has shown that low pH treatment of
Vero cells transfected with the F protein of HMPV strain CAN97-83 (Clade A2) leads to F
triggering and subsequent syncytia formation (299). Furthermore, inhibitors of endosomal
acidification such as bafilomycin A and concanamycin were able to confer partial protection
against infection with a recombinant GFP-expressing HMPV CAN97-83 as well as a B1 strain of
the virus (203, 298). Certain strains of HMPV Clade A1 also show low pH-promoted fusion (143).
While low pH triggering is unusual for paramyxoviruses, several viruses from other virus
families require low pH for membrane fusion. A classic example of a type I fusion protein
triggered by low pH is influenza HA, which has a triggering threshold of approximately pH 5.4
(276). Mechanistically, it is thought that electrostatic repulsive forces that arise between
residues that become protonated at low pH and their neighboring residues are responsible for
destabilizing the prefusion form and allowing it to trigger and refold into its postfusion
conformation (133, 147). The effects of electrostatic interactions on the stability of a protein
vary dramatically depending on the location of the interaction and the surrounding
environment. For instance, modeling studies showed a strong attraction between the positively
charged HA1 subunits and the negatively charged HA2 subunits of influenza HA. At low pH,
however, the HA1 subunits become protonated, increasing the repulsive force between
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neighboring HA1 subunits in the trimeric protein. This results in protein destabilization, which
aids in facilitating the transition to the postfusion structure (146).
Previous studies have emphasized the role of histidine residues in the influenza HA
triggering event as well as for other fusion proteins (162). These moieties, with a side chain pKa
value of 6.04 in solution, can undergo protonation under physiological conditions. Interestingly,
sequence analysis of different influenza serotypes showed that a number of histidine residues
are conserved across strains, highlighting the potential role of these residues for the function of
the fusion protein (162). Analysis of a homology model of the prefusion form of the HMPV F
protein showed the presence of a region in the HRB-linker domain consisting of a central
histidine, H435, that is surrounded by several basic residues, most notably K295, R396 and K438
(Figure 6 and (298)). Previous studies indicate that the HRB-linker domain is important for
modulating fusion in the F protein of PIV5 (289). Mutagenesis studies confirmed the importance
of this region for the low pH-dependent trigger of HMPV F as alanine substitutions to the
abovementioned basic residues resulted in a dramatic decrease in fusion activity (298). Thus the
electrostatic repulsion forces that arise upon protonation of H435 at low pH could be a driving
force for fusion triggering of HMPV F.
In this study, we tested the hypothesis that changes in the ionization state of H435
provide the driving force to trigger fusion. While the introduction of a negatively-charged
residue stabilized the protein, preventing it from triggering, a positive charge at this position
restored triggering at pH5 but not at a higher pH. These results indicate a positive charge in this
region is required but not sufficient for triggering. Further analysis of the HMPV F protein
revealed a second unique, highly-charged region located in F2. We therefore performed
mutagenesis studies in this region and report that residues E51, D54 and E56 are also important
in the triggering and stability of HMPV F. The results reported in this study shed new light on the
potential roles of electrostatic interactions for HMPV F-mediated membrane fusion and suggest
that interactions in multiple regions drive F conformational changes.

Results
A Positive Charge at Residue 435 is Required but not Sufficient for Efficient Triggering of HMPV F
We have previously reported that the histidine at position 435 (H435), located at the
HRB-linker domain (289), and the basic residues K295, R396 and K438 that surround it (Figure
6A) are important for low pH triggering of HMPV F (298). Because estimating the position of the
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side chains from a homology model is less accurate than estimating that of the protein
backbone, the distance between the β-carbons of H435 and K295, R396 and K438 were
measured and were estimated to be less than 15 Å apart (Table 1). Therefore, the side chains of
these residues could be positioned such that addition of another positive charge through the
protonation of H435 at pH 5 could destabilize the metastable prefusion form, causing it to
trigger. To test this, a positive charge at position 435 was introduced by making arginine and
lysine substitutions (HMPV F H435R and H435K). Additionally, HMPV F H435D and H435E
mutants were created to introduce a negative charge in the region.
Surface biotinylation was performed using an antibody against the cytoplasmic tail of
HMPV F to examine surface expression and proteolytic cleavage of the mutant proteins. For all
mutant proteins, the inactive F0 precursor form and the cleaved, active F1 form were expressed
at the cell surface (Figures 7A-B), suggesting that these proteins are properly folded. Total and
surface expression levels of the F1 form of HMPV F H435D, H435K and H435E mutants were
decreased by 30-50% compared to wild type (WT) whereas the HMPV F H435R mutant was
expressed at WT levels. The percentage of cleaved protein varied from 54 to 59% for the wt and
mutant F proteins, a difference that was not statistically significant.
Fusogenic activity of these mutants was determined using a syncytia assay, where cells
expressing the mutant proteins were exposed to four 4-minute low pH pulses (Figure 7C). Both
the HMPV F H435R and H435K mutants were capable of promoting cell-to-cell fusion when
exposed to pH 5 pulses, and formed syncytia at a number equivalent to or slightly higher than
WT. Like WT, however, these mutants did not show significant fusion activity at pH 6 or pH 7
(data not shown). These data indicate that a positive charge at position 435 is not sufficient to
drive membrane fusion, though our results suggest a positive charge at this position is necessary
for triggering. Similar to the previously published HMPV F H435A and H435N protein mutants
(298) and in agreement with results shown by Mas, et. al. (203), fusion activity was not detected
for the HMPV F H435D or H435E mutants, potentially because the positive charge involved in
triggering was replaced by a negative charge that stabilized the prefusion form of the protein.
To confirm the findings from the syncytia assay and quantify fusogenic activity, a firefly
luciferase reporter gene assay was employed. Briefly, Vero cells co-transfected with the
different HMPV F proteins and a T7-luciferase plasmid were overlaid onto T7 polymeraseexpressing BSR cells. Upon membrane fusion of the two cell lines, luciferase production occurs,
allowing quantification of fusion. Consistent with the syncytia assay, the HMPV F H435R and
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H435K mutants were fusogenically active at pH 5 but not at pH 6 or pH 7 (Figure 7D).
Interestingly, luciferase production of cells expressing the HMPV F H435R mutant increased by
25% compared to WT. Despite a 45% decrease in surface expression for the HMPV F H435K
mutant, cells transfected with this mutant F protein retained 84% of fusion activity compared to
WT, suggesting that HMPV F H435K may have a hyperfusogenic phenotype, as previous studies
with other paramyxovirus F proteins indicate that fusogenic activity correlates with levels of
surface expression of F (101, 289, 314). Fusion levels above background at pH 6 or 7 were not
detected for any of the mutants tested and, as seen in the syncytia assay, HMPV F 435D and
H435E mutants did not show any fusion above background at pH 5 (Figure 7D, p > 0.05, ANOVA).
Together, these results suggest that a positive charge at position 435, likely present after
protonation at low pH, is necessary but not sufficient for the triggering of HMPV F.

Mutations in H435 and the Surrounding Basic Residues Impair Viral Growth
Our previous studies showed that H435 and its surrounding basic residues are important
for low pH-dependent cell-cell fusion activity of HMPV F (298). To determine if these changes in
fusion activity translated into changes in viral growth, recombinant GFP-expressing HMPV
carrying the mutations HMPV F H435A, H435N, K295A, R396A or K438A were created by
replacing the HMPV F WT gene in the rgHMPV full length cDNA plasmid (30) with the mutant
HMPV F genes. Mutant viruses were recovered by transfection of BSR cells (30), sequenced to
confirm the presence of the desired mutation and the absence of other mutations in the F
protein, and used subsequently to generate later passages. Viruses were then titered to ensure
that cells were infected at an equal MOI of 0.01. Compared to WT, all mutant viruses exhibited
at least a 100-fold reduced viral growth. On day six after infection with WT rgHMPV, 100% of the
cells in a plate were infected, resulting in high GFP expression levels and a titer between 106 and
107pfu/mL, while the rate of infection and growth of the mutant viruses was dramatically less
(Figure 8). Consequently, propagation of these viruses required a much longer incubation period
to achieve workable viral titers (data not shown). Interestingly, viruses carrying the mutations
K295A and R396A were more impaired relative to HMPV carrying the mutations H435A and
H435N in their F protein, producing titers of less than 102pfu/mL. These results confirm that
alterations of H435 and the region surrounding it are deleterious for HMPV growth, verifying
that this region is important for the fusion activity of HMPV F and the overall fitness of the virus.
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An Electrostatic-rich Region in F2 Modulates HMPV F Low pH-dependent Fusion
As our results suggested that a positive charge at position 435 was necessary but not
sufficient to trigger HMPV F, the homology model was further examined for additional regions
where changes in charge-charge interactions could potentially contribute to low pH triggering.
When the amino acid sequence of HMPV F was aligned against those of other paramyxovirus
fusion proteins, a distinct stretch of negatively-charged residues, including E51, D54 and E56,
was identified in the HMPV F2 domain that was not present in other paramyxovirus F proteins.
This region is homologous to the CBF2 region shown to modulate fusion of PIV5 F (121).
Structural analysis of PIV5 F indicated that a portion of CBF2 interacts with sections of the
heptad repeat A (HRA) to form a 3-strand β-sheet that is hypothesized to stabilize the F protein
structure in its prefusion conformation (121, 384). Interestingly, the homology model of HMPV F
predicts these CBF2 residues to be positioned in proximity to two positively-charged moieties
from the HRA region—R163 and K166 (Figure 6B). Measurements from our homology model
estimate the distance between β-carbons of these residues to be between 4 and 11 Å (Table 2),
a distance permissible for the formation of salt bridges between side chains at neutral pH,
potentially stabilizing the overall structure of HMPV F. For salt bridges to form, the charged
groups of the side chain need to be less than 4 Å apart (16, 175). The highly charged local
environment in this region could theoretically alter the pKa of the side chains such that a drop in
pH from 7 to 5 could lead to changes in the protonation state of E51, D54 and/or E56, resulting
in destabilization and facilitating triggering. To determine if these amino acids play a role in low
pH-dependent fusion activity, the HMPV F mutants E51A, D54A and E56A (F2 mutants) as well as
R163A and K166A (HRA mutants) were created and tested for proper expression and fusogenic
activity at various pH.
With the exception of the E51A mutant, for which surface F1 expression was 66% of WT,
all F2 and HRA mutants were expressed close to or above WT levels on the surface of transfected
Vero cells (Figure 9A-B). The fusogenic activity of the mutant proteins was determined with
syncytia and reporter gene fusion assays. All the mutants were able to promote efficient
syncytia formation at pH 5 except HMPV F E51A (Figure 9C). Cells transfected with HMPV F
D54A, E56A, R163A and K166A mutants produced more numerous and larger size syncytia
compared to WT at pH 5. In contrast syncytia formation was not detected in cells transfected
with HMPV F E51A despite a significant amount of protein being expressed at the cell surface
(Figure 9A-C). To our surprise, all the mutants except HMPV F E51A also showed syncytia at pH
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6, albeit smaller (Figure 9C). However, compared to pH 5, syncytia formation was significantly
lower at pH 6 and undetectable at pH 7 (data not shown).
In agreement with the syncytia assay, all the mutant HMPV F proteins with the
exception of E51A were able to efficiently promote fusion at pH 5 in the reporter gene assay
(Figure 9D). In fact, the D54A, E56A and K166A mutants promoted fusion by at least 25% above
WT. The HMPV F R163A mutant exhibited similar fusogenic activity as WT while fusion activity
for HMPV F E51A was diminished to near background levels. The HMPV F D54A, E56A and K166A
mutants also promoted fusion above WT levels at pH 5.5 though, as seen with WT, the fusogenic
activity was reduced by more than 50% compared at pH 5. Fusion levels for HMPV F R163A were
similar to WT and no fusion above background was observed for HMPV F E51A at pH 5.5.
Interestingly, no fusion activity above background was detected at pH 6 or above for any of the
mutants. The disparate results between the syncytia and the reporter gene assays at pH 6 may
be due to differences in the kinetics of the fusion process triggered at this pH as well as by
different amounts of activate F present at the surface. While luciferase production was assessed
after two pulses spaced one hour apart, syncytia formation was induced by a total of four pH
pulses given every two hours. Additionally, for the luciferase reporter to be synthesized, a pore
large enough to transfer plasmid DNA or the T7 polymerase must be formed between the time
of the pH pulse and cell lysis (4 hours). Syncytia formation, on the other hand, was assessed
after an overnight incubation, which allows sufficient time for slower proteins to undergo the
conformational changes needed to enlarge the fusion pore (103).

E51 is Required for the Proper Local Folding and Cleavage Activation of HMPV F
The results from the F2 and HRA mutants suggest that this region plays two important
yet different roles in the stability and triggering of HMPV F. E51 appears to be involved in the
overall fusion activity of HMPV F and could potentially serve as another pH sensor. Therefore, to
test whether E51 acts similarly to H435, expression and fusion of the HMPV F E51K mutant was
assessed.
Replacement of E51 with a lysine (E51K) decreased the surface expression levels of the
F1 form of HMPV F by nearly 50% (Figure 10A-B). The reduction in surface expression observed
for both the E51A and E51K mutants suggests that the negative charge at this position is
important for stability and expression of the protein at the cell surface. The importance of this
residue is underscored by the fact that the portion of the HMPV F E51K mutant that remained
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on the surface also failed to promote cell-to-cell membrane fusion at any pH, as assessed by our
reporter gene and syncytia assays.
To test whether there is crosstalk between E51 and H435, the mutation E51K/H435R
was also made and analyzed. Like HMPV F E51K, surface expression of E51K/H435R was
reduced. Furthermore, cell-to-cell fusion activity was not detected at any pH despite the
introduction of the hyperfusogenic mutation H435R (Figure 10C-D). These results suggest that
the E51K mutation is dominant over H435R and confirms that residue E51 plays a key role in the
overall function of F.
Even though the HMPV F E51A, E51K AND E51K/H435R mutants showed a lower surface
expression, a significant amount of the mutant F reached the cell surface, suggesting that the
effect of these mutations on the overall structure is not severe enough to result in complete ER
retention due to gross misfolding. Since E51 is near the cleavage site of HMPV F, electrostatic
interactions involving this moiety may be important for the proper folding and positioning of the
proteolytic processing site. To test this, surface expression of HMPV F E51A and E51K was
examined in the absence of trypsin. Though HMPV F strains or mutants have been identified in
which some processing to the mature F1+F2 is observed in the absence of exogenous trypsin (28,
293), wt HMPV CAN97-83 F protein cleavage in vitro has been shown in our laboratory and
others to require trypsin treatment (29, 299, 352). Fitting with this, WT HMPV F protein was
observed in the mature, cleaved F1 form only after addition of trypsin (Figure 11A-B).
Interestingly, more than 30% of the E51A and E51K mutants were cleaved in the absence of
trypsin (Figure 11A-B), suggesting that the removal of the negative charge at position 51 caused
local misfolding that exposed a cleavage site normally not accessible to an endogenous
protease. Indeed, analysis of the sequence of HMPV F revealed the presence of an arginine
residue located two residues upstream of the putative cleavage site that could be utilized by an
endogenous trypsin-like protease. This aberrant cleavage event, however, did not result in a
fusogenically active F protein (Figure 10C-D). These results therefore suggest that E51 is
important for positioning of the fusion peptide for proper proteolytic processing.

Charged Residues in F2 are Important for HMPV F Prefusion and Postfusion Stability
The hyperfusogenic phenotype of HMPV F D54A and E56A suggests that these residues
are involved in modulating the stability of the protein, potentially through salt bridge
interactions with R163 and K166 in the prefusion state. At low pH, neutralization of D54 and/or
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E56 could disrupt these salt bridges, allowing F to trigger. HMPV F double mutants D54A/E56A
and D54N/E56Q were created and analyzed to determine the effects of disrupting these
potential interactions. The latter mutation, D54N/E56Q, is a more conservative, isosteric
substitution that removes the charged residues while maintaining polarity at these residues.
Analysis of the R163 and K166 mutations was not pursued further due to the location of these
residues in HRA, as their potential role in six-helix bundle formation means fusion changes may
not be directly attributed to triggering. Additionally, HMPV F D54A/H435R, E56A/H435R,
D54A/E56A/H435R and D54N/E56Q/H435R mutants were made to test whether changes in one
region influence the other.
Though the HMPV F D54A or E56A mutants expressed at or above WT levels (Figure 9A),
surface expression of the F1 form of the double alanine mutant (D54A/E56A) decreased by more
than 40%. Consistent with a decrease in surface expression levels, a reduction in fusion activity
was also observed for the HMPV F D54A/E56A mutant. The more conservative polar
substitutions (D54N/E56Q), however, restored the surface expression to WT levels (Figure 10AB), suggesting that either polar residues or steric similarity is needed to stabilize the prefusion
form of the protein.
According to our reporter gene fusion assay, fusion activity is significantly enhanced for
HMPV F D54N/E56Q at pH 5 (Figure 10C) to levels equivalent to E56A. However, the effect of
these mutations on the stability and fusogenic activity of the protein is different. D54N/E56Q is
more hyperfusogenic at pH 5.5 compared to E56A and, while the addition of the H435R
mutation to D54N/E56Q (D54N/E56Q/H435R) had a modest effect on fusion at pH 5.5,
E56A/H435R exhibited a dramatic increase in fusion activity at the same pH. More importantly,
analysis of the syncytia assay revealed that cells expressing the HMPV F D54N/E56Q and
D54N/E56Q/H435R mutants produced numerous syncytia but significantly smaller in size
compared to WT, E56A and E56A/H435R when triggered at pH 5 (Figure 10D). The greater
amount of smaller syncytia agree with the hyperfusogenic phenotype observed in the reporter
gene fusion assay as this would result more cells fusing and increased luciferase production. No
syncytium formation was detected at pH 6 or pH 7 (data not shown). Thus, our data indicate
that the replacement of the negative charges at positions 54 and 56 leads to changes in the
stability of the fusion protein that can be seen by changes in surface expression and fusogenic
activity.
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The addition of the hyperfusogenic mutation H435R (D54A/H435R, E56A/H435R,
D54A/E56A/H435R AND D54N/E56Q/H435R) did not significantly alter the fusion levels of the
mutant proteins at pH 5 (Figure 9A and D, Figure 10C-D). However, the presence of the H435R
mutation led to a modest increase in fusion activity at pH 5.5 with the notable exceptions of
D54A/H435R and E65A/H435R, where the increase in fusion was significantly more pronounced.
Together with a minor decrease in F1 surface expression (Figure 9A and Figure 10A), our data
suggest that H435R also affects the stability of the protein, allowing it to trigger at a higher pH.
The destabilizing force of adding a basic residue to an already positively charged region can
indeed be responsible for the hyperfusogenic phenotype of H435R, as disruptions of chargecharge interactions has been shown to alter the triggering threshold of influenza HA (83, 276).
The pH dependency of HMPV F-mediated membrane fusion, however, was not abolished by
mutations at positions 54 and/or 56. Therefore, while H435 mediates the stability of the HRBlinker region to behave as a pH sensor, the stability effect conferred by residues D54 and E56 is
not involved in sensing low pH.

Discussion
The results presented in this study present new insights into the multiple roles that
electrostatic interactions play in the folding, stability, and triggering of HMPV F. We
demonstrated that a positive charge at position 435 is necessary but not sufficient to trigger
HMPV F, with this charge most likely arising though protonation of H435 upon its exposure to a
low pH environment. This conclusion is supported by a recent report in which this histidine
residue was mutated in the F protein of phylogenetically distinct HMPV with similar results
(203). Furthermore, our mutagenesis studies revealed that the novel enrichment of charged
residues present in the F2 and HRA domains of HMPV F are important for proper local folding
and the overall stability of the protein. Removal of the negative charge at position 51 affected
proteolytic processing and led to an inactive protein on the cell surface, consistent with an
alteration to local conformation. Loss of charge at positions 54, 56, 163 and/or 166 also affected
stability and fusogenic activity of HMPV F.
Several reports have shown important differences between members of the
pneumovirinae subfamily and their paramyxovirinae counterparts. While viruses in the
paramyxovirinae subfamily require the expression of the attachment protein for membrane
fusion and infection to occur, both RSV and HMPV remain infectious in vitro in the absence of
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their putative attachment proteins (31, 164). Further, our laboratory has shown that triggering
of HMPV F can occur in the absence of the HMPV G protein (299). Indeed, recent studies suggest
that the protein responsible for the primary attachment step for both of these viruses is F (65,
342). The possibility of triggering the F protein of certain clades of HMPV by low pH further
distinguishes this virus from the rest of the family (143, 299). Close examination of the sequence
alignment of HMPV F against other paramyxovirus F proteins and a homology model based on
the prefusion form of PIV5 F (384) reveal areas rich in charged residues that are absent in other
F proteins. Therefore changes in the ionization state of these residues could explain the
triggering of HMPV F by low pH, as seen in influenza HA (276, 290, 348).
The first highly-charge region identified is located at the HRB-linker domain and is
centered at H435 (298). Based on mutagenesis studies, we and others determined that H435
and the neighboring K295, R396 and K438 in addition to G294 are important for low-pH
mediated fusion (143, 298) and the severe attenuation of recombinant HMPV bearing the
mutations H435A, H435N, K295A, R396A or K438A in their F protein (Figure 8) highlights the
importance of this region for the virus. Furthermore, analysis of HMPV F H435R and H435K
mutants presented here and elsewhere strongly suggests that a positive charge in this region is
required though not sufficient for low-pH triggering of HMPV F. Both the H435D and H435E
mutants were not fusogenically active, likely due to the presence of a negative charge. Such a
phenotype, we hypothesize, is due to stabilization of the prefusion form via electrostatic
attraction in contrast to the hyperfusogenic profile observed when a positive charge is present
at position 435.
Despite the dramatic reduction in cell-to-cell fusion observed when the charged
residues around HMPV F H435 were removed (298), we were able to rescue infectious HMPV
particles bearing mutations in these residues (Figure 8). Interestingly, while viral titers from all
mutant viruses were reduced by three or more logarithmic units compared to wild type, titers
from recombinant viruses expressing the H435A and H435N mutations were higher compared to
those bearing the K295A and R396A mutations. Our homology model of the HMPV F protein in
its prefusion conformation indicates that K295 and R396 are freely exposed at the surface of the
protein (Figure 6). It is possible that these residues have other important roles in the lifecycle of
the virus, thereby increasing the selective pressure and making these mutations more difficult to
overcome. We have shown that HMPV entry is initially mediated by interactions between the F
protein and heparan sulfate (65). Therefore, one possibility is that the positively charged
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residues K295 and R396 are needed for interactions with the negatively charged heparan sulfate
during virus entry. Even though the residues around H435 are located at the base of the head
domain, interactions could take place at an intermediate step or with longer branches of
heparan sulfate.
Protonation of H368 was recently suggested by Mas et al. to also be important for low
pH-dependent F proteins (203). Our homology model predicts this residue to be more than 20Å
apart from H435 (data not shown), and is predicted to lie adjacent to and interacting with the
fusion peptide (298). Alanine and asparagine mutations of H368 in HMPV F CAN97-83 suggest
that protonation of this residue is not essential for low-pH mediated fusion of this F protein
(298). Furthermore, with the exception of H368A, for which fusion activity was not detected,
none of the mutations to H368 reported for CAN97-83 (298) or NL/1/00 (203) showed a pHindependent triggering unless it was paired with a positively charged residue at position 435.
These results further emphasize the importance of a positive charge at position 435 and support
our previous hypothesis that side chain packing around the fusion peptide modulate the fusion
efficiency and stability of the F protein (298, 314).
Another unique region in HMPV F CAN97-83 where charged residues are predicted to be
concentrated in our homology model is the interface between the F2 and HRA domains of the
protein. While the charged residues are novel relative to other paramyxovirus F proteins,
sequence alignments indicate this enrichment is conserved across different HMPV clades (data
not shown). This region has been shown to be important in modulating fusion for PIV5 F (121)
and structural analysis of PIV5 F in its prefusion conformation (384) indicates that residues in
this area form a three-strand β-sheet with two of the three strands derived from HRA residues
and the remaining strand by residues from F2. Though HMPV and PIV5 belong to different
subfamilies, the importance of this region for the proper folding of F and the promotion of
membrane fusion is preserved. Interestingly, there are striking differences between the F2
region of PIV5 F and that of HMPV F. This region in PIV5 F is composed primarily of non-polar
residues while polar and charged moieties are more predominant in this region of HMPV F.
Mechanistically, the way this region modulates folding and fusion in PIV5 F is still unclear.
However, because these charged residues in the F2 domain of HMPV F are predicted to lie near
those in HRA, we suggest that potential electrostatic interactions between HRA and this region
in F2 are involved in the folding and fusion of HMPV F.
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The results shown in this study identify several areas where electrostatic interactions,
including salt bridges, may play important roles in HMPV F function. We found that a positive
charge at the previously identified residue H435 (298) results in a hyperfusogenic state but is
not sufficient alone to cause pH-independent fusion while a negative charge in this position
blocks F fusogenic activity. Furthermore, we show a charged region in F2 to be important for
proper proteolytic activation and the overall stability of HMPV F. We have previously shown that
HMPV infection can be partially inhibited by agents that raise endosomal pH. Additionally,
HMPV infection was greatly reduced after inhibition of clathrin-mediated endocytosis and
dynamin by chlorpromazine and dynasore respectively (298). A recent report found variable
inhibition of infectivity of other strains of HMPV by concanamycin A, without a clear link
between a pH triggered F protein and inhibition by the drug, and no inhibition by ammonium
chloride of any tested HMPV strain (203). While our previous results using chlorpromazine and
dynasore suggest a role for endocytosis on HMPV entry, the correlation between viral entry by
endocytosis and the requirement for low pH remains unclear. Electrostatic interactions may also
play a role in viral binding, as we have recently shown that an interaction between HMPV F and
heparan sulfate plays a critical role in initial binding (31, 65), suggesting that a cascade of
electrostatic interactions occur to drive HMPV F binding and fusion promotion.
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Table 1. Estimated distance between β - carbons of H435 and surrounding basic residues in the
HMPV F homology model.
From
H435
H435
H435

To
K295
R396
K438

54

Å
10
13
6

Table 2. Estimated distance between β - carbons of selected amino acid residues in F2 in the
HMPV F homology model.
From
E51
D54
E56
E51
D54
E56

To
R163
R163
R163
K166
K166
K166

55

Å
4
5
10
8
5
10

Figure 6. Homology model of HMPV F in its prefusion conformation highlighting residues
around H435 and the F2 region.
The amino acid sequence of HMPV F was threaded onto the crystal structure of the PIV5 F in its
metastable prefusion form (384). A. HRB-linker domain showing H435 (yellow) at close distance
to K295, R396, and K438 (cyan). B. The amino acid residues E51, D54, and E56 (red) lie at close
proximity allowing potential salt bridge interactions with R163 and K166 (green).
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Figure 7. A positive charge at position H435 is required but not sufficient for HMPV Fmediated membrane fusion.
A. Quantification of the total and surface expression of the F1 form of metabolically labeled Vero
cells expressing HMPV F WT, H435R, H435K, H435D, and H435E in the presence of TPCK-trypsin.
Data represented as percent WT HMPV F set to 100% (n = 4). MCS = multiple cloning site, empty
vector control. B. Representative gel of surface proteins used for quantification in A. C.
Representative images of syncytium formation of cells expressing the H435 mutants after pH 5
pulses (n = 4). D. Luciferase reporter gene assay of Vero cells transfected with mutant HMPV F
that were overlaid onto BSR cells and subjected to two pH pulses. Data presented as percent of
WT luminosity (fusion) at pH 5 (n=5). Error bars = SEM.
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Figure 8. Recombinant HMPV carrying mutations in the HRB-linker domain of HMPV F show a
drastic decrease in infectivity.
GFP expression of WT and mutant HMPV-infected plates 6 days post-infection of passage 2 virus
grown in Opti-MEM with 200mM L-glutamine and 0.3µg/mL TPCK-trypsin. Values in parenthesis
are representative titers obtained as described in materials and methods after a six-day
incubation.
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Figure 9. Charged residues in F2 and HRA regions of HMPV F are important for the stability and
fusogenic activity of the protein.
A. Quantification of total and surface expression levels of the cleaved F1 form of mutant proteins
HMPV F E51A, D54A, E56A, R163A, and K166A expressed in Vero cells (n=4). Data represented
as percent of WT HMPV F set to 100%. Asterisk indicates significant difference compared to WT
control at the same pH (p < 0.05). Error bars = SEM. MCS = multiple cloning site, empty vector
control. B. Representative surface biotinylation of mutant HMPV F used for quantification in A.
C. Representative pictures of syncytia assay of HMPV F mutants at pH 5 and pH 6 (n=4). Arrows
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point to small syncytia seen at pH 6. Area limited by the black squares in D54A and E56A at pH 6
were enlarged and shown in below (D54A 2x and E56A 2x respectively). D. Luciferase reporter
gene assay of mutant F tested in A, B, and C (n=3) presented as percent of WT luminosity
(fusion) at pH 5. Asterisks indicate significant differences compared to WT control (p < 0.05).
Error bars = SEM.
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Figure 10. Different charged residues in F2 are responsible for the stability and local folding of
HMPV F.
A. Quantification of total and surface expression of the F1 form of HMPV F E51K, E51K/H435R,
D54A/H435R,

E56A/H435R,

D54A/E56A,

D54A/E56A/H435R,

D54N/E56Q,

and

D54N/E56Q/H435R mutant protein as previously described (n=5). Data represented as percent
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of WT HMPV F set to 100%. Error bars = SEM. B. Representative gel used for quantification in A.
C. Luciferase reporter gene assay of HMPV F mutant protein mentioned in A. Data presented as
percent of WT luminosity (fusion) at pH 5 (n=6). Error bars = SEM. D. Representative
photographs of syncytium formation of HMPV F mutants at pH 5 using Vero cells (n=4). Arrows
point at smaller syncytia.
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Figure 11. E51 is important for the proper folding on the HMPV F cleavage site.
A. Representative gel of the surface expression levels of HMPV F WT and HMPV F E51A and
E51K mutants in the presence or absence of 0.3µg/mL of TPCK-trypsin. B. Quantification of
percent cleavage for HMPV F WT and HMPV F E51A and E51K mutant calculated from gels
shown in A. Percent cleavage = F1/(F1+F0) (n=3). Error bars = SEM.
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Chapter 4: Human Metapneumovirus Binding and Infection is Mediated by Interactions
between the HMPV Fusion Protein and Heparan Sulfate

* This work was made in collaboration with Cyril Masante, who made an equal intellectual
contribution to this work. In addition, he performed the experiments shown in Figure 13C – E,
Figure 15A – D, and Figure 16D – E, and collaborated in the generation of the data shown in
Figure 15E – F and Figure 18A – B.

Introduction
Human metapneumovirus (HMPV) is a major worldwide respiratory pathogen first
isolated in 2001 from children with respiratory syncytial virus (RSV)-like symptoms (352). Several
studies since have confirmed the importance of HMPV, generally placing it as the second or
third most common cause of severe acute upper and lower respiratory tract disease in children.
Though children and infants, the elderly, people with underlying cardiopulmonary conditions,
and immunocompromised individuals are more susceptible to severe disease from this virus,
HMPV affects people in all age groups (reviewed in (252)). Seroprevalence studies have shown
that most individuals have been exposed to this virus by the age of five though reinfections with
this virus are frequent (352). HMPV infection results in a range of disease severities from mild
cold-like symptoms to bronchiolitis, pneumonia, and febrile seizures, and can potentially lead to
death (159, 252).
Most paramyxoviruses express two major surface glycoproteins: an attachment protein
and a fusion (F) protein. Some paramyxoviruses, including HMPV, express an additional putative
membrane-spanning protein: the small hydrophobic (SH) protein (180). For a paramyxovirus to
infect a cell, the virus must attach to a cellular receptor, usually through the attachment protein,
and then fuse the viral and cellular membranes, a process driven by the F protein (180).
Paramyxovirus F proteins are synthesized as a precursor (F0) form which is then proteolytically
cleaved to the fusogenically active F1+F2 form (180). For HMPV, this cleavage is accomplished by
an exogenous protease (299, 307). This proteolytic cleavage primes the F protein for triggering,
which, for some clades of HMPV, is driven by low pH (143, 299). There is no evidence that the
SH protein plays a role in viral entry. In fact, HMPV SH protein is dispensable for virus growth in
vitro and in vivo (26).
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The paramyxovirus attachment protein is a type II integral membrane protein called
either HN, H, or G (180). Paramyxoviruses with a G protein do not bind sialic acid but instead
bind to cellular factors such as Ephrin B2 for the henipaviruses (41, 232). Members of the
pneumovirinae subfamily express a functionally different G protein which has been shown to
interact with cell surface proteoglycans in the case of RSV and HMPV (174, 347). Although it has
been shown that most paramyxoviruses require the attachment protein for binding and
infection, a role for HMPV G protein in receptor binding has not been confirmed.
Interestingly, while the attachment protein is essential for virus attachment and
subsequent membrane fusion in the paramyxovirinae subfamily, studies have shown that some
members of the pneumovirinae subfamily can be infectious in the absence of the attachment
protein. RSV lacking G can be propagated in vitro but could not replicate efficiently in vivo (115,
344) and bovine respiratory syncytial virus (BRSV) lacking G can still infect its host (295).
Similarly, a recombinant avian metapneumovirus (AMPV), the closest relative of HMPV, lacking
the SH and G proteins was able to grow, albeit slower than wild-type AMPV, in cell culture (231).
Studies from our laboratory and others indicate that the G protein of HMPV is also dispensable
for attachment and fusion, as cell-cell fusion can be accomplished in the absence of G and
recombinant HMPV particles lacking G are infectious in vitro (299). Furthermore, a mutant virus
devoid of the G protein can efficiently infect African green monkeys (27) suggesting that the F
protein of HMPV is capable of performing both the attachment and fusion steps in vivo. Indeed,
the HMPV F protein has been shown to be an important marker of human infection (257).
Most cells express a large number of different surface carbohydrates that mediate
multiple functions such as adhesion, growth and signaling (284). The glycan synthesis of
glycoproteins is based on two main processes: N-glycosylation, which involves an addition of Nacetylglucosamine (GlcNAc) to the nitrogen atom of an aspargine residue, or O-glycosylation,
which is the addition of N-acetylgalactosamine (GalNAc) or xylose to the oxygen atom of a
serine or a threonine residue. GalNAc addition leads to the synthesis of mucins, whereas xylose
addition leads to synthesis of glycosaminoglycans (GAG). GAGs can be classified into six different
groups based on their composition: chondroitin sulfate, heparan sulfate, dermatan sulfate,
keratan sulfate, hyaluran, and heparin (24, 273, 334).
Heparan sulfate (HS) is the most often implicated GAG in virus-cell interactions. HS has
been described as a receptor for multiple herpesviruses and is also necessary during the first
step of adhesion of other viruses such as HIV and influenza (reviewed in (318)). HS plays an
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important role in the initial steps of RSV entry, the closest related human pathogen to HMPV
(45, 131, 132, 174). This interaction, however, appears to be largely mediated by RSV G, and
viruses lacking G show a significant decrease in binding to CHO-K1 cells (344). A recent study
showed that the HMPV G protein also has the ability to bind GAGs and suggested that this
interaction might be a significant factor for virus-cell interactions (347).
Integrins are extracellular matrix binding proteins expressed in nearly all cell types and
play multiple roles including the regulation of cell adhesion, tissue growth, and migration
(reviewed in (15)). These heterodimers, composed of at least 18 different α and 10 different β
subunits, bind to a myriad of proteins including HS proteoglycans (HSPG), and many proteins
that express the amino acid sequence Arg-Gly-Asp (RGD) (285). Due to their broad distribution
on the surfaces of many cell types, several integrins have been implicated in viral entry.
Integrins are part of the receptor complex of some picornaviruses, hantaviruses, and
papillomaviruses, and are also involved in adeno-associated virus, Ebola virus, and reovirus
entry, though not as cellular receptors (84, 222, 297, 328). Furthermore, it has recently been
reported that the αvβ1 integrin plays a major role in promoting HMPV infection (80).
In this study, we investigated the role of GAGs and the integrin αvβ1 in HMPV infection
using wild-type HMPV, a mutant virus lacking the G protein, and a mutant virus devoid of G and
SH (27). We show that the αvβ1 integrin is not essential for HMPV F-mediated fusion or for the
initial binding step. Rather, our data indicate that integrins promote infection at a step
downstream of the initial binding. Additionally, we demonstrate that the G and SH proteins do
not play a major role in viral attachment, making F the main viral determinant for HMPV
binding. Finally, we show that HMPV F interacts specifically with heparan sulfate and that HS is
an indispensable component of the HMPV binding receptor complex.

Results
The RGD Motif in HMPV F is not Required for Cell-to-cell Membrane Fusion
Integrin αvβ1 has been shown to play a role in promoting HMPV infection, potentially by
interacting with the RGD-motif of HMPV F (80). To determine whether RGD-dependent binding
of HMPV F to αvβ1 integrin is required for fusion activity of HMPV F, we mutated the aspartic
acid residue in the RGD motif of HMPV F to alanine (F RGA, D331A) using site directed
mutagenesis. Since the RGD-integrin interaction is dependent on the presence of all three
residues (285), an RGA mutation should abolish interactions between HMPV F and αvβ1 integrin
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through this motif. To verify that this mutation did not affect protein folding and expression, the
cell surface expression and proteolytic processing of wild-type F (F WT) and mutant HMPV F RGA
was determined. Vero cells were transiently transfected with the pCAGGS expression vector
(239) encoding the genes for the HMPV F WT or HMPV F RGA mutant. After metabolic labeling
in media with TPCK-treated trypsin to proteolytically cleave the F protein (299), the surface
proteins were labeled covalently with biotin. The F proteins were immunoprecipitated with a Fspecific antisera following cell lysis, the surface population separated with streptavidin beads,
and samples were analyzed by SDS-PAGE electrophoresis. Both HMPV F WT and HMPV F RGA
mutant were expressed at the cell surface (Figure 12A-B) and the addition of trypsin to HMPV F
RGA produced the lower molecular weight F1 form. Although the total and surface expression of
the inactive F0 precursor form of HMPV F RGA mutant was slightly greater than WT, the
fusogenically active, cleaved F1 form was expressed at WT levels. The proper surface expression
of the both F0 and F1 forms of HMPV F RGA indicate that this mutant adopts an intracellular
transport-competent conformation and the cleavage site remains accessible to trypsin,
suggesting that HMPV F RGA mutant adopts a similar conformation as HMPV F WT.
To assess the fusogenic activity of HMPV F RGA, syncytia assays were performed (299).
Briefly, Vero cells expressing HMPV F WT or HMPV F RGA were subjected to four – 4-minute pH
5 pulses (pH 7 as control) to trigger the trypsin-activated F protein; pictures of syncytia
formation were then taken the next day. Our laboratory has previously shown that expression of
HMPV F alone is sufficient for promoting syncytia formation (299). Both HMPV F WT and the
HMPV F RGA mutant were triggered by pH 5 treatment, leading to the formation of an similar
number and size of syncytia (Figure 12C). Neither HMPV F WT nor the HMPV F RGA mutant were
fusogenically active at neutral pH. These results confirm that the RGA mutation does not affect
the pH dependency of the fusion protein, and that expression of the HMPV F RGA mutant is still
sufficient to induce membrane fusion in the absence of HMPV G (299).
The fusogenic activity of the RGA mutant was quantified using a firefly luciferase
reporter gene assay. Vero cells expressing a luciferase plasmid under the control of the T7
promoter and either HMPV F WT or HMPV F RGA mutant were overlaid onto BSR cells that
constitutively express the T7 polymerase (51). Luciferase activity of the cell lysates was assayed
following two 4-minute pH pulses (299). Luciferase expression directly correlates to fusion
activity as production of luciferase occurs only after Vero cells carrying a luciferase plasmid and
expressing a fusogenically active F protein fuse with BSR cells. The HMPV F RGA mutant
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efficiently promoted membrane fusion at levels approximately 80% of wild-type at pH 5 (Figure
12D). As in our syncytia assay, both HMPV F WT and the HMPV F RGA mutant did not promote
fusion at neutral pH, and the HMPV G protein was not required for promotion of cell-to-cell
membrane fusion. These results indicate that the RGD motif in HMPV F is not essential for the
promotion of cell-to-cell membrane fusion.

β1 – Integrin is Required for Efficient Infection by HMPV but not for the Initial Binding Step
To determine whether interaction of HMPV F with αvβ1 integrin is necessary for initial
virus-cell binding, we directly analyzed virus binding to cells lacking β1 integrin. GD25 cells are
mouse embryonic fibroblasts deficient in β1 integrin expression due to the introduction of a null
mutation within the β1 integrin gene. Expression of β1 integrin was rescued by stable
transfection of a wild-type β1 integrin gene (β1GD25 cells) (367). The expression levels of αv and
β1-integrins for GD25 and β1GD25, were confirmed using fluorescence automated cell sorting
(Figure 13A). GD25 and β1GD25 cells were spinoculated with different multiplicities of infection
(MOI, between 0.5 and 50) of HMPV at 4°C to prevent internalization. After thorough washes,
cell-bound viruses were labeled with an anti-HMPV N monoclonal antibody followed by an HRPconjugated secondary antibody. Binding efficiency of HMPV to GD25 cells and β1GD25 cells did
not vary significantly, indicating that the expression of β1 integrin does not play a critical role in
the initial virus-cell binding (Figure 13B). HMPV bound to GD25 and β1GD25 cells at similar
levels compared to Chinese Hamster Ovary (CHO-K1) cells, which express β1 integrin but nondetectable levels of αv integrin.
The results from the first binding assay were verified with a different binding assay using
western blots (Figure 13C-D). In addition to WT-HMPV, binding efficiency of recombinant
mutant viruses lacking the putative attachment protein HMPV G (ΔG) or both HMPV G and the
small hydrophobic protein HMPV SH (ΔG/ΔSH) (27) was also assessed to determine which viral
surface glycoprotein is involved in the initial binding step. Gene deletions for each virus were
verified by RT-PCR and the quantity of HMPV F incorporated into the mutant viruses compared
to WT was similar (Figure 13E). As previously reported (31), infectivity of these mutant viruses
was similar to WT HMPV (data not shown). HMPV WT, ΔG, and ΔGΔSH viral particles at an MOI
of 7 were then added to cells and incubated at 4°C for binding. After thorough washes, the cells
were lysed and a volume corresponding to 6 x 104 cells for each cell line was loaded onto an
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SDS-PAGE gel, analyzed by western blot, and the band intensities quantified using the Odyssey
application software.
While WT HMPV binding to Vero cells was 5 times higher than binding in β1GD25 and
GD25 cells, the amount of HMPV bound to GD25 did not significantly differ from the quantity of
virus bound to β1GD25 (Figure 13D, black). The absence of G alone or both G and SH did not
significantly affect the binding efficiency of HMPV (Figure 13D, gray and white respectively, p >
0.05), providing direct evidence that the initial binding step of HMPV to the cell is predominantly
mediated by the fusion protein. Similar results were obtained when cells were treated with an
MOI of 100 (data not shown). These observations were further supported by a binding assay
using biotinylated HMPV and quantified with streptavidin-FITC by flow cytometry (data not
shown). These results strongly indicate that the initial binding step for HMPV does not require
β1-integrin.
As β1 integrin had been reported to play a role in HMPV infection but did not
significantly alter HMPV binding or HMPV F-promoted membrane fusion, we assessed whether
β1 integrin expression promotes infection by HMPV. A recombinant HMPV, strain CAN97-83,
expressing the green fluorescent protein (rgHMPV) was used to infect the various cell lines at
different MOIs. Both β1GD25 and GD25 cells were permissive to HMPV infection, though a
much higher MOI was required to achieve significant infection levels in cells lacking β1 integrin
(Figure 14). Approximately 70% of Vero and β1GD25 cells were infected at an MOI of 10
whereas only approximately 20% of GD25 cells were infected with the same MOI. Increasing the
MOI to 50 resulted in an additional 10% increase in the number of GD25 cells infected by
rgHMPV. Taken together, our results confirm that β1-integrin expression is indeed important for
HMPV infection though the initial binding step does not require expression of β1-integrin.

Productive HMPV Infection is Dependent on a Proteinaceous Receptor
Our data clearly show that HMPV binding is primarily driven by HMPV F and does not
require β1 integrin, but the nature of the cellular receptor is still unclear. To test whether a
proteinaceous receptor is needed for HMPV infection, Vero and CHO-K1 cells pretreated with
trypsin (Figure 15A and C) or proteinase K (Figure 15B and D) were infected with control
parainfluenza virus 5 (Figure 15A-B) or rgHMPV (Figure 15C-D). Cellular binding of PIV5 occurs
through the interactions of the PIV5 attachment protein HN with sialic acid moieties at the cell
surface. Consistent with this, pretreatment of cells with trypsin or proteinase K did not
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significantly affect PIV5 infection (Figure 15A-B). However, rgHMPV infectivity was decreased by
50% or more after trypsin treatment. Proteinase K treatment resulted in a more drastic
reduction of infection (Figure 15D), likely due to the more efficient digestion of proteins
compared to trypsin. Cell surface integrins have been reported to be insensitive to protease
treatment (142). Therefore, to verify that αvβ1 integrin was not the protease sensitive
component involved in HMPV infection, the amounts of αv- and β1-integrin on the cell surface
were measured after trypsin or proteinase K treatment. As expected, protease treatments did
not remove the antibody epitopes from the cell surface (Figures 15E-4F). Together these results
indicate that efficient HMPV infection requires the proper expression of a trypsin- and
proteinase K-sensitive proteinaceous receptor.

Heparan Sulfate is Important for HMPV F-dependent Virus-cell Binding
Glycoconjugates, including glycosaminoglycans (GAGs), are involved in many virus-cell
interactions (318), and a previous report showed that the HMPV G protein interacts with GAGs
(347). Since our results indicated that HMPV F is the major viral binding protein, we directly
analyzed the role of GAGs in virus binding and infection to the mutant CHO cell lines pgsA745,
Lec1, and ldlDLec1 (Table 3). pgsA745 cells carry a mutation in the xylosyltransferase gene
abolishing expression of any GAG. Lec1 cells carry a mutation in the N-acetylglucosamine
transferase 1 (GlcNAc Transferase 1) resulting in the inability of these cells to express complex
N-linked glycans whereas the ldlDLec1 cells carry an additional mutation (4-epimerase)
preventing them from expressing complex N-linked glycans, mucins, and GAGs in the absence of
galactose and GalNAc (169). However, because ldlDLec1 cells were cultured with serum, these
cells produce heparan sulfate as their only GAG (Table 3) (66, 107).
WT HMPV was unable to bind pgsA745 cells as efficiently as binding to CHO-K1 cells
(Figure 16A). Surprisingly, binding to ldlDLec1 and CHO-K1 cells was similar (Figure 16A). The
binding profile of HMPV was similar for the HMPV ΔG (Figure 16B) and the HMPV ΔG/ΔSH
mutants (Figure 16C), confirming that the primary viral binding factor is HMPV F. The binding
profile of HMPV to the different cell lines was confirmed by the western blots. While binding of
WT and mutant HMPV to pgsA745 decreased by 90 percent compared to Vero cells, binding to
Lec1 and ldlDLec1 cells was not significantly decreased (Figure 16D-E). The differences in binding
efficiencies between Lec1 and ldlDLec1 cells in the two binding assays could be due at least in
part to the spinoculation step performed only in the ELISA-based assay as ldlDLec1 cells have a
70

higher tendency to aggregate, resulting in artificially higher normalized values in an ELISA-based
assay, where the initial number of cells employed is already small. Nonetheless, our data
confirm that HMPV F is the predominant viral protein involved in the initial binding step for
HMPV, and that cellular binding of HMPV depends on the proper synthesis of GAGs.
The need for proper GAG synthesis for HMPV binding and infection was confirmed by
the inability of wild-type rgHMPV to infect pgsA745 even at high MOIs despite a high degree of
infectivity of CHO-K1, Lec1, and ldlDLec1 cells (Figure 17). At an MOI of 10, for instance, nearly
100 percent of CHO-K1, Lec1, and ldlDLec1 cells were infected whereas only 3 percent of
pgsA745 were infected. The infectivity of pgsA745 did not significantly increase even at an MOI
of 50. Importantly, the absence of GAGs did not affect PIV5 infection as this virus was able to
infect pgsA745 and CHO-K1 cells with similar efficiency (Figure 18C), indicating that not all
paramyxoviruses require proper synthesis of GAGs for binding and infection. These data
demonstrate that HMPV F – GAG interaction is specific for HMPV and that this interaction is
essential for infection.
The fact that ldlDLec1 cells were permissive for binding and infection at levels
equivalent to CHO-K1 cells suggested that the primary GAG involved in these processes is
heparan sulfate. To confirm that heparan sulfate is indeed the specific GAG required for HMPV
binding and infection, pgsD677 cells were exposed to HMPV at different MOI and assessed for
binding and infectivity. pgsD677 cells are unable to synthesize heparan sulfate, but chondroitin
sulfate synthesis is enhanced 3 to 4 fold due to a deficiency in N-acetylglucosaminyltransferase
and glucuronyltransferase (192). Wild-type HMPV binding efficiency to pgsD677 cells, using both
our ELISA and western blot analyses, was comparable to that of pgsA745 (data not shown).
Importantly, ΔG HMPV (data not shown) and ΔG/ΔSH HMPV (Figure 18A-B) also showed a
drastic decrease in binding efficiency to these cells, providing additional evidence that F is the
primary binding factor for HMPV. As expected, HMPV was unable to infect pgsD677 cells since
the virus cannot bind to these cells (Figure 18C). Importantly, no significant differences in the
levels of control PIV5 infectivity were seen in pgsA745 and pgsD677 cells (Figure 18C). Since PIV5
is known to bind to sialic acid, our results suggest that binding to HS is an event specific for
HMPV.
To further confirm that heparan sulfate is indeed the primary binding partner for HMPV
F, CHO-K1, ldlDLec1, pgsD677, and pgsA745 were treated with either a mixture of 2mIU/mL of
heparinase 1 and 3 or with 20mIU/mL of chondroitinase ABC for 2 hours prior to analysis of
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binding for both wild-type HMPV and ΔG/ΔSH HMPV. Binding efficiency for wild-type HMPV was
greatly reduced after pretreatment with heparinase 1 and 3, but not after pretreatment with
chondroitinase ABC (data not shown). This drastic reduction in binding efficiency after
treatment with heparinase 1 and 3 was reproduced using ΔG/ΔSH HMPV (Figure 18A-B) and was
also seen after heparinase treatment of Vero cells (data not shown), whereas pretreatment with
chondroitinase ABC did not have an effect on binding. As seen in Figure 18B, treatment with a
combination of heparinase 1 and 3 decreased HMPV binding to both CHO-K1 and ldlDLec1 cells
to levels equivalent to pgsD677 and pgsA745 cells. Similarly, HMPV infection was drastically
reduced below 5% for CHO-K1 cells after pretreatment with either 2mIU/mL heparinase 1 or
heparinase 3 for 1 hr, but not after treatment with 20mIU/mL chondroitinase ABC (Figure 18D).
Importantly, PIV5 infection was unaffected by heparinase 1, heparinase 3, or chondroitinase
ABC treatment, confirming that the interaction between HS and HMPV F is specific to HMPV.
Additionally, the lack of HMPV binding and infection of heparinase-treated β1 integrinexpressing CHO-K1 cells further confirms that the initial binding step of productive infection is
dependent on heparan sulfate, and that the F-heparan sulfate interaction cannot be replaced
with integrins.

Discussion
The results presented in this study indicate that the initial interaction between HMPV
and its target cell occurs through heparan sulfate moieties expressed at cell surface.
Importantly, we provide direct evidence that the critical virus-cell attachment step is
predominantly mediated by the fusion protein of a paramyxovirus. Furthermore, our results
support the report from Cseke, et. al. that αvβ1 integrin is important for HMPV infection,
though our studies suggest that the role of this integrin is not as the initial binding receptor.
Rather, our results indicate that β1 integrin promotes efficient HMPV infection after the virus
binds to cell surface heparan sulfate.
In this study, we confirmed that the fusion protein of HMPV is the primary entry factor
of the virus, promoting both virus-cell binding and membrane fusion. No differences in binding
or infectivity were observed between the WT virus and the mutant viruses lacking HMPV G or
both HMPV G and SH (Figures 13 and 16). A recent report showed that cell surface nucleolin is a
functional receptor for RSV F (342). This interaction, however, is likely preceded by interactions
between GAGs and RSV G, as G expression is still required for efficient growth in vivo (164, 174,
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342, 344). Our previous observation that HMPV F-mediated cell-to-cell fusion occurs in the
absence of HMPV G ((299) and Figure 12) and our current study indicating that HMPV binding is
very different from other paramyxoviruses, both support the idea that the HMPV F protein is the
major factor driving both viral attachment and entry. We cannot, however, rule out the
possibility that the HMPV G could confer a selective advantage for viral attachment in some
tissues as it has been demonstrated previously that the HMPV ΔG mutant is less efficient at
infecting the lower respiratory tract (31).
It has been reported that all strains of HMPV isolated clinically have a conserved ArgGly-Asp (RGD) sequence in their F protein, raising the possibility of an interaction between F and
integrins (80). Indeed αvβ1 integrin has been shown to be a major factor promoting HMPV
infection (80). A direct interaction between αvβ1 integrin and the prefusion conformation of
HMPV F, however, has not been confirmed. In this study, we investigated the role of β1 integrin
and the RGD sequence in HMPV F by performing functional studies with an HMPV F RGA mutant
and assessing the binding and infectivity of recombinant HMPV in cells lacking β1 integrin. Our
data show that the RGD motif of HMPV F is not necessary for cell-to-cell membrane fusion
(Figure 12), suggesting that this motif is not needed for F-mediated membrane fusion.
Additionally, three independent approaches to assess virus binding clearly indicate that
expression of β1 integrin, or lack thereof, does not significantly affect binding (Figure 13). Cells
lacking β1 integrin, however, are significantly more resistant to HMPV infection. Interestingly,
infectivity of CHO-K1 is equivalent to that of Vero (Figure 14) and LLC-MK2 cells (data not
shown) even though there were no detectable levels of αv integrin in CHO-K1 cells. This suggests
that the β1 integrin subunit plays a more important role in HMPV infection than the αv subunit.
Thus, our data show that β1 integrin expression dramatically enhances the infectivity of HMPV,
but is not required for the initial binding of the virus.
It is not clear what role β1 integrin plays in HMPV entry, especially since a HMPV
carrying an RGA mutation in its F protein is currently not available, but our data suggest that β1
integrin is involved after initial binding and not as a direct initial cellular receptor for the virus.
Analysis of a homology model of HMPV F in its prefusion and postfusion conformations, based
on the crystal structure of the prefusion form of PIV5 F (384) and postfusion form of Newcastle
disease virus F respectively (336), suggests that the RGD motif in HMPV F is covered by other
stretches of the protein in its prefusion form (Figure 19A, RGD shown in red). Although partially
buried, the RGD motif appears to be more accessible for protein-protein interaction in its post73

fusion conformation (Figure 19B), suggesting that an RGD-dependent integrin interaction is
more likely to occur in an intermediate step of the viral entry process, after a change in
conformation from the prefusion form of F that exposes the RGD motif (15, 328). Integrins are
well-known for their signaling capabilities and their ability to orchestrate a myriad of cellular
processes. Indeed, the involvement of integrins in these processes has been shown to influence
viral infectivity. The regulation of endosomal cathepsins by the α5β1-integrin, for instance,
mediates Ebola virus entry (297) and the presence of a cellular receptor is presumably
dependent on membrane trafficking of proteins mediating cell adhesion (96, 97). Since HMPV
infectivity is decreased without changes in cell binding when β1 integrin expression is altered, it
is possible that, after a conformational change that results from the initial binding step, HMPV F
interacts with αvβ1 integrin, triggering a signal that increases cell permissiveness. Alternatively,
αvβ1 integrin could direct HMPV to a more efficient route of entry without necessarily
interacting with the virus, as it has been hypothesized for HSV (123).
We report that the primary cellular binding partner for HMPV is proteinaceous in
nature, as infection is decreased by protease treatment (Figure 15). Importantly, integrins,
including β1, are known to be trypsin resistant (142), and we confirmed that neither αv nor β1
are sensitive to cleavage by trypsin or proteinase K since the antibody epitope was not affected
by the proteases (Figure 15). Since pre-treatment of Vero or CHO cells at trypsin concentrations
higher than 0.0625% does not further reduce HMPV infectivity (Figure 15 and data not shown),
HMPV entry appears to involve more than one component of which at least one is trypsin
sensitive and at least another is trypsin resistant. While the antibody epitopes were unaffected
by protease treatment, there remains a possibility that the interaction sites with HMPV F were
destroyed.
Our analysis of HMPV binding and infectivity of mutant cell lines derived from the CHOK1 indicate that binding and infectivity are highly dependent on the presence of GAGs,
especially heparan sulfate. The drastic reduction of binding and infectivity of pgsA745 and
pgsD677 cells compared to WT suggests that HMPV specifically interacts with HS (Figure 16-18).
Importantly, this robust reduction in binding and infection was reproduced by treating the
parental, β1 integrin-expressing CHO-K1 cells with heparinases (Figure 13A and 18). Since β1
integrin is not an HSPG, it should not be affected by heparinase treatment. The dramatic loss in
both binding and infection of CHO cells after treatment with heparinase confirms that the
heparin sulfate-F interactions are needed for productive infection, and cannot be replaced by
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the presence of integrins. Altogether our data strongly suggest that the inhibition of HMPV
infection with heparin treatment reported by Wyde, et. al. (380) was due to a direct and specific
interaction of the virus with HS. Importantly, our data show that the dependence on HS for
infection is driven by HS interactions with the F protein rather than the G protein as previously
hypothesized (380). The use of the F protein as the primary viral protein for cellular attachment
highlights the uniqueness of HMPV among the paramyxoviruses, as other human pathogens in
this family use the attachment protein for this step.
Carbohydrates play an important role in entry for many viruses including RSV, the
closest human pneumovirus related to HMPV (132, 174, 202). Indeed, earlier studies have
suggested that both RSV F but primarily RSV G are capable of binding GAGs (115, 174, 176). Here
we report that, unlike RSV, the fusion protein of HMPV is the main GAG-binding protein. It has
been reported that a recombinant HMPV G protein has the ability to bind GAGs (347). In light of
our findings, this interaction is not required for the initial viral attachment step. Nonetheless,
since HMPV G is present in all clinical isolates sequenced so far (27, 31) and studies by Biacchesi,
et. al. demonstrated that HMPV lacking the G protein is significantly attenuated for infection in
the upper respiratory tract of hamsters (31), this protein could confer an advantage for the virus
to grow in vivo by either facilitating infection of certain cells with a specific GAG (or a specific
protein) recognized by G at a higher affinity or by providing a protective mechanism against the
host immune defenses (27, 31, 346).
Since the sequence of the F protein from the virus used in this study was verified to be
identical to the original CAN97-83 sequence directly isolated from the patient, the interaction
between HS and the HMPV F protein is likely relevant in vivo. Some studies have shown that cell
surface HS is located primarily on the basolateral side of differentiated ciliated airway epithelial
cells (52, 226, 389). Thus, binding to HSPG may be used to infect non-ciliated cells in the
respiratory tract, or to promote cell-to-cell spreading from the basolateral side. Moreover, the
small amount of HSPG present on the apical side (52, 75) could be enough for HMPV to establish
an initial infection in the upper respiratory tract. Since apical levels of HSPG are upregulated
upon injury and basolateral HSPGs can be exposed when the monolayer is disrupted (including
during tissue regeneration) (52), this initial infection would in turn increase the accessibility of
HSPGs to the virus.
By examination of viruses using HS as their first attachment factor (245, 390), it is
possible to distinguish three potential mechanisms leading to infection (Figure 20). Like most
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viruses that bind HS, HMPV could attach to this specific GAG to concentrate at the cell surface
and facilitate a subsequent interaction with a more specific secondary receptor, which could be
another HSPG (Figure 20A) (2, 120, 181, 220). Alternatively, HMPV could interact with a specific
chemical modification of HS which then directly triggers fusion, as it has been reported as one of
the entry pathways for HSV-1 (Figure 20C) (241, 308, 349). While not reported yet, the high
affinity attachment and promotion of fusion could also be carried out by one specific HSPG
(Figure 20B). Like HSV (72), HMPV could also be interacting with different cellular proteins and
using different entry pathways depending on the cell type. While the data reported in this study
indicate that HMPV binds to HS, whether HS alone is sufficient to trigger fusion remains
unknown.
In this study, we demonstrated that the F protein is the major protein driving
attachment of HMPV. We also showed that αvβ1 integrin is not responsible for viral attachment,
but instead that the cell-virus interaction is highly dependent on the presence of HS. Several
HSPGs have been identified to date with a wide range of function including basement
membrane barrier organization, cell signaling, and cellular crosstalk (78). Interestingly, some of
HSPGs have the ability to interact with integrins. Since interactions with integrins enhance
HMPV infection and HMPV binds to HS, a specific HSPG could mediate the interaction between
the virus and integrins, allowing the virus to efficiently infect its target cell.
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Table 3. Cell lines used in this study.
Phenotype under culture conditions
Name

Mutation

Complex N-

O-linked Glycans

linked glycans Mucins

GAGs

Vero

N/A

Yes

Yes

Yes

CHO-K1

N/A

Yes

Yes

Yes

pgsA745

Xylosyltransferase

Yes

Yes

No

Yes

Yes

No HS

No

Yes

Yes

No

No

Only HS

N-acetylglucosaminyltransferase
pgsD677 and glucuronyltransferase-deficient
CHO mutant
Lec1

ldlD.Lec1

GD25

β1GD25

GlcNAC Transferase 1-deficient
CHO mutant
GlcNAC Transferase 1 and 4Epimerase-deficient CHO mutant
β1 integrin null mouse embryonic
fibroblast
GD25 cells stably transfected with
human β1 integrin
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Figure 12. HMPV F RGA mutant promotes cell-to-cell membrane fusion at levels similar to
HMPV F WT.
A. Representative SDS-PAGE gel of lysates from metabolically labeled and biotinylated Vero
cells transfected with F WT vs F RGA. The total amount of F was immunoprecipitated with an Fspecific antisera and the surface population separated using streptavidin beads. Slower
migrating bands represent higher oligomeric forms of HMPV F. B. Quantification of SDS-PAGE
bands (n=3) corresponding to total (black column) and surface (white column) expression of
HMPV F WT and RGA mutant. Data represented as percent of surface or total WT F0 or F1
expression. C. Representative pictures (n=4) of syncytia assays in Vero cells transfected with F
WT or the HMPV F RGA mutant are shown. D. Luciferase reporter gene assay (n=3) used to
compare fusion activity between HMPV F WT (black) and HMPV F RGA mutant (gray). MCS
(white) = multiple cloning site, empty vector pCAGGS control. Error bars = mean ± standard
error of the mean.
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Figure 13. Initial HMPV binding is independent of β1 integrin expression.
A. Expression levels of αv and β1 integrins in Vero, GD25, β1GD25, and CHO-K1 cells assessed by
flow cytometry. Control (gray) = secondary antibody only. B. Different MOIs (0.5, 1, 2, 5, 10, 25,
and 50) of HMPV were bound to GD25 (close circle), β1GD25 (close square), and CHO-K1 (open
circle) cells. HMPV binding was assessed by HRP activity following immunolabeling of the HMPV
N protein. Data were normalized to virus bound to Vero cells at an MOI of 10. Results shown are
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average of duplicate wells for 3 independent experiments. Error bars = mean ± standard error of
the mean. C. Representative western blots used for quantification in D. WT rgHMPV (lanes 2, 6,
and 10), ΔG mutant HMPV (lanes 3, 7, and 11), and ΔG/ΔSH mutant HMPV (lanes 4, 8, and 12) at
an MOI of 7 were bound to Vero (1-4), GD25 (5-8), and β1GD25 (9-12). Lysates of virus bound to
cells were collected and a volume corresponding to an equal number of cells was analyzed with
an anti-HMPV F antibody. The control cell lane without virus is shown in lanes 1, 5, and 9. D. The
signal intensity of specific bands for HMPV F protein on the western blot was quantified for WT
(black), ΔG (gray), and ΔGΔSH HMPV (white) bound to the different cell lines and normalized to
WT Vero cell binding efficiency (n=6). Error bars = mean ± standard error of the mean. Brackets
= p > 0.05, ANOVA. E. an equal number of WT, ΔG, and ΔGΔSH viral particles concentrated by a
sucrose cushion were lysed, and blotted for HMPV F using anti-HMPV F antisera. Figure shows
quantification of the signal of the specific bands on the western blot (n=10). Data were
normalized to control WT GFP-expressing HMPV. Error bars = mean ± standard error of the
mean.
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Figure 14. HMPV infection is enhanced by the expression of β1 integrin.
Vero (close circle), GD25 (close square), β1GD25 (open circle), and CHO-K1 (open square) cells
were infected with different amounts of WT rgHMPV. GFP-expression of at least 10,000 cells
was analyzed by FACS the following day. Results shown are average for 3 independent
experiments done in duplicate. No statistical significance was seen between CHO-K1 and Vero
infectivity. Error bars = mean ± standard error of the mean. Significant difference was observed
in infectivity between GD25 cells and β1GD25 cells.
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Figure 15. Effective HMPV infection requires the expression of a trypsin- and proteinase Ksensitive cellular surface protein.
Vero or CHO-K1 cells were treated with 0% (black), 0.0625% (gray), or 0.125% (white) of trypsin
(A, C, and E) or 0µg/mL (black) or 300µg/mL (white) of proteinase K (B, D, and F) prior to either
infection by control rgPIV5 (A and B) or rgHMPV (C and D), or analysis of αv and β1 integrin
expression (E and F, n=3). GFP-expression or FITC fluorescent intensity of at least 10,000 cells
were analyzed by FACS the following day (n=5 for trypsin and n=6 for proteinase K treatment).
Data in A and B are expressed as percent of total infected cells whereas data in C and D are
expressed as percent of cells infected normalized to Vero cells not treated with proteinase K.
Error bars = mean ± standard error of the mean.
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Figure 16. Initial HMPV binding is dependent on GAG expression and is mediated by the F
protein.
A-C. CHO-K1 (close circle), pgsA745 (close square), Lec1 (open circle), and ldlDLec1 (open
square) cells were exposed to different MOIs (0, 1, 10, and 50) of HMPV WT (A), ΔG (B), or
ΔG/ΔSH (C) at 4°C. Results shown are average of 6 independent experiments done in duplicate.
D. Representative western blot used for quantification in E. WT rgHMPV (lanes 2, 6, 10, and 14),
ΔG HMPV (lanes 3, 7, 11, and 15), and ΔG/ΔSH HMPV (lanes 4, 8, 12, and 16) at an MOI of 7
were bound to Lec1 (1-4), ldlDLec1 (5-8), pgsA745 (9-12), and control CHO-K1 cells (13-16).
Lysates of virus bound to cells were collected and a volume corresponding to an equal number
of cells was analyzed with an anti-HMPV antibody. The control cell line without virus is shown in
lanes 1, 5, 9, and 13. E. Quantification of western blots signal showing binding activity of the WT
(black), ΔG mutant (gray), and ΔG/ΔSH mutant HMPV (white). Data were normalized to WT Vero
binding efficiency (n=10). Error bars = mean ± standard error of the mean. Asterisks p < 0.001
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Figure 17. HMPV infection is greatly reduced in the absence of GAGs.
CHO-K1 (close circle), pgsA745 (close square), Lec1 (open circle), and ldlDLec1 (open square)
cells were infected with different MOIs (0, 1, 10, and 50) of rgHMPV, and GFP-expression of at
least 10,000 cells was analyzed by FACS the following day. Results shown are average of 3
independent experiments done in duplicate. Error bars = mean ± standard error of the mean.
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Figure 18. HMPV binding and infection is decreased in the absence of heparan sulfate.
A and B. HMPV ΔG/ΔSH binding to CHO-K1 (1 – 4), ldlDLec1 (5 – 8), pgsD677 (9 – 12), and
pgsA745 (13 – 16) cells was assessed after a 2 hr treatment with heparinase 1 and 3 (lanes 4, 8,
12, and 16, white), chondroitinase ABC (lanes 3, 7, 11, and 15, gray) or mock (lanes 2, 6, 10, and
14, black). The control cell line without virus is shown in columns 1, 5, 9, and 13. The signal for
the specific bands on the western blots represented in A (n = 3) were quantified and shown in B.
C. pgsD677 cells were exposed to HMPV (black) or PIV5 (white) at an MOI of 10. Data shown is
normalized to infectivity of CHO-K1 cells and represents the average of 3 independent
experiments done in duplicate (n=3). D. CHO-K1 cells treated for 1 hr at 37°C with 2mIU/mL of
Heparinase 1, Heparinase 3, or 20mIU/mL of Chondroitinase ABC (mock treatment as control)
were exposed to 1 MOI of either HMPV (black) or PIV5 (white) at 4°C followed by normal
incubation to allow for infection to occur. pgsA745 infection is shown as control. Data shown are
normalized to infectivity of CHO-K1 cells in the absence of any treatments and represents the
average of 3 independent experiments done in duplicate (n=3). Error bars = mean ± standard
error of the mean.
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Figure 19. Homology model of the prefusion and postfusion form of HMPV F.
A. The amino acid sequence of HMPV F was threaded onto the crystal structure of the prefusion
form of PIV5 F (384) using Deepview Swiss-PDV Viewer v4.0.1. The RGD sequence of HMPV (red)
is covered by two stretches of amino acid (yellow and green in insert). B. Individual sequences of
the F1 and F2 subunits of HMPV F were threaded onto the crystal structure of the postfusion
form of NDV F (336).
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Figure 20. Potential mechanisms for the initial steps of HMPV infection via HSPG interactions.
A. HMPV could bind to any heparan sulfate proteoglycan, or any specific modification in the HS
moiety, through HMPV F, concentrating the virus and allowing HMPV F to interact with a more
specific viral receptor or coreceptor, which could also be an HSPG. This interaction in turn, could
allow the virus to interact with a potential fusion receptor that will activate HMPV F. B. HMPV
could bind to a specific HSPG, or any specific modification in the HS moiety, through HMPV F
and that interaction could be sufficient for HMPV F triggering and viral entry. C. HMPV could
bind to any HSPG, or any specific modification in the HS moiety, through HMPV F and that
interaction could be sufficient for HMPV F triggering and viral entry. Integrin αvβ1 expression
renders the cell to be more permissive to HMPV infection.
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Chapter 5: Studies to Identify a High Affinity Receptor for HMPV

Introduction
We have shown that the initial attachment of HMPV occurs through interactions
between the fusion protein of the virus and cellular HSPGs (65). HMPV binding and infection
decreased to background levels after enzymatic removal of HS and cells without the ability to
synthesize HS were largely protected from HMPV infection. It has also been shown that RSV
interacts with cell surface HS during entry (45, 115, 174, 176). Our studies have also shown that
binding and infection of PIV5, a member of the paramyxovirinae subfamily, is independent of
HSPGs (65). Thus, differences in the requirement for HSPGs appear to be present between
members of different subfamilies. It has been proposed, however, that the interaction between
RSV and HSPGs occurs only in vitro as RSV grown in tissue culture expresses an altered
attachment protein (176). While interactions between GAGs and the HMPV G have been
documented (347), our studies and others indicate that the HMPV G glycoprotein is dispensable
for HMPV infection (31, 65, 312) and that interactions between the HMPV F protein and HSPGs
are necessary for infection to occur (65). Since the sequence of the F protein used in our studies
is identical to the sequence of the original viral strain, we hypothesize that the interaction
between HMPV F and HSPGs are likely to be important in vivo.
Even though HSPGs are ubiquitously expressed and can be found in intracellular
vesicles, at the cell surface, or as component of the basement membrane, only a small subset of
proteins are actually modified by GAGs. To date, only a few proteins expressed at the cell
surface have been found to be HSPGs. These proteins include the four members of the syndecan
family of transmembrane proteins and the six members of the glypican family of GPI-anchored
proteins (78, 190). Syndecans usually possess three to five HS chains located near the
extracellular tips and occasionally also present chondroitin/dermatan sulfate chains near the cell
surface. Three of the four syndecans are tissue specific: syndecan-1 (CD 138) is present in many
epithelial tissues and some plasma cells, syndecan-2 is present in mesencyhymal cell types
(those that differentiate into chondrocytes and adipocytes among others), and syndecan-3 is
specific to neural tissue and in developing musculoskeletal system. Syndecan-4, however, is
widely distributed among many cell types (78). Glypicans usually carry several HS chains near
the surface of the cell and can have an additional chain near the tip of the ectodomain (190). In
addition to syndecans and glypicans, there are three unrelated transmembrane proteins that
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may or may not be present as HS-modified proteins: betaglycan (a.k.a. transforming growth
factor β receptor type III), neuropilin-1, and CD44. Furthermore, glycan forms of betaglycan and
neuropilin-1 can present with HS or chondroitin/dermatan sulfate (78).
While progress has been made toward understanding the early events that promote
HMPV infection, there are several aspects that remain to be understood. Importantly, our
studies indicating that HMPV binding to HSPGs is essential for infection paves the way towards
better understanding the early events that mediate viral entry. Based on studies of other viral
systems, it is possible to distinguish three distinct mechanisms by which HMPV binding to HSPGs
could lead to infection. Like many other pathogens, HMPV could use HSPGs as lower affinity
attachment sites to concentrate the virus at the cell surface and facilitate a subsequent
interaction with a higher affinity receptor that would dictate tissue tropism and facilitate
internalization (Figure 20A) (11, 138, 284, 318). As shown for HTLV-1, this secondary, high
affinity receptor could also be a HSPG (181). Alternatively, HMPV could bind directly to a specific
modification of HS, regardless of the protein HS is attached to, that also mediates internalization
(Figure 20C), as has been reported for HSV-1 (72, 308). Finally, like HEV, HMPV binding and entry
could be promoted by interactions with a single HSPG (Figure 20B) (161). A better
understanding of how HSPGs are utilized in HMPV pathogenesis as well as the discovery of
higher affinity receptors or coreceptors will significantly advance our knowledge of the lifecycle
of this virus, paving the way for the development of therapeutics that will block the attachment
of HMPV to cells.

Results
HMPV Colocalizes with HSPGs and this Interaction is Required for HMPV Infection in BEAS-2B
Cells
Our previous studies showed that CHO-K1 mutants lacking the ability to synthesize HS
were protected from HMPV infection. Furthermore, treatment of parental CHO-K1 cells with
heparinase I and III dramatically decreased HMPV infectivity (65). We therefore attempted to
visualize the interaction between HMPV and HSPGs. Imaging analysis of HMPV bound to Vero
cells showed some colocalization between viral particles and cell surface HS (Figure 21A).
However, a large proportion of the staining from the HMPV F polyclonal antibody (red) did not
colocalize with the staining from HS (green). This could be due to incomplete staining of the
anti-HS antibody, as it recognizes only a specific epitope in the glycan chain (epitope 10E4) that
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may or may not be present in all HSPGs (350, 356). Nonetheless, these results provide visual
evidence that at least some HMPV particles localize near cell surface HSPGs.
While these studies provide evidence of the proximity between HMPV and HSPGs and
support our hypothesis that HMPV binding to HSPGs are important for cell infection, CHO-K1
cells are murine cells of ovarian origin and Vero cells are monkey kidney cells. Thus, to test the
involvement of HSPGs in HMPV infection in a more relevant model, immortalized, noncancerous human bronchial epithelial cells were treated with heparinases and then tested for
HMPV infection. As expected, BEAS-2B cells were permissive to infection by HMPV. However,
HMPV infection was reduced by more than 95% when BEAS-2B cells were pretreated with either
heparinase I or heparinase III (Figure 21B). As seen with CHO-K1 cells, treatment with
chondroitinase ABC did not protect BEAS-2B cells from infection by HMPV. This indicates that
HMPV infection is also mediated largely by HSPGs in this more physiologically relevant cell line.

Syndecan-4, Betaglycan, and Glypicans
To test whether a specific cell surface HSPG serves as a receptor for HMPV,
permissiveness of HMPV infection was assessed in cells where expression of specific HSPGs were
knocked down by RNA interference. Due to the ubiquitous nature of syndecan-4 and betaglycan,
these two proteins were chosen initially as potential candidates. A549 cells, a human lung
carcinoma cell line, were treated with siRNAs against syndecan-4 (sdc4) and betaglycan to
decrease the expression of these proteins. Briefly, 3 x 106 cells were resuspended in 400 µL
RPMI media without additives, electroporated with 200mM siRNA, and incubated for 72 hours
at 37˚C. Transfected cells were then infected with equal amounts of GFP-expressing HMPV, RSV,
or control PIV5 and VSV for four hours and infectivity was assessed by detecting GFP expression
by flow cytometry the following day. Our data suggest that infectivity of HMPV, PIV5, VSV, or
RSV was unaffected by siRNA-mediated knockdown of sdc4 or betaglycan (Figure 22A)
suggesting that these HSPGs do not serve as receptors for HMPV. However, we have been
unable to confirm knockdown of these proteins at the protein level as all the antibodies
obtained thus far failed to detect sdc4 and betaglycan. Experiments to measure RNA levels of
transfected cells will be performed to determine the knockdown efficiency of these siRNAs.
To test whether glypicans are involved in HMPV binding and infection, the
permissiveness of HMPV infection in A549 cells treated with phospholipase C (PLC) was
determined. Treatment of cells with PLC should remove cell surface glypicans as these proteins
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are anchored to the cell surface by glycophosphatidylinositol (GPI). As shown in Figure 22B,
pretreatment of A549, Vero, CHO-K1, or BEAS-2B cells with PLC had a modest effect on HMPV
infectivity, decreasing the overall number of infected cells by less than 20%. This suggests that
HMPV interaction with glypicans is not required for HMPV infection. Experiments to determine
the efficiency of PLC treatment to remove surface GPI-anchored proteins, however, are required
and will be performed to ensure that PLC activity efficiently removes glypicans from A549 cells.

HMPV Binding and Infection are Significantly Impaired in HeLa Cells
For receptor binding studies, it is important to identify cell lines which bind virus to
different extents. We have previously shown that HMPV binding to CHO pgsA745 and pgsD677
mutant cell lines was significantly impaired due to the lack of HS in their cell surface (65).
However, the identification of a parental cell line that lacks the ability to bind HMPV would be a
valuable tool for future studies aimed at identifying high affinity receptors as this cell line would
serve as an important negative control. Thus, I tested HMPV infectivity in several cell lines and
identified HeLa cells as poorly permissive to HMPV binding and infection (Figure 23). Despite
expressing some HSPGs (237, 263, 378) and normal amounts of β1 integrin (155) at the cell
surface, binding of HMPV to HeLa cells decreased by up to 95% compared to control Vero cells
(Figure 23A). In the same way, HMPV infectivity was reduced by up to 98% of that of Vero cells
(Figure 23B). Importantly, HeLa cells were permissible to PIV5 infection to the same degree as
Vero cells. Surprisingly, A549 cells were also less permissive to HMPV binding and infection as
binding and infection decreased by 30 to 40% compared to Vero cells. However, PIV5 infection
in A549 cells was also lower compared to Vero and HeLa cells, suggesting that these cells are
less permissive to infection by paramyxoviruses. Thus, A549 cells appear to bind HMPV with less
affinity whereas HeLa cells appear to express very low to no levels of HMPV binding proteins
and are largely protected from HMPV binding and infection.

Virus Overlay Protein Binding Assay (VOPBA)
A recent study published by Tayyari, et. al. identified nucleolin, a protein primarily
present in the nucleolus but also at the cell surface, as a receptor for RSV using a technique to
identify virus-receptor interactions using SDS-PAGe electrophoresis and mass spectrometry
(342). Briefly, surface proteins from different cell types are biotinylated and pulled down using
neutravidin beads. Cell surface proteins were released from the beads by incubation in SDS
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loading buffer containing DTT and the samples were resolved in a 4 – 12% Bis-Tris gel. Two
samples per cell line were loaded symmetrically on the gel. After electrophoresis, one sample
was transferred to a PDVF membrane while the other sample was fixed in 50% methanol, 10%
acetic acid and stored at 4 ˚C. The membrane was then incubated in the presence of virus and
then blotted with an antibody that recognizes the fusion protein. The resulting western blot
image was superimposed with the fixed gel and the VOPBA bands were excised and analyzed by
mass spectrometry to identify the surface proteins present in the sample. We attempted to
adapt this protocol to identify a high affinity receptor for HMPV. Thus, cell surface proteins of
Vero, A549, HeLa, CHO-K1, and pgsA745 cells were isolated as described and resolved by SDSPAGE. Successful isolation of cell surface proteins was demonstrated by determining the amount
of protein in the sample using the Nanodrop and a BCA assay followed by blotting for the
presence of EGF receptor (data not shown). Samples transferred to the PDVF membrane
incubated in the presence of 1.6 x 107 pfu of rgHMPV. Because our HMPV F and N antibodies
epitopes are located inside the viral membrane, the PDVF membrane was washed with t-TBS
after viral incubation to permeabilize the viral particles. No signal was detected in the
membrane using the anti-HMPV N monoclonal antibody (data not shown). Multiple bands were
seen after blotting with our anti-HMPV F polyclonal antibody (Figure 24A). However, all these
bands were also present in PDVF membranes that were not incubated with HMPV (Figure 24A,
overlay), suggesting that the amount of background signal is too high for this antibody to be
used in this technique.
Because the initial mass spectrometry analysis of one of the bands seen after blotting
with anti-HMPV F antibody showed the presence of nucleolin, and RSV, which has been shown
to use nucleolin as a receptor (342), belongs to the same subfamily of paramyxoviruses, we
tested whether nucleolin is required for HMPV infection. For this, A549 cells were pretreated
with an antibody against nucleolin and then infected with rgHMPV. The percent of infected cells
was determined by FACS as described in materials and methods. While it has been shown that
pretreating cells with an antibody against nucleolin blocked RSV infection (342), pretreatment
with this antibody did not abolish HMPV infectivity in A549 cells (Figure 24B), providing evidence
that HMPV infection does not require cell surface nucleolin. Interestingly, RSV infectivity was
not reduced after cell treatment with the antibody against nucleolin (Data not shown). The
reason for the difference between my results and that of Tayyari and coworkers (342) is unclear
but it is possible that different strains of RSV use different receptors or coreceptors for cell
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binding. Pretreatment with antibodies against syndecan-4 and betaglycan did not alter HMPV
infectivity (Figure 24B), suggesting that these HSPGs are not required for HMPV infection.
However, because we were unable to detect syndecan-4 and betaglycan in western blot
samples using these antibodies, further testing are needed to determine whether these
antibodies bind to their target proteins. Interestingly, HMPV infection decreased by more than
30% in cells pretreated with anti-cathepsin B antibody (Figure 24B). Anti-cathepsin B antibody
was initially chosen as a negative control due to availability and because cathepsin B are
localized to the endosomal pathway. The role for cathepsin B in HMPV infection, however, is still
unknown.

Discussion
The preliminary results shown in this chapter provides important insights into the crucial
process of viral attachment. First, we demonstrated that HMPV infection of BEAS-2B cells also
depends on cell surface HS. Furthermore, we have preliminary data that two ubiquitously
expressed HSPGs do not play a role in HMPV infection. In addition, we showed that, unlike
previously published for RSV (342), cell surface nucleolin does not mediate HMPV attachment.
Importantly, we identified a human cell line that is poorly permissive to HMPV infection that can
serve as a negative control for future studies and we began the development of new techniques
that can be used to identify potential high affinity receptors for HMPV.
We have recently reported that cellular attachment of HMPV is mediated by HSPGs (65).
Even though this work was done primarily in murine cells, we hypothesized that a similar HSdependent mechanism is required for infection in human bronchial epithelial cells. Here we
confirm that cell surface HS is required for HMPV infection of BEAS-2B cells (Figure 22), which
are immortalized cells derived from non-cancerous human bronchial epithelium and therefore
represent a more physiologically relevant model than CHO-K1 cells. While some studies suggest
that most of the cell surface HS is located primarily on the basolateral side of differentiated
ciliated airway epithelial cells (11, 40, 72), the small amount of HSPG present on the apical side
(11, 14) could be enough for HMPV to establish an initial infection in the upper respiratory tract.
Upon tissue injury, apical levels of HSPG are upregulated and basolateral HSPGs can be exposed
as it occurs during tissue regeneration, increasing the accessibility of HMPV to HSPGs (11).
Furthermore, as seen for some papillomaviruses (168), HMPV infection could occur through the
basolateral side after binding to HSPGs.
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As mentioned previously, there are many ways in which HMPV could use HSPGs for cell
entry (Figure 20). Our studies with syndecan-4, betaglycan, and glypicans favor a model similar
to HSV-1 and HEV (72, 161, 308), where an interaction with one or more specific HSPGs is
required for HMPV infection. Conversely, our preliminary results disfavors a model where HSPGs
serve as generic, low affinity attachment sites as treatments to remove these proteoglycans,
which would decrease the total amount of HS at the cell surface, did not alter HMPV infectivity.
While it is possible that removal of one type of HSPG results in the overexpression of other
HSPGs, it would be highly unlikely as these proteins regulate different cellular pathways. It is
also possible that HSPGs are in such excess that removal of one does not alter HMPV binding.
However, this is less likely because of the limited number of proteins modified by HS and the
fact that we targeted the most common ones. Furthermore, HeLa cells, which express some
HSPGs were unable to bind to HMPV. It is therefore possible that HeLa cells do not express a
specific HSPG that is required for HMPV binding. Therefore, further experiments are needed to
determine whether the surface concentration of these HSPGs was indeed reduced in the
abovementioned experiments and to determine whether these HSPGs are present in HeLa cells.
Whether the HMPV F protein recognizes a specific modification of HS or a site that also depends
on the proteinaceous nature of the HSPG remains unknown.
The studies described in this chapter represent initial steps at elucidating the
attachment factors required for HMPV infection. We determined that HeLa cells expresses
HSPGs but is largely protected from HMPV infection and we provide evidence that the inability
of HMPV to infect these cells are primarily due to the failure of the virus to bind these cells
(Figure 23). Importantly, PIV5 infectivity in HeLa cells was comparable to that in Vero cells. Since
HeLa cells are not protected from infection by all paramyxoviruses, it is likely that HeLa cells do
not express protein that serves specifically as a receptor for HMPV. While previous studies have
shown that HeLa cells express HSPGs at their surface (237, 263, 378), it is possible that the
HSPGs expressed by HeLa cells do not support HMPV binding, suggesting that one or more
specific HSPGs are required for the binding of the virus. Interestingly, HMPV binding and
infection was slightly reduced in A549 cells, a human lung carcinoma cell line, compared to Vero
cells, which are monkey kidney cells. The decrease in both binding and infection suggest that the
binding of HMPV to A549 cell is weaker than HMPV binding to Vero cells. This could be due to
different expression levels of the HMPV receptor(s) or due to higher expression of other
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glycoproteins that shield the viral binding site in A549 cells. This would also explain why HMPV
binding was not significantly increased when higher amounts of virus was used (Figure 23B).
In addition to establishing a negative control for receptor and entry studies of HMPV,
the studies described in this chapter also provides foundational work for the development of
new techniques to identify high affinity receptors for HMPV. The results shown in by Tayyari, et.
al. (342) and the promising data described in this chapter warrants further exploration of the
use of the VOPBA as a method for detecting cellular binding partners for HMPV. For this
technique to work, however, the use of a higher affinity and more specific antibody is needed as
background bands decrease the possibility to identify specific ones. Furthermore, the use of
different types of PAGE gels may be needed to identify very high molecular weight complexes
that may be interacting with HMPV. The development and use of non-denaturing screening
techniques may also be required to identify proteins that only bind to HMPV under native
conditions.
Even though great progress has been made in the understanding of HMPV entry, most
of the cellular factors that the virus hijacks to gain access to the cell are still unknown. The
preliminary studies described in this chapter suggests that HMPV binding occurs through specific
HSPGs that are not sdc4, betaglycan, or members of the glypican family of proteins. In addition,
unlike RSV, HMPV binding does not occur through nucleolin. We have also identified a parental
cell line that can be used with techniques like VOPBA to screen for factors that are important for
HMPV cellular attachment. More work is therefore warranted to get a better understanding of
the initial steps of the lifecycle of this virus.
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Figure 21. HMPV colocalizes with HSPGs and BEAS-2B cells are protected from HMPV infection
after treatment with heparinases.
A. representative image of HMPV bound to Vero cells at 4˚C and stained with an anti-HS (green)
monoclonal and an anti-HMPV F (red) polyclonal antibody. Purple = wheat germ agglutinin
labeling plasma membrane proteins. B. Infectivity of rgHMPV was assessed in BEAS-2B cells
after treatment with heparinase I, heparinase III, chondroitinase ABC, or PLC. GFP expression of
at least 10,000 cells was determined by FACS the following day. Results shown are normalized to
infection in BEAS-2B cells in the absence of treatment and are average of one experiment done
in duplicate.
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Figure 22. Syndecan-4, betaglycan, and glypicans do not play a significant role in HMPV
infection.
A. siRNA-mediated knockdown of syndecan-4 and betaglycan does not alter HMPV infectivity in
A549 cells. Cells electroporated with siRNA were incubated for 72 hours and exposed to HMPV
and control PIV5, VSV, and RSV for four hours. HMPV infectivity was assessed by GFP expression
of at least 10,000 cells 24 hours post infection by FACS. Results shown are normalized to
infectivity of A549 cells electroporated in the absence of siRNA and represents the average of 3
independent experiments done in duplicate (n=3). Error bars = mean ± standard error of the
mean. B. Vero, A549, BEAS-2B, and CHO-K1 cells pretreated with PLC were exposed to HMPV.
Infectivity of at least 10,000 cells was assessed by GFP expression at 24 hours post infection by
FACS. Data shown are normalized to HMPV infectivity in control cells not treated with PLC (n=1
or 2). Error bars = mean ± standard error of the mean.
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Figure 23. HeLa cells are poorly permissive to HMPV binding and infection.
A. Representative western blot used for quantification in B. Red depicts signal from anti-HMPV
polyclonal antibody and green shows actin loading control. B. HMPV binding to Vero, A549, and
HeLa cells at an MOI of 10 and 15 was assessed and quantified as described previously. Data
were normalized to WT Vero binding efficiency (n=4). Error bars = mean ± standard error of the
mean. C. HMPV infection in Vero, A549, and HeLa cells was assessed at an MOI o f 1. Results
shown are normalized to infection in Vero cells and represents the average of up to 3
independent experiments done in duplicate (n=3 for HMPV and n=1 for PIV5). Error bars = mean
± standard error of the mean.
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Figure 24. Virus overlay protein binding assay (VOPBA) optimization and the role of nucleolin
in HMPV infection.
A. Cell surface proteins of Vero, A549, HeLa, CHO-K1, and pgsA745 cells were isolated, resolved
by SDS-PAGE, transferred to a PDVF membrane, and blotted with 1.6 x 107 pfu/mL of HMPV for
four hours. The location of the HMPV F protein in the membrane was detected using the
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Odyssey system after labeling the HMPV F protein with an anti-HMPV F antibody. A control gel
not exposed to HMPV and the overlay between the two gels (green = +HMPV, red = - HMPV) are
also shown. B. Infection by rgHMPV of at least 10,000 A549 cells was assessed by FACS following
incubation with antibodies targeted against syndecan-4, betaglycan, nucleolin, or control
antibodies targeting cathepsin B and myc. Results shown are normalized against infection in the
absence of antibodies and represents the average of up to 3 independent experiments done in
duplicate (n=3 except for cathepsin B – n=1 – and myc – n=2). Error bars = mean ± standard
error of the mean.
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Chapter 6: Examination of the Entry Pathway for HMPV

Introduction
It has long been thought that viruses with a pH-independent fusion protein, including
members of the paramyxovirus family, enter cells at the plasma membrane (180). This
hypothesis is substantiated by the ability of their fusion proteins to promote cell-to-cell fusion
under neutral pH conditions when expressed at the cell surface and the failure to inhibit viral
infection in the presence of chemicals that raise endosomal pH. However, direct evidence of
viral entry at the cell surface has not been obtained (203, 320). Low pH does not block fusion
mediated by F proteins from PIV5 (35), HeV (63), RSV (320), NDV (54, 292), and pH-independent
strains of HMPV (203), suggesting that the fusion protein could be active either on the surface
or in endosomes. Furthermore, RSV and NDV fusion has been shown to be enhanced with low
pH (54, 292, 320). Therefore, the pH requirement for fusion does not necessarily clarify the
location of the fusion reaction.
Earlier studies performed by Dr. Rachel Schowalter which I completed provided initial
evidence that HMPV strain CAN97-83, which expresses a fusion protein that can be triggered by
low pH (143, 299), could enter cells through endocytosis, as agents that raise endosomal pH and
chemicals that block clathrin and dynamin-dependent endocytic pathways all blocked infection
by HMPV (298). Thus, the fusion protein of HMPV CAN97-83 could use the low pH environment
in the endocytic pathway to promote membrane fusion.
Even though viruses with fusion proteins that are triggered by low pH enter cells
through endocytosis, a low pH-triggering fusion protein is not a requirement for viruses to use
endocytic pathways. Indeed, studies have shown that some viruses with pH-independent fusion
proteins such as HIV can enter cells through endocytosis (218). Additionally, it has been
reported that some members of the paramyxovirus family could enter cells through different
endocytic mechanisms (54, 171, 262). Since we obtained initial evidence that HMPV uses
endocytosis for cell entry ((298) and Figure 25), we performed studies to characterize its entry
pathway. Additionally, we engineered GFP-tagged viral proteins with the ultimate goal of
creating fluorescently label viral particles to perform live cell studies on the entry pathway of
the virus.
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Results
HMPV and PIV5 Infection is Partially Inhibited by Methyl-β-cyclodextrin and is Likely Independent
of Caveolin-mediated Endocytosis
Our initial results using inhibitors of different endocytic pathways, including the
dynamin inhibitor dynasore, suggested that HMPV could be using endocytosis for entry.
Interestingly, treatment with dynasore, an inhibitor of dynamin, also decreased PIV5 infection.
HMPV and PIV5 infection decreased significantly after cells were treated with dynasore in a
dose-dependent manner, though inhibition of PIV5 infection was only partial (Figure 25A and
(298)). We have previously shown that chlorpromazine, which promotes misassembly of clathrin
at the cell surface and inhibits clathrin-mediated endocytosis (364), partially inhibits HMPV
infection in Vero cells. Infectivity of PIV5, however, was not affected by treatment with
chlorpromazine (298). Our data therefore suggests that HMPV and PIV5 use different pathways
for cell entry although both require the activity of dynamin. The unexpected data suggesting
that two paramyxoviruses are using different endocytic pathways for entry prompted us to
examine the entry pathways of the two viruses. To date, clathrin- and caveolin-mediated
endocytosis are the two endocytic pathways that are best understood. To examine whether
caveolin-mediated endocytosis plays a role in infection by these viruses, we performed initial
studies examining the effects of nystatin and methyl-β-cyclodextrin (mβCD) on viral infectivity.
Nystatin is an antifungal that disrupts lipid rafts by binding to and sequestering sterols. Methylβ-cyclodextrin (mβCD) is a cyclic glucose oligomer that primarily binds to and extracts
cholesterol but can also extract other lipids from the plasma membrane (23). It was previously
shown that cholesterol is important for caveolae maintenance and dynamics and that depletion
of cholesterol inhibits caveolae-mediated endocytosis (204). Even though disruptions in plasma
membrane cholesterol can affect the formation of clathrin-coated vesicles (283, 333), it has
been determined that mβCD and nystatin do not affect clathrin-mediated endocytosis (274).
HMPV infection was not affected by pretreatment of Vero cells with nystatin or when
nystatin was present at the time of infection (Figure 25B), suggesting that disruption of lipid
rafts are not important for viral infectivity and providing initial evidence that HMPV does not use
caveolae-mediated endocytosis. However, HMPV infection was reduced by more than 60% after
treatment with 5 mM mβCD. Furthermore, PIV5 infectivity was reduced by at least 40% when
infection was conducted in the presence of mβCD. VSV infection was almost abolished despite
being internalized primarily by clathrin-mediated endocytosis (156), suggesting that treatment
102

with mβCD is also affecting clathrin-mediated entry (Figure 25C). Interestingly, the effect of
mβCD on viral infection was significantly less pronounced when infection took place after
pretreatment with but in the absence of mβCD (Figure 25C, white bars). The discrepancy in the
effectiveness of mβCD inhibition could be due to a rapid replenishment of certain plasma
membrane lipids or due to a deleterious effect caused by extraction of certain lipids in the viral
envelope. Taken together, our data thus far show evidence that both HMPV and PIV5 can enter
cells through a dynamin-dependent endocytic process. Nonetheless, control experiments
assessing the efficiency of nystatin at disrupting lipid rafts and the changes that occur after
treatment with mβCD are needed and will be performed. While more studies are clearly needed
to elucidate the entry pathway for these viruses, our data provides evidence that clathrinmediated endocytosis is an entry pathway for HMPV entry whereas PIV5 takes advantage of a
clathrin- and caveolin-independent pathway but dependent on dynamin.

HMPV and PIV5 Infection can Occur in the Presence of DN Dynamin and CA Rab5
Unlike viral entry at the plasma membrane, entry by endocytosis is a much more
complex pathway that invokes the activity of many cellular proteins in order to carry the viral
particle to the site of fusion. While there are several pathways for viral internalization by
endocytosis (reviewed in (213)), it appears that in most cases, the cargo in primary vesicles are
transported into early endosomes, where the cargo is subsequently sorted through the
endosomal system (213, 259). To test whether HMPV and PIV5 entry occurs through the
endosomal system, access to early endosomes through clathrin and caveolin-mediated
endocytosis was blocked by overexpressing the dominant negative mutant of dynamin K44A
(DN), which is defective in its GTP-binding activity (82) and prevents vesicle budding at the
plasma membrane. HMPV or PIV5 were then added to transfected cells and, as previously
reported, the cellular morphology of cells overexpressing the DN dynamin changed from having
a polygonal shaped to a more round-edged appearance ((82) and Figure 26). Surprisingly, our
data shows that cells overexpressing of DN dynamin can be infected by HMPV and PIV5 as GFP
expression, which indicates translation of the viral genomic RNA, was observed in cells
transfected with WT or DN dynamin (Figure 26, red cells express dynamin, green cells are
infected with virus, yellow are areas with dynamin and GFP). Interestingly, the GFP expression
pattern in cells expressing WT and DN dynamin that were infected by HMPV differed. Most cells
accumulate GFP at very distinct locations in the cytoplasm after infection with rgHMPV
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(presumably near the plasma membrane) while only a small subpopulation of cells express GFP
in the nucleus. However, a higher proportion of rgHMPV-infected cells transfected with DN
dymanin showed a diffused GFP-expression pattern in the cytoplasm and expressed GFP in the
nucleus. GFP distribution after PIV5 infection, nonetheless, appears to be unaffected by the
overexpression of either WT or DN dynamin (Figure 26). While this data suggest that HMPV and
PIV5 can infect cells expressing DN dynamin, more studies with higher populations of
transfected cells are needed to quantify changes in infectivity between cells expressing WT and
DN dynamin. Furthermore, control experiments testing the efficacy of DN dynamin at blocking
endocytosis need to be performed.
HMPV and PIV5 infection was also tested after transfection with WT Rab5 and the
constitutively active (CA), GTP-bound Rab5 Q79L mutant (327) as infectivity of cells
overexpressing these proteins should be high. Cells overexpressing Rab5 WT or CA were
permissive to HMPV and PIV5 infection and no changes in GFP localization after infection was
seen in these cells (Figure 26). Experiments testing the effect of dominant negative Rab5 will be
performed to determine if these cells can be infected by HMPV and PIV5. Additionally, studies
with higher populations of transfected cells will be performed to quantify differences between
infectivity of cells expressing WT, DN, and CA Rab5.

HMPV Entry Colocalizes with Rab7 but not with Rab5
The results shown in Figure 26 indicate that HMPV and PIV5 infection can occur in the
presence of WT and DN dynamin as well as WT and CA Rab5. This is surprising given that both
clathrin and caveolin-mediated endocytosis require the activity of dynamin for the formation of
the endocytic vesicle and our results using chemical inhibitors suggest that these viruses use
endocytosis for entry. Thus, we attempted to track viral entry at different time points to
determine whether these viruses colocalize with endosomes. Initial studies were performed
using HMPV and VSV as control. Briefly, HMPV and VSV were bound to Vero cells at 4˚C for one
hour and then allowed to internalize for 5 to 15 mins at 37˚C. Viral internalization was stopped
by washing extensively with PBS chilled to 4˚C followed by fixation with 4% paraformaldehyde.
Cells were washed and fixed immediately after viral binding for the t = 0 mins as control. After
the samples were permeabilized with 1% Triton X-100 and blocked with normal goat serum,
HMPV was labeled with an antibody against its nucleoprotein and VSV was labeled with an
antibody against its matrix protein followed by incubation with a secondary antibody conjugated
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to the fluorophore Dylight488. Endogenous cellular EEA-1, Rab5, and Rab7 were labeled at the
same time to determine whether viral particles colocalize with these proteins. Furthermore, cell
surface sialic acid and N-acetylglucosamine were labeled with wheat germ agglutinin conjugated
with Alexa Fluor647 to determine the location of the plasma membrane.
As expected, HMPV particles were found at the plasma membrane immediately after
the binding step and did not colocalize with EEA-1 or Rab5, both markers of the early
endosomes. However, a small number of HMPV particles colocalized initially with Rab7, a
marker of the late endosome and lysosome (Figure 27). This colocalization was also observed
after five minutes but colocalization with EEA-1 and Rab5 was still not observed. No
colocalization was observed between VSV and EEA-1, Rab5, or Rab7 at the same time point.
Experiments with longer time points were also performed but they provided inconclusive results
(data not shown). It has been shown that VSV enters primarily through clathrin-mediated
endocytosis particles reached the early endosomes but not the late endosomes (8). However,
VSV internalization has been shown to be synchronized and occur very rapidly, with some
estimates as fast as two minutes (156). Thus, it is possible that colocalization of VSV with early
endosomal markers were not seen because the viral particles had already fused with the cell. It
is unclear why we observed colocalization between HMPV and Rab7 at both time points. It is
possible that a subpopulation of Rab7 molecules is localized near the plasma membrane at a site
very near to the binding site of HMPV but not near the binding site of VSV. More experiments
will be required to determine whether HMPV attachment occurs in distinct areas of the cell
surface and whether Rab7 are localized near that area. Experiments involving live-cell imaging
will greatly help elucidate the entry pathway of HMPV but these experiments required the
availability of a fluorescently-tagged viral particle.

GFP-tagged HMPV G Protein is Expressed at the Cell Surface
The availability of fluorescently tagged viral particles would facilitate the study of viral
entry as it would allow direct visualization of the entry process. Thus, to generate a fluorescent
viral particle, we engineered the GFP-tagged HMPV G and HMPV M proteins and attempted to
incorporated into the viral particles in trans. Briefly, DNA fragments bearing the genetic
sequence for HMPV G and HMPV M and flanked by restriction sites were ligated onto the
pEGFP-C1 or pEGFP-N1 mammalian expression vectors. Because HMPV G is a type II
transmembrane glycoprotein and possess an N-terminal cytoplasmic tail, ligation into the
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pEGFP-C1 vector resulted in a GFP tag located inside the viral and cellular membranes (GFPHMPV G) whereas ligation into the pEGFP-N1 vector produced a HMPV G protein with the GFP
tag in the ectodomain (HMPV G-GFP). Because the HMPV G protein is dispensable for the HMPV
lifecycle in vitro, a GFP tag in this protein is less likely to induce deleterious effects to the virus.
The resulting plasmids were sequenced to confirm the presence of the fused protein and were
then transfected into Vero cells. Our preliminary studies showed that both the HMPV G-GFP and
GFP-HMPV G plasmids were expressed at the surface of Vero cells (Figure 28). Experiments are
currently under way to determine whether the proteins expressed from these plasmids can be
incorporated into the viral particle. Due to the abundance of HMPV M protein inside viral
particles, we decided to tag this protein in addition to HMPV G. We are currently determining
whether the GFP-tagged HMPV M protein is expressed in Vero cells.

Discussion
The preliminary results presented in this chapter provide useful information about the
entry process of HMPV and PIV5. We showed evidence that infectivity of both these viruses
could be blocked by inhibiting the activity of dynamin with the compound dynasore.
Furthermore, we provide evidence against a role of caveolin-mediated endocytosis in HMPV and
PIV5 entry, as nystatin has been shown to inhibit endocytosis mediated by caveolin and not by
clathrin (274). Additionally, we performed initial studies assessing viral infectivity in the
presence of dominant negative dynamin as well as a constitutively active Rab5 mutant and we
carried initial colocalization studies to identify the spatial location of viral particles over time.
Finally, we have tagged the HMPV G and HMPV M proteins with GFP and are continuing to work
on creating a fluorescent labeled viral particle.
Even though our initial evidence suggest that HMPV and PIV5 use an entry pathway that
depends on dynamin and that HMPV infection can also be inhibited by chlorpromazine (Figure
25 and (298)), the data obtained using dominant negative dynamin shows that cells expressing
this mutant protein are still susceptible to HMPV and PIV5 infection (Figure26). Dominant
negative mutant proteins act by outcompeting endogenous wild type proteins and preventing
them from acting on the substrate. Thus, the apparent discrepancy could be due to incomplete
inhibition of vesicle scission by DN dynamin, as only one viral particle needs to reach the
cytoplasm for infection to take place and GFP to be produced. Furthermore, our studies with
dynasore indicate that PIV5 infection is only partially dependent on dynamin and still a small
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population of cells was infected by HMPV after treatment with dynasore, suggesting that
alternative pathways for infection exist for both of these viruses. Due to the lack of a highly
efficient transfection method, cells were infected with a much higher MOI to minimize the
chance that an insufficient number of viruses in the sample result in large numbers of
noninfected cells. Exposure to more viruses and imaging of a limited number of cells could
therefore result in imaging of cells infected by alternative entry pathways.
We have also shown that HMPV and PIV5 infectivity is decreased when cells were
treated with mβCD but not after treatment with nystatin. While both chemicals bind to
cholesterol with high affinity, their overall mechanism of action and the effect on cells differs.
Nystatin usually binds to sterols (including cholesterol and ergosterol) at the cell surface and
causes an increased in membrane permeability by forming pores (173). Compounds like mβCD,
on the other hand, extract cholesterol and other lipids from the plasma membrane without
perturbing the bilayer (23). It is possible that the differences in inhibition of viral infectivity be
due to the differences in the mechanism of action of these compounds. Additionally, it has been
shown that mβCD also extracts lipids like sphingomyelin (274). It has been shown that the lipid
composition of viral and cellular membranes play an important role in HCV infectivity (6, 362). It
is possible that extraction of lipids like sphingomyelin from viral and cellular membranes explain
the effect of mβCD on viral infection. Thus, it would be of interest to determine whether
differences in viral and plasma membrane lipid composition have an effect on paramyxovirus
infectivity.
Elucidating the entry pathway of HMPV is of great importance as it will provide
information that could be used in the development of therapeutics. With the data presented in
this chapter, we have only begun to dissect the entry pathway of HMPV. Many more studies are
therefore required to clearly elucidate the route of entry of HMPV as well as the viral and
cellular compounds, including proteins and lipids, that are responsible for viral invasion.
Important experiments that are currently underway include testing the effect of overexpression
of dominant negative Eps15 and caveolin as well as colocalization studies with molecules
involved in the clathrin and caveolin endocytic pathways. Furthermore, the availability of a
fluorescently labeled virus would help in colocalization studies using live microscopy.
Confirmation that viral entry of HMPV and PIV5 occur through endocytosis would represent an
important step forward in our understanding of paramyxovirus entry, as these viruses belonged
to different subfamilies and PIV5 has long been used as a model for paramyxoviruses.
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Figure 25. HMPV and PIV5 infection likely occurs through endocytosis.
A. HMPV, PIV5, and control VSV entry in Vero cells treated with dynasore. Cells in 24-well plates
pretreated with dynasore or vehicle control diluted at 80 µM (black) or 120 µM (white) were
infected in the presence of drug for 2 hrs. For analysis of the effects of dynasore postinfection,
drug or vehicle control was added for 2.5 hrs after infection. Cells were analyzed by FACS for
GFP expression the following day. Data shown represent the number of GFP-expressing cells as
a percentage of control (infectivity of cells treated with vehicle control) and are the average of 3
independent experiments done in duplicate. Error bars = mean ± standard error of the mean. B.
Infectivity of HMPV was determined in Vero cells after pretreatment (black) and/or in the
presence of nystatin (gray = pretreatment + coinfection, white = coinfection only). The
fluorescence intensity of at least 10,000 cells was determined by FACS the following day. Results
shown are normalized to infection in no nystatin control and represents the average of 4
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independent experiments done in duplicate (n=4). Error bars = mean ± standard error of the
mean. C. Vero cells were infected with HMPV, PIV5, or VSV after (black) or during (white)
treatment with 5mM mβCD. Cells were analyzed by FACS for GFP expression the following day.
Data shown represent the number of GFP-expressing cells as a percentage of control (infectivity
of cells treated with vehicle control) and are the average of 3 independent experiments done in
duplicate. Error bars = mean ± standard error of the mean.
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Figure 26. HMPV and PIV5 can infect cells expressing dominant negative dymanin and
constitutively active Rab5.
Vero cells grown in coverslips and transfected with either WT dynamin or dynamin K44A mutant
or either Rab5 WT or Rab5 Q79L mutant fused with mCherry and mRFP respectively (red) were
infected with either GFP-expressing HMPV or PIV5 (green) for three hours. Following an
overnight incubation, cells were fixed, mounted on a slide, and imaged using a Nikon A1
confocal microscope. Images shown are representative of four images taken from a single
experiment (n=1). Arrows indicate cells expressing the transfected protein that have been
infected.
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Figure 27. HMPV entry colocalizes with endogenous Rab7 but not with endogenous Rab5.
HMPV or VSV were bound to Vero cells grown in coverslips at 4˚C. After extensive washing, cells
were either incubated in media prewarmed to 37˚C for 5 mins to allow viral entry before fixing
or fixed right away (t = 0 mins). Samples were permeabilized, stained with antibodies against
HMPV N or VSV M (green) and Rab5, Rab7, or EEA-1 (red), and mounted on a slide for imaging.
Plasma membrane proteins were stained using wheat germ agglutinin conjugated with Alexa
Fluor647 (purple). Images shown are representative of images taken from four independent
experiments (n=4).
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Figure 28. Cellular expression of HMPV G – GFP and GFP – HMPV G.
The gene sequence of the HMPV G protein was placed into the pEGFP-C1 and pEGFP-N1
plasmids in frame with the sequence of EGFP to tag the HMPV G protein with GFP at the N- and
C- terminus (GFP-HMPV G and HMPV G-GFP respectively). Plasmids were purified and
transfected into Vero cells and expression was observed using a Nikon A1 confocal microscope.
High expression levels were seen with both constructs.
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Chapter 7: Discussion and Future Directions

Studies performed on HMPV since its discovery in 2001 (352) have shown that HMPV
differs from other paramyxoviruses in several aspects of the entry cycle. Despite expressing
three surface glycoproteins, only the F protein is required for viral infection (27, 31, 65), which
demonstrates that the F protein possesses receptor-binding activity and that, unlike most
paramyxoviruses, its triggering is not dependent on nor enhanced by the homotypic attachment
protein (180, 299). Moreover, the HMPV F protein is proteolytically cleaved by exogenous
proteases (299, 352) and some strains of HMPV have F proteins that can be triggered by low pH
(143, 180, 298, 299). The results presented here increase our understanding of some of these
unique characteristics of HMPV and elucidate some key aspects in the entry pathway of this
important human pathogen. We confirmed that HMPV binding to cells does not depend on
expression of the HMPV G protein as we showed that the F protein of HMPV specifically binds to
HSPGs and that this interaction is enough for viral binding to the cell ((65) and Chapter 4). We
also confirmed the observation made by Cseke and coworkers that integrins play a role in HMPV
infection (80) though the specific step at which these cellular proteins act remains unknown
((65) and Chapter 4). Furthermore, we explored mechanistically the regulatory role of the
histidine residue at position 435 for low pH triggering of HMPV F and identified new areas in the
F protein where potential electrostatic interactions function to stabilize the F protein and allow
proper local folding (Chang, et. al., manuscript submitted, Chapter 3). Finally, we provided
preliminary evidence on potential candidate receptors for HMPV binding (Chapter 5) and the
potential role of different endocytic pathways on viral entry (Chapter 6). The studies presented
here therefore represent important steps forward in our understanding on the entry cycle of
HMPV and could potentially serve as the basis for the development of therapeutic agents.

The Triggering of HMPV F
Most studies to date have provided strong evidence that paramyxovirus F proteins were
able to efficiently promote membrane fusion at neutral pH and that fusion activity could not be
promoted by low pH. This holds true for most paramyxoviruses (180) as prior to the studies
carried by Dr. Schowalter in our laboratory (299), there was only one study that showed some
increase in RSV fusion at lower pH values (320) and another one implicating low pH triggering
for the paramyxovirus SER (302). In the latter study, cells expressing the SER F protein after
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infection with a vaccinia virus vector were able to efficiently form syncytia after treatment with
low pH and SER virus was unable to infect cells after treatment with lysosomotropic agents
(302). These studies, however, remain controversial as they were not able to be replicated in
cells expressing SER F after transfection (35). Since Dr. Schowalter’s finding on low pH triggering
of HMPV F (299), others have shown that the F protein of other strains of HMPV can also be
triggered by low pH (143, 203).Thus, the studies on HMPV from our laboratory represent the
first confirmed example of a paramyxovirus F protein whose membrane fusion activity can be
significantly promoted by low pH.
The ability of HMPV F to be triggered by low pH poses interesting questions about the
differences between the F protein of HMPV and the rest of paramyxoviruses. Previous studies
from our laboratory showed that histidine residues, particularly one at position 435 (H435),
have an important role in the regulation of low pH triggering (298). With a pKa of 6.4, histidine
residues are important physiological regulators of pH-dependent processes as changes in the
protonation state of these residues can occur under physiological conditions and translate into
drastic changes in protein conformation. In the case of viruses, it has been shown that
protonation of histidine residues at low pH are involved in the activation of all three classes of
membrane fusion proteins including the fusion proteins of influenza (HA protein, also a class I
fusion protein), dengue virus (E protein, a class II fusion protein), and VSV (G protein, a class III
fusion protein)(56, 162, 348). Mutations of histidine residues in influenza HA destabilize the
protein leading to triggering at higher pH values (348). Our initial studies suggested that the
protonation of the histidine residue H435 is important for triggering of HMPV F by low pH (298).
The studies presented in Chapter 3 and those of Mas, et. al. (203) have confirmed the
requirement of a positive charge at this position for the triggering of HMPV F.
Despite the dramatic reduction in cell-to-cell fusion observed when the charged
residues around HMPV F H435 were removed (298), we were able to rescue infectious HMPV
particles after introducing these mutations into the viral genome (Figure 8). Interestingly, while
viral titers from all mutant viruses were reduced by three or more logarithmic units compared to
WT, titers from recombinant viruses expressing the H435A and H435N mutations were
significantly higher than viruses bearing the K295A and R396A mutations (Figure 8). The reason
why the HMPV F mutations R396A and K295A appear to be more deleterious to the viral
lifecycle compared to mutations in H435 is still unclear. Our homology model of the HMPV F
protein in its prefusion conformation predicts K295 and R396 to be freely exposed at the surface
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of the protein (Figure 6). It is possible that these residues have other important roles in the
lifecycle of the virus and thereby increasing the selective pressure and making these mutations
more difficult to overcome. We have shown that HMPV entry is initially mediated by
interactions between the F protein and heparan sulfate ((65) and Chapter 4). Therefore, one
possibility is that the positively charged residues K295 and R396 are needed for interactions
with the negatively charged heparan sulfate during virus entry. While H435 and its surrounding
residues are located at the base of the head domain, interactions between HS and this region
could take place at an intermediate step in the fusion process or with longer branches of
heparan sulfate.
Based on our data from fusion assays, it was remarkable that we were able to recover
infectious particles carrying these mutations in their F proteins. Moreover, our preliminary
studies indicate that the efficiency of viral growth is significantly enhanced in subsequent
passages (data not shown). The ability to recover recombinant viruses bearing these mutations
and for them to replicate more efficiently over time suggest that the initial mutations did not
abolish fusion completely and provided a selective pressure for these viruses to evolve
mechanisms to bypass the requirement for protonation of H435 to trigger the F protein.
Interestingly, conventional sequencing data, which presents the average sequence in a sample
population, provided no evidence of compensating mutations in the F protein of these viruses
(data not shown). Studies have shown that RNA viruses are capable of generating a very diverse
population of ‘quasispecies’ that act cooperatively to evolve and adapt to new environments
(359). Thus, the presence of a heterogenous population in which subset of viruses harbor
mutations that together provide the adaptive changes that allow viruses with mutations at or
around H435 to grow is possible. Because these quasispecies represent a fraction of the viral
population, they cannot be detected by traditional sequencing methods. Identification of these
quasispecies by deep sequencing the viral genomes is therefore of great interest as they would
provide information on the adaptive changes in the viral population that allowed it to overcome
the mutations around the H435 region. Deep sequencing data could also provide information on
compensatory mutations in the surface glycoproteins, especially in F, increasing our
understanding on the different regions that are important for triggering at low pH. Mapping the
regions important for HMPV F will in turn allow us to determine if those regions are also
important in other paramyxovirus F proteins and will give us a better understanding of this key
step in the viral lifecycle.
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Additional Roles for Potential Electrostatic Interactions in HMPV F
While our experiments and those of others (203) indicate that protonation of HMPV F
H435 is essential for low pH mediated membrane fusion, it is also clear that changes in the
protonation state of H435 alone is not sufficient for F triggering at low pH. Further analysis of
the amino acid sequence of HMPV F revealed another region where potential electrostatic
interactions could play an important role in the trigger of the protein. Interestingly, this region,
which is a three-stranded β-sheet domain made up from residues that are part of HRA and F2,
has been shown to modulate fusion in PIV5 (121). While there is very little sequence similarity in
this region between PIV5 and HMPV, as non-polar residues predominate in PIV5, the importance
of this region in the stability of the protein and the triggering process remains.
Our studies showed that mutations of residues D54 and E56 produced hyperfusogenic F
proteins while mutation at position E51 abolished fusion activity. Despite the proximity of these
residues, it is clear that charges in the region between F2 and HRA control different aspects of
the F protein. We showed that mutation of residue E51 exposes a cleavage site that is normally
hidden from endogenous proteases. While the exact location of this cleavage site is still
unknown, it must be near the usual cleavage site as cleaved mutant proteins were similar in size
compared to WT F1. The HMPV F sequence contains an arginine residue two residues upstream
of the predicted WT cleavage site (RQSR/F, / = predicted cleavage site) that could become
accessible to endogenous trypsin-like proteases after mutation of E51. If proteolytic cleavage
occurs at this residue, it would result in an F1 protein with polar and charged residues (QSR) at
the N-terminus upstream of the hydrophobic fusion peptide. It would not be surprising that F
protein mutants with polar and charged residues at the N-terminus of the F1 subunit cannot
promote membrane fusion. Our homology model predicts E51 to be in close proximity to
residues K138 and K142. It would be interesting to know if these residues are also important for
proper cleavage of the F protein. Replacement of these residues with alanine or negatively
charged residues (which should produce a phenotype similar to E51K) as well as experiments
identifying the novel cleavage site should provide useful information on how electrostatic
interactions promote proper cleavage activation.
It is possible that the sequence differences in this region between HMPV and PIV5 are
related to the requirements for their homotypic attachment proteins. While PIV5 HN is essential
for viral-cell binding and fusion (180), the G protein of HMPV is not required for neither step (31,
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65, 299). Therefore, the presence of charged residues in this region of HMPV F could help
supplant the need for interactions with G for the regulation of triggering. The electrostatic
interactions in this region could help stabilize the metastable prefusion conformation until
binding of HMPV F to negatively-charged HSPGs forces conformational changes that disrupts
this interaction and primes F for triggering at low pH.

HMPV – Receptor Interactions
Initial studies by Biacchesi and coworkers showed that the HMPV F protein alone can
promote virus-cell binding and infection (31), indicating that the F protein must have receptor
binding abilities. The studies detailed in the preceding chapters have confirmed this hypothesis
and show that HMPV F binds to HSPGs and that this interaction is sufficient for cell infection
(Chapter 4 and (65)). Carbohydrates play an important role in entry for many viruses including
several members of the paramyxovirus family. It is well known that paramyxoviruses that
express HN attachment proteins like PIV5 bind to cell surface sialic acid. Furthermore, RSV and
BRSV binding to HSPGs has also been reported (115, 163, 174, 176). The crystal structures of
several HN proteins have been solved and indicate that the binding site for sialic acid is located
at the top of the head domain (184, 385, 386). The binding site for SLAM, however, is located at
the side of the MeV H protein (135). While structures of pneumovirus F proteins in the prefusion
form are unavailable to date, our homology model indicates that positively charged residues are
more concentrated at the top of the head domain of HMPV F (data not shown). Therefore, the
binding site for negatively-charged HSPGs could also be located at the top of the head region.
Nonetheless, more experiments are needed to determine the exact location of the binding site
for HSPGs.
Even though the prevailing hypothesis for many viruses is that binding to GAGs is a
nonspecific event that serves only to concentrate viral particles at the surface of the cell to
facilitate subsequent interactions with higher affinity receptors, we believe that the interaction
between HMPV F and HSPGs is specific, as interactions between paramyxoviruses and HSPGs
has only been documented for members of the pneumovirinae subfamily and our experiments
show significant impairment in viral binding and infection in the absence of HSPGs. Moreover,
our preliminary data suggest that not all HSPGs interact with HMPV F for virus binding (Chapter
5). Therefore, it is possible that only a few specific proteoglycans can serve as platforms for
HMPV F anchoring though the identity of these HSPGs are still unknown. It has been shown that
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HSPGs can promote particle internalization (237, 378). Thus, binding to HSPGs alone could
directly promote viral internalization as has been reported for HSV-1 and HEV (161, 241, 308,
349) or could allow interaction with higher affinity receptors or coreceptors. Whether
interactions with one or a few specific HSPGs alone can directly lead to viral internalization
alone still needs to be determined.
Cell surface nucleolin has been recently proposed to be a functional receptor for RSV
(342). Previous studies have shown that RSV infection is facilitated by interactions between RSV
G and GAGs (174). While RSV F has also been shown to interact with GAGs (115), a more recent
study showed that a virus with a truncated RSV G protein showed decrease binding to GAGs,
suggesting that the G protein is the primary binding partner for GAGs in RSV (176). Binding of
RSV F to nucleolin is thought to occur after interactions between RSV G and GAGs. Despite
belonging to the same subfamily of viruses, our preliminary results indicate that cell surface
nucleolin does not play a significant role in HMPV infection (Figure 24). Moreover, HMPV
binding to cells was not enhanced in the presence of HMPV G, suggesting that the G protein
does not play a role in viral binding at least in vitro. The observation that any potential cellular
interactions mediated by HMPV G are not essential for viral attachment further underscores the
importance of the interaction between HMPV F and specific HSPGs and suggests that this
interaction could directly mediate viral entry. It would be interesting and extremely valuable,
however, to learn whether HMPV F binds to other cell surface proteins and the role those
binding events play in viral infectivity. Techniques such as the VOPBA (Chapter 5) should prove
to be useful in the search for those surface proteins.
It was suggested that interactions between RSV and HSPGs are likely irrelevant in vivo as
immunofluorescence studies using an antibody against epitope 10E4 suggested that HS is
located primarily on the basolateral side of differentiated ciliated airway epithelial cells (52, 226,
389). While 10E4 is the most commonly used monoclonal antibody against HS, the specificity of
10E4 varies between different HS (350, 356). It is possible that HSPGs recognized by 10E4 locate
preferentially to the basolateral side while other HSPGs are present in the apical side of
polarized cells. Indeed, some studies show HSPG expression, including glypicans, on the apical
side of polarized cells (52, 75, 199, 214). The amount of HSPGs present on the apical side of cells
could allow HMPV to establish an initial infection in the upper respiratory tract. It has been
shown that, after viral infection, the morphology of cells that make up human airway epithelium
changes resulting in increased mucin production and a loss of ciliated epithelial cells due to
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shedding (389). Additionally, tissue injury and disruptions of cell layers cause an increase in
apical levels of HSPG and exposure of basolateral HSPGs (52). Initial infection by HMPV
therefore could in turn increase the accessibility of HSPGs to the virus. Furthermore, while it is
commonly believed that viral infections occur initially at the apical surface of polarized cells,
infection through the basolateral side after binding to HSPGs has been documented for some
papillomaviruses (168). Detailed studies with polarized human airway epithelial cells would be
essential to identify the physiological location of viral attachment and entry during HMPV
infection.

Potential Roles for the HMPV G Protein
The evidence that cellular attachment of HMPV is mediated by the fusion protein forces
the field to reconsider the role of HMPV G in viral entry. Interestingly, RSV, BRSV, and AMPV
have also been shown to be infectious in the absence of their attachment proteins in vitro (163,
164, 231) and very little sequence homology is seen between the attachment proteins of the
two subfamilies of paramyxoviruses (351). Therefore, it appears that there is a difference in the
requirement for the homotypic attachment protein for viral attachment and fusion between the
members of the paramyxovirinae and pneumovirinae subfamilies. However, even though
pneumoviruses can grow in the absence of the attachment protein, in vivo studies show that
viruses devoid of this protein either cannot replicate, as in the case of RSV (346), or are
significantly attenuated, as BRSV and HMPV (27, 295). Therefore, while the role of the G protein
is still unknown, it appears that this protein confers an advantage for the virus in vivo though it
is not essential for viral growth in vitro. Studies have shown that RSV G improves the efficiency
of cell fusion (139), packaging, and particle formation (345). It has been shown that infectious
particles lacking the HMPV G protein can be recovered (31, 65) and our laboratory has
demonstrated that cell-to-cell fusion mediated by HMPV F is not enhanced by the presence of
the HMPV G protein (299). Furthermore, in vivo studies show that infectivity of HMPV ΔG virus
is attenuated in the lower respiratory tract of nonhuman primates but not in the upper
respiratory tract (27). Therefore, it is likely that HMPV G is not required for fusion and/or viral
packaging though we cannot rule out the possibility that it is required for fusion and/or viral
packaging the environment of the lower respiratory tract.
Pneumovirus G proteins are highly glycosylated and, in the case of RSV, can exist as a
soluble form that is about half in size and is secreted from infected cells (141). Interestingly,
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Teng and coworkers showed that the infectivity in mice of recombinant RSV expressing only the
soluble form of G was only mildly reduced compared to WT whereas a drastic reduction was
seen in viruses that did not express G at all (346), suggesting that the ectodomain alone is
largely responsible for most of the G activity. Therefore, it appears that the primary role of
pneumovirus G proteins is something other than mediating viral attachment. Several studies
have shown that paramyxovirus attachment proteins are major targets for antigenic response
though the antibodies produced are many times poorly neutralizing (71). In addition, the
secreted form of RSV G interferes with antibody-mediated neutralization and plays a role in
modulating the immune response (71, 158). Interestingly, the HMPV G gene presents the largest
sequence variability in the viral genome, resulting in less than 50% homology between the G
proteins of the two subgroups of HMPV (18). It has been shown that protective neutralizing
antibodies were not produced in hamsters after immunization with HMPV G expressed in a
HPIV1 vector (312). Moreover, Bao and coworkers showed that the HMPV G protein inhibits
innate immune responses (14). Therefore, while a soluble form of HMPV G has not been
characterized, the high degree of glycosylation and sequence variability could be essential for
immune evasion.
Previous studies have demonstrated that the G proteins of both RSV and HMPV also
bind to GAGs (304, 347). While our studies indicate that the HMPV F protein is the primary
attachment factor and no significant differences in viral binding to cells in vitro was observed
between WT and viruses lacking the G protein (65), the HMPV ΔG mutant virus was less efficient
at infecting the lower respiratory tract of animals (31). Therefore, it is still possible that the
HMPV G protein could confer a selective advantage for viral attachment in some tissues either
by recognizing a specific GAG or a higher affinity receptor. Even though the exact function of
HMPV G in the viral lifecycle is still unknown, the gene encoding HMPV G is present in all clinical
isolates sequenced so far (27, 31) and therefore must serve an important function in the viral
lifecycle. More studies are clearly warranted to get a better understanding on the function of
this viral protein.

HMPV Entry Into Cells
The finding that the HMPV F protein mediates the initial viral attachment step (65), that
it can be triggered by low pH (299), and that inhibitors of endocytosis and agents that raise
endosomal pH can reduce HMPV infectivity (298) all suggest an entry mechanism that is
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significantly different from the entry pathway hypothesized for most paramyxoviruses. While it
has long been thought that paramyxoviruses gain access to the cell at the plasma membrane
after cell binding mediated by the attachment protein (180), our data suggest that HMPV entry
occurs through endocytosis and is independent of the activity of the attachment protein. In
addition, our preliminary data also suggest a role for endocytosis on entry of PIV5, questioning
the general belief that entry of paramyxoviruses with F proteins that can be triggered by neutral
pH occurs at the plasma membrane.
Even though most members of the paramyxovirus family express F proteins that can be
triggered at neutral pH and inhibitors of endosomal acidification do not block infectivity in most
cases, there is evidence that, in addition to HMPV, at least some other paramyxoviruses could
also enter cells through endocytic pathways. Kolokoltsov and coworkers showed that RNAimediated knockdown of proteins involved in clathrin-mediated endocytosis significantly
reduced RSV infectivity (171). Pernet, et. al. showed that NiV entry can occur by
macropinocytosis after binding to its receptor EphrinB2 and low endosomal pH was not required
for NiV to exit the vesicle (262). Furthermore, studies with chemical inhibitors suggest that NDV
may infect cells through caveolin-mediated endocytosis (54). In addition to our work with
HMPV, we also showed that inhibition of dynamin decreases PIV5 infectivity (Figure 25). The
microenvironment in endosomes can be significantly different to that of the cell surface, from
the membrane lipid composition to the protein content inside the vesicles. Infection by tickborne encephalitis virus, Semliki Forest virus, and dengue virus require different lipid membrane
compositions in endosomes (166, 236, 329, 388) while other viruses like SARS coronavirus and
Ebola virus require proteolytic cleavage by endosomal proteases for infection to occur (62, 296,
310). Interestingly, cleavage of Ebola virus GP1 protein reveals a binding domain for the
endosomal/lysosomal cholesterol transporter Niemann-Pick C1 (NPC1) (55, 77). Binding to NPC1
is essential for Ebola infection and is therefore considered a postendocytic intracellular receptor
required for viral fusion. Even though intracellular receptors have not been characterized for
paramyxoviruses, infection by members of this family could take place via endocytosis
regardless of the ability on their F proteins to be triggered by low pH.
Numerous studies have shown that viral entry pathways are largely defined by the cell
surface receptors being used by the virus (reviewed in (129)). Even though influenza virus can
bind to a wide range of sialic acid-containing molecules, cell entry occurs through different
endocytic pathways depending on viral interactions with other cellular proteins (67, 86). Since
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many paramyxoviruses also bind to sialic acid, the entry pathways of these viruses could be
similar to that of influenza. Interestingly, while HMPV does not bind to sialic acid, there appears
to be a significant resemblance between the entry of HMPV and influenza as both viruses
express a class I membrane fusion protein that is also responsible for viral binding to cell surface
carbohydrates and must be proteolytically cleaved to be active (hemaglutinin, HA for influenza
and HMPV F)(311). Like some sialylated proteins, some HSPGs also have sorting capabilities
(187, 275) and, like most cell surface proteins, are endocytosed after ligand binding for recycling
or degradation (273). Thus, the pathway of internalization of some syndecans is thought to be
clathrin-independent (118) while some glypicans use caveolin-mediated endocytosis (198) to get
to endosomes. The exact pathway of internalization for other HSPGs is still largely unknown.
However, it remains possible that the HSPG receptor of HMPV dictates the entry pathway of the
virus.
Our laboratory and others have shown that β1 integrins play an important role in
promoting HMPV infection (65, 80). While the results from Cseke, et. al. were initially
interpreted by many to mean that αvβ1 integrins was the initial attachment receptor for HMPV,
our studies indicate that integrins have an important role after binding to HSPGs (65). It is
unclear what role of β1 integrins have in HMPV entry. It has been shown that integrins have an
important role in the regulation of a complex set of signaling pathways that are responsible for
many aspects of cell behavior including endocytosis. Integrins signal through many pathways
including those mediated by PI3-kinase (PI3K), protein kinase C (PKC), Src-family protein tyrosine
kinases, and ERK (124, 151). Because the activity of many of these signaling pathways promotes
endocytosis (94), it is not surprising that integrins can dictate the route of viral entry (123).
Indeed, internalization and proper endocytic sorting of mammalian orthoreoviruses depend on
β1 integrin and Src kinases even though their initial attachment receptor is JAM-A (84, 197). In
addition, it has recently been shown that activation of the PI3K/Akt pathway by β1 integrin
promotes the internalization of mature vaccinia virus (153). Interestingly, vaccinia viruses also
bind to cell surface GAGs and enter cells mainly through endocytosis (59, 212) even though viralcell membrane fusion can occur at the plasma membrane (59). Thus, it is possible that proper
signaling through β1 integrin is required for efficient internalization and proper sorting of HMPV
in the endosomal pathway.
In addition to regulating endocytic processes, integrins are also internalized and
recycled through these endocytic pathways (61). The internalization of integrins themselves can
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occur

through

clathrin-dependent

and

clathrin-independent

endocytosis,

and

their

internalization is often accompanied by internalization of the bound ligand (61, 305). The
internalization and recycling of integrins bound to their ligands allows them remain active
intracellularly and to direct receptor and cargo trafficking through different compartments
(309). Indeed, integrin signaling through endocytic compartments could be responsible for the
regulation of endosomal cathepsins, which has been shown to influence Ebola virus entry (297).
If HMPV binds directly to β1 integrin, the entry pathway viral particle could be the same as the
route of internalization of β1 integrin. Furthermore, integrins could be required for the proper
expression and localization of an unknown endosomal factor that is required for HMPV entry.
Our studies and those performed in other viral systems allow us to propose a model for
HMPV entry. Initial attachment of HMPV to the surface of the cell is mediated by interactions
between HMPV F and HSPGs (65) at the apical or basolateral side of polarized cells in vivo.
Attachment of HMPV to HSGPs would then allow the virus to interact with other cell surface
proteins including β1 integrin to promote viral internalization through endocytosis. While HMPV
entry could occur through more than one pathway of endocytosis, our results suggest that at
least a subpopulation of HMPV use clathrin-mediated endocytosis for cell entry. Because the
optimal pH for triggering of HMPV appears to be less than 5 (299), we hypothesize that the viral
cell-membrane fusion step would occur in a late endosomal/endolysosomal compartment.
Studies using live-cell imaging and polarized cells are clearly needed to confirm this model as
these studies would determine the site of cell attachment and the entry pathway the virus takes
to establish a productive infection. Furthermore, expanding these studies to other
paramyxoviruses like PIV5 will provide valuable information that could change our hypothesis of
how paramyxovirus infection occurs.

Remaining Questions in Paramyxovirus Fusion and Entry and Potential Applications to
Medicine
Despite the wealth of information that has been gathered about paramyxovirus F
protein-mediated membrane fusion and viral entry, many important questions remain to be
answered. Foremost among these is the identification of the triggering signal(s) that are
transmitted from the attachment protein to the F protein upon receptor binding. What kinds of
conformational changes occur in the attachment protein that signal the F protein to trigger?
Where are the interactive sites between the attachment and the F proteins? Are conformational
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changes and/or interactive sites different between paramyxoviruses so that a homotypic
attachment protein is required? While current data suggest that, for some paramyxoviruses, this
interaction is between the stalk domain of the attachment protein and the head domain of the F
protein (43, 89, 185, 209), the exact location in the F protein remains unknown. Furthermore,
the F protein of members of the pneumovirinae subfamily can be triggered in the absence of the
homotypic attachment protein, suggesting that the triggering mechanism differs significantly
between the two subfamilies.
Important questions also remain on the process of fusion itself. What are the structural
intermediates of F in the fusion process? While recent biophysical data have provided us with
evidence of the prehairpin intermediate of PIV5 F (167), structural information about the
prehairpin intermediate as well as the conformational changes leading to it and after the
formation of it remain to be elucidated. Furthermore, the precise role of the attachment protein
as an active participant of the refolding of the F protein during fusion beyond the prehairpin
intermediate state (268) is still unknown. Are interactions with the attachment protein needed
for the F protein to achieve certain intermediate states? If so, what replaces this function of the
attachment protein in members of the pneumovirinae subfamily?
Another significant area of study is to clarify the role of different cellular pathways in
the viral entry process. Increasing amount of data suggest a more complex mechanism of entry
that, in many cases, may involve the endocytic machinery of the cell. There are advantages for a
virus to enter through an endocytic pathway, as endosomes protect viruses from the host
immune system and provide a unique environment for fusion to occur, therefore potentially
decreasing the probability of triggering the fusion protein prematurely. However, data to date
do not rule out the possibility that paramyxoviruses enter at the plasma membrane or have
more than one entry pathway. Lipid mixing and particle uptake do not necessarily correlate with
productive infection (218), and thus determining the route of entry for productive infection
remains an important goal.
While a remarkable wealth of information has been gathered since the discovery of
HMPV a little over a decade ago (352), a lot of basic questions about the lifecycle of the virus
and the cellular factors involved in infection remain to be answered. The work presented here
represents an important step forward in our understanding of the physiology of HMPV infection.
We provided evidence that the viral attachment step is mediated by HSPGs and that entry likely
occurs through endocytosis. Furthermore, we identified important regions where potential
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electrostatic interactions could play a role in the triggering of HMPV F at low pH. A better
understanding of the triggering of HMPV F, the conformational changes that take place, and a
more comprehensive understanding of the roles of HSPGs in the context of HMPV pathogenesis
as well as the discovery of higher affinity receptors or coreceptors will significantly advance our
knowledge of the lifecycle of this virus, paving the way for the development of therapeutics that
will block the attachment of HMPV to cells.
Recent studies on membrane fusion and entry of paramyxoviruses have provided
significant advancements in our understanding of these processes, paving the way for the
exploration of potential therapeutic targets using small molecules (335) and peptide inhibitors
against the fusion protein (186, 324). While there are indeed conserved regions in the surface
glycoproteins that translate into similarities in overall mechanisms of binding and entry, there is
a significant degree of diversity in this family that provides for unique aspects of receptor
binding, triggering, membrane fusion, and viral entry. Given the importance of this family of
viruses to human health and global economy, more studies are clearly needed to better
understand both the conserved mechanisms and the unique aspects of paramyxovirus
glycoprotein function.
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Appendix I: Abbreviations Used in this Document
6-HB

Six-helix bundle

CA

Constitutively active

DN

Dominant negative

ER

Endoplasmic Reticulum

F

Fusion

FBS

Fetal Bovine Serum

FP

Fusion peptide

GAG

Glycosaminoglycan

GFP

Green fluorescent protein

GPI

Glycophosphatidylinositol

HeV

Hendra virus

HEV

Hepatitis E virus

HIV

Human immunodeficiency virus

HMPV

Human metapneumovirus

HN/G/H

Paramyxovirus attachment protein

HPIV1

Human parainfluenza virus 1

HRA

Heptad repeat A

HRB

Heptad repeat B

HS

Heparan sulfate

HSPG

Heparan sulfate proteoglycans

HSV-1

Herpes simplex virus 1

HTLV-1

Human T-cell leukemia virus 1

MeV

Measles virus

mβCD

Methyl-β-cyclodextrin

NiV

Nipah virus

P/S

Penicillin/Streptomycin

PAGE

Polyacrylamide gel electrophoresis

PI3K

Phosphoinositide 3 – kinase

PIV3

Parainfluenza virus 3

PIV5

Parainfluenza virus 5
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PKC

Protein kinase C

RSV

Respiratory Syncytial virus

Sdc4

Syndecan-4

SeV

Sendai virus

TM

Transmembrane domain

VOPBA

Virus overlay protein binding assay

VSV

Vesicular stomatitis virus

WT

Wild type
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